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The Frailty Syndrome: An Overview 
Abstract: 
Objective: To describe the current definitions, aetiology, assessment tools and clinical 
implications of frailty in modern surgical practice. 
Background: Frailty is a critical issue in modern surgical practice due to its association with 
adverse health events and poor post-operative outcomes. The global population is rapidly 
ageing resulting in more older patients presenting for surgery. With this, the number of frail 
patients presenting for surgery is also increasing. Despite the identification of frailty as a 
significant predictor of poor health outcomes, there is currently no consensus on how to 
define, measure and diagnose this important syndrome.  
Methods: Relevant references were identified through keyword searches of the Cochran, 
MEDLINE and EMbase databases.  
Results:  Despite the lack of a gold standard operational definition, frailty can be 
conceptualised as a state of increased vulnerability resulting from a decline in physiological 
reserve and function across multiple organ systems, such that the ability to withstand 
stressors is impaired. Multiple studies have shown a strong association between frailty and 
adverse peri-operative outcomes. Frailty may be assessed using multiple tools, however the 
ideal tool for use in a clinical setting has yet to be identified. Despite the association 
between frailty and adverse outcomes, few interventions have been shown to improve 
outcomes in these patients.    
Conclusion: Frailty encompasses a group of individuals at high risk of adverse post-operative 
outcomes. Further work exploring ways to optimally assess and target interventions towards 





Frailty is a critical issue in modern surgical practice as it is associated with adverse 
outcomes following surgical intervention. It is typically seen in older patients, and the 
number of older patients is increasing disproportionately worldwide. In 2015, an estimated 
8.5% of the world’s population was aged 65 years or older (defined as older adults or 
elderly)1. It is estimated this will increase to be more than 12% by the year 2030, and 17% by 
20501 (Figure 1.1). In contrast, the proportion of individuals 20 years and younger is 
projected to remain static over the same time period1.  
 
 
Figure 1:1. Older people and young children as a percentage of global population, 1950 – 2050. 
Reproduced with permission from He et al.1 
 
New Zealand’s elderly population is growing rapidly, and is expected to double from 
700,000 in 2016 to around 1.4 million by 20402. In the United States of America in 2012, 
despite only accounting for 12% of the total population, older patients accounted for 35% of 
all hospital admissions3. Older patients also had a significantly longer average hospital stay 
and an increased average cost per stay3. In 2005-2006, patients aged 65 or over, whilst 
comprising only 13.2% of Australia’s population, represented 35% of all hospital admissions 
and 47% of occupied bed days4. 
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Older surgical patients have higher rates of adverse health outcomes including major 
complications, prolonged hospital stay, readmission and unplanned discharge to care 
facilities5-15.  Increasingly, care of the older patient is becoming a component of modern 
surgical practice.  These patients are an increasing proportion of the general population, and 
when combined with an expectation of reasonable quality of life and function, surgery in this 
age group will become more common.  Consistent with this, older adults are a 
disproportionate group of patients seen in surgical practice. In the  United States 13% of the 
population was aged 65 years or older in 2010, but accounted for 37% of all inpatient 
operations16.  
Defining surgical risk in the elderly can be difficult.   Age alone is insufficient to 
capture the physiologic heterogeneity observed in this population, which arises from both 
comorbidity and variable functional status. In the first part of the 21st Century most efforts 
to quantify surgical risk in the elderly were based on age and comorbidity as the main 
predictors of adverse post-operative outcome in the elderly surgical patient17, 18.  
At present there is a paucity of tools for predicting peri-operative risk in elderly 
surgical patients. Chronological age alone is not a sensitive predictor of inpatient mortality19.  
Commonly used metrics include the American Society of Anaesthesiology (ASA) score20, the 
Charlson comorbidity score21, Lee’s Revised Cardiac Risk Index22 and the Physiological and 
Operative Severity Score for the enUmeration of Mortality and Morbidity (‘POSSuM’) 
score23.  
These tools are often based on a single organ system and often do not include 
physiological variables. The ASA score was originally designed for statistical data 
management and then modified. It does not include physiological variables and provides a 
subjective classification of patients into one of six categories. Owens et al24 showed that 
when 255 anaesthetists attempted to grade 10 patients on average only 5.9% of the patients 
were given the same rating.   A recent review of the utility of ASA by Moreno et al25 showed 
a lack of discriminatory power between groups. Lee’s revised cardiac index only assesses the 
cardiovascular system and risk of cardiac complications in the perioperative period. 
Risk indices have inherent limitations and stratify patients into expected risk 
categories, but cannot correctly assign risk to an individual patient26. They are most useful at 
identifying very low risk patients with few or no clinical factors, however they fail to 
discriminate between levels of risk for higher risk patients26. None of the commonly used 
 4 
metrics assess a patient’s physiological reserve. Frailty assessment offers the ability to 
identify individuals who have a limited capacity to cope with the physiological stressors 
encountered with surgery and in the perioperative period.  
Recent research has focused on the holistic concept of frailty.   Frailty can be thought 
of as a state of increased vulnerability across multiple organ systems, resulting in poor 
physiologic reserve, and thus inability to respond to stressors.  Defining frailty in clinical use 
is intended to identify those patients who are at increased risk of adverse health outcomes.  
This concept is increasingly recognised as a separate entity from ageing and comorbidity27; 
and when appropriately measured  is an independent risk factor for adverse postoperative 
outcomes14, 15, 28, 29. Not all older patients are frail, suggesting therefore that frailty is not an 
inevitable consequence of ageing and may be the target of intervention. In the literature, 
numerous tools have been developed to measure frailty, however, there is no standardised 
and validated method for assessment or screening in the perioperative context. 
The present discussion reviews the current literature pertaining to frailty in the elderly 
surgical patient. It examines the current definitions of frailty and reviews the conceptual 
models, aetiology, and natural history of this syndrome.  It also outlines the clinical 
significance of frailty and the current tools available for its measurement. In doing so, a 
number of research questions are identified, which are subsequently addressed in the 
following chapters of this thesis.  
1.2 Defining Frailty: 
Frailty has only recently been recognised in the surgical literature, first appearing in 
the title of a surgical scientific publication in 200930. Since then it has been the source of 
considerable research interest generating nearly 4000 publications in the last decade.  
Prior to 1980 the term “frailty” was scarcely used. A leading article in the British 
Medical Journal published in 1968 described frail patients as being “confused, restless and 
incontinent”31. In 1978 the Federal Council on Ageing USA introduced the term “frail elderly” 
to describe a subset of the older population who “because of an accumulation of various 
continuing problems often require one or several supportive services in order to cope with 
daily life”32. In the 1990s Rockwood and colleagues proposed a frailty index and a clinical 
frail scale33, 34. In 2001, Fried and colleagues developed a frailty phenotype in an attempt to 
separate the concept of frailty from disability and comorbidity35. More recently a number of 
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groups have met in an attempt to standardise a frailty definition and decide on a tool for 
assessment; however to date a consensus has yet to be reached36-38.  
In this literature, disability, comorbidity and frailty are terms often used 
interchangeably to identify a group of vulnerable older patients who require enhanced care.  
While all are potentially predictive of adverse health outcomes, each term describes distinct 
concepts. Disability is defined as an impairment in a patient’s ability to undertake their 
activities of daily living. Comorbidity is defined by the concurrent presence of two or more 
diseases. There is complex inter-relationship between these concepts in the elderly patient.  
Frailty can overlap with both comorbidity and disability and frailty and comorbidity can 
predict disability27. Disability may exacerbate frailty and comorbidity may contribute to the 
development of frailty and disability.  
In the Cardiovascular Health Study, Fried et al.39 examined the overlap between 
these three concepts in 2762 patients. They defined comorbidity as having 2 or more of the 
following: arthritis, claudication, chronic obstructive airways disease, angina, congestive 
heart failure, myocardial infarction, cancer, diabetes and hypertension. They defined 
disability as impairment in one or more activity of daily living, and they define frailty based 
on their phenotypic model, as outline below. Of those who met the criteria for frailty, 27% 
were solely frail, 46% had associated comorbidity, 6% had associated disability and 22% had 
associated comorbidity and disability. Figure 1.2, reproduced from their study, shows the 
overlap of these concepts.  It should be highlighted, however, that while disability and 




Figure 1:2. Relationship between Frailty, Comorbidity and Disability. Adapted with permission from 
Fried et al35.  
 
Interpreting the frailty literature suffers from this lack of a consensus definition36, 37. 
It is generally conceptualised as a state of increased vulnerability resulting from age-
associated declines in physiological reserves and function across multiple organ systems, 
such that the ability to cope with every-day or acute stressors is compromised15, 35, 40. This 
lack of standardized definition contributes to widely variable prevalence in the literature, 
with reports ranging from 4.1 to 50.3%15.   
In spite of the lack of a gold standard operational definition an international 
consensus group concluded that it is a distinct clinical syndrome with multiple causes and 
contributors that is characterised by “diminished strength, endurance, and reduced 
physiological function that increases an individual’s vulnerability for developing increased 
dependency and or death36.”  
Increasing age has a clear correlation with frailty, however ageing alone is not 
necessarily synonymous with frailty6. Ageing is often conceptualised as an accumulation of 
deficits due to random damage throughout life, resulting in an increased risk of death41. As 
defects accumulate an individual becomes less and eventually non-resilient41. Frailty has 
been considered a model for unsuccessful or “pathological” ageing6 and is thought to be a 
potentially reversible state between successful and pathological ageing41. Although 
chronological age is associated with frailty, young patients can also be frail; in the Canadian 
*Comorbidity – 2 or more of the 
following myocardial infarction, 
angina, congestive heart failure, 
claudication, arthritis, cancer, 
diabetes, hypertension, COPD 
**Disability – with impairment of 
activity of daily living 
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Heath Measures Survey, 2 to 5% of those age 18 to 34 years, 4 to 6% in those aged 35 to 49 
and 7 to 12% in those aged 50 to 64 were classified as frail42.  
For the purpose of this thesis, frailty will be defined as a state of increased 
vulnerability resulting from age-associated declines in physiological reserves and function 
across multiple organ systems, such that the ability to cope with every-day or acute 
stressors is compromised. 
1.3 Models of Frailty: 
Two conceptual models of frailty seek to combine these observations: the frailty 
phenotype and the frailty index. 
1.3.1 Frailty Phenotype Model: 
The frailty phenotype model, proposed by Fried et al, was derived from the 
Cardiovascular Health Study, a study of risk factors for mortality in older adults in the USA35.   
This model views frailty as a clinical syndrome of decreased physiological reserve resulting 
from cumulative declines across multiple systems35. The hypothesised phenotype was 
operationalised into a screening tool that includes measurement of weakness (grip 
strength), slowness (gait speed), physical activity, weight loss and exhaustion (Figure 1.3).  
 
 
Figure 1:3. Frailty Phenotype Criteria. Adapted from Fried et al35 with permission 
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This tool was validated in 5317 community dwelling men and women 65 years and 
older in the USA, defining frailty as meeting three of the five criteria, and a pre-frail state 
meeting one or two criteria. In this validation cohort, the overall prevalence of frailty was 
7.2%.  Increased frailty positively correlated to age and female sex: prevalence was 3.9% 
amongst 65 to 74-year olds compared to 25% in the over 85 group; and 8% of women versus 
5% of men. Those who were pre-frail had twice the risk of becoming frail over 3 years 
compared to those who were non-frail (OR=2.63, CI =1.94, 3.56). Mortality at seven years 
was 12% for the non-frail population, 23% for the pre-frail and 43% for the frail population 
showing a clear correlation between frailty and mortality (p<0.05). After adjustment for 
covariates the frailty phenotype was an independent predictor for the development of 
adverse outcomes at 3 and 7 years; including hospitalisation, falls, worsening mobility and 
worsening activities of daily living (p<0.05 for all except falls where p=0.06). 
Criticisms of the frailty phenotype is that it predominantly focusses on the physical 
manifestations of frailty. Psychological, cognitive and social factors have been shown in the 
literature to also be key components of the frailty syndrome40. These are not assessed in the 
frailty phenotype model, potentially therefore underestimating the prevalence of frailty and 
instead focussing on physical frailty.  
1.3.2 Accumulation of Deficits Model: 
The accumulation of deficits model was developed by Rockwood et al as part of the 
Canadian Study on Health and Ageing43.  This study followed over 10 000 Canadians over a 
10-year period from 1991 to 2001 collecting data on health outcomes.  This model reflects 
the number of deficits an individual accrues over several different domains. The frailty index, 
the tool created from this model,  is based on a comprehensive geriatric assessment, 
comprised of  ninety-two variables covering  a range of physical, functional, social and 
cognitive domains, as well as incorporating comorbidities34, 43, 44. A wide range of deficits can 
be measured and can include symptoms, medical diagnoses, functional and laboratory 
assessments45, 46. Criteria for consideration as a deficit is that it must be: acquired, 
associated with increasing age and adverse health outcomes and must not saturate too 
early.  
Multiple derivations of the frailty index (FI) exist, with most tools using 30 – 70 such 
deficits46.  In general, across the tools developed to measure frailty, the greater the number 
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of deficits, the greater the likelihood of frailty and thus adverse health outcomes. Compared 
to the frailty phenotype, which either classifies patients as non-frail, pre-frail or frail, the 
frailty index is often regarded as more sensitive as it is a more finely graded risk scale40. The 
large range of health deficits measured to compute the frailty index takes into account the 
multidimensionality of frailty and includes its physical and mental aspects. One criticism is 
the inclusion of disability and comorbidity with no attempt to distinguish them from frailty. 
The frailty index also assigns equal weighting to all components; however, some are more 
likely to be clinically significant and contribute to frailty. 
1.4 Prevalence: 
The prevalence of frailty varies greatly in the literature, typically as a result of varying 
definitions and criteria for the diagnosis of frailty. In the Cardiovascular Health Study39 the 
overall presence of frailty in community dwelling adults aged 65 years or older in the United 
States ranged from 7% to 12%.  The prevalence increased with increasing age being 3.9% in 
those aged 65 to 74 and 25% in those older than 85.  
In the Women’s Health Initiative Study47, a prospective study of 47,657 women aged 
65–79 years, the incidence of frailty over three years was approximately 15%. Strong 
associations were found between frailty and increasing age (p<0.01), poverty (p<0.01), lower 
levels of education (p<0.01), African American or Hispanic race (p<0.01), very low or high 
body mass index (p<0.01) and chronic physical and/or mental illnesses (p<0.01).  
A systematic review by Collard et al48 assessed 21 community based cohort studies of 
61500 elderly people. Definitions of frailty as well as assessment tools differed between 
studies, leading to a substantial variation in reported prevalence rates of between 3.0% and 
59.1%. Eleven of the studies reported frailty to be more prevalent in women, with a rate of 
9.6% compared to 5.2% in men. As expected, frailty increased steadily with age, as seen in 
Figure 1.4. The authors identified rates of 4% for ages 65-69, 7% for 70-74, 9% 75-79, 16% 




Figure 1:4. Prevalence of Frailty. Reproduced with permission from Collard et al48 
 
Gender appears to have an influence on the prevalence and development of frailty. 
In the systematic review by Collard et al48, 11 studies described frailty according to sex and 
included 17,746 women and 22,596 men. In women, the weighted average prevalence of 
frailty was statistically higher in women, 9.6%, compared to in men, 5.2% (p<0.001).  
Most data have been collected in Caucasian populations and there is little data on 
variation between ethnicities. Fried et al35, in the cardiovascular health study, recruited 
separately 582 African American patients subsequent to their initial recruitment of 4735 
patients. They noted an increased rate of phenotypic frailty in the African American cohort, 
12% vs 6%. In the Women’s Health and Ageing Studies49 the rates of frailty in the African 
American cohort was 26% compared to 10% in the Caucasian population. This may suggest 
higher rates of frailty in this population, or that different cut-offs may be needed for 
different populations. 
In a survey of 7510 community dwelling elderly residents from 10 European countries 
it was found that the prevalence varied greatly between countries, ranging from 5.8% in 
Switzerland to 27% in Spain50. Prevalence was significantly higher in southern than northern 
Europe, even after adjusting for age and gender, suggesting a geographic variation. Given 
the data was from a self-reported survey, however, it is possible that differences may be due 
to cultural differences in perception of health and interpretation of the questions.  
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1.5 Aetiology and Pathophysiology: 
Mechanistically, frailty is a synergistic, multifactorial phenomenon and at present, a 
single underlying cause to frailty, has not been identified.  Frailty shares common pathways 
with ageing, but is typified by an accelerated decrease in reserve and subsequent 
vulnerability to stressors relative to physiologic ageing51. Frailty has been described as an 
intermediate between successful and pathological ageing41. Pathologic changes in several 
inter-related physiological systems lead to the common outcome of frailty52, 53.  
Dysregulation of the immune and endocrine systems, basal metabolism, and factors such as 
genetics, mitochondrial dysfunction, poor nutrition and reduced physical activity have been 
linked to frailty development6, 51.    
“Inflammaging” has been described as the presence of a low grade chronic pro-
inflammatory state that may be a hallmark between ageing and frailty54-56. This state is 
characterised by increased levels of pro-inflammatory cytokines including interleukin-6 (IL-
6), tissue necrosis factor alpha (TNFα) and C-reactive protein (CRP) as well as leucocytosis52, 
55, 57.   This state has been associated with poorer outcomes in patients undergoing 
colorectal surgery58.   Mechanistically, inflammation leads to a catabolic state, with resultant 
anorexia, sarcopenia, and loss of adipose tissue, leading to the lack of resilience that typifies 
frailty. Further, this states may lead to anaemia, subclinical cardiovascular disease and 
nutritional dysregulation causing a cascade of detrimental effects on other organ systems 
propagating frailty59-61,62, 63.  
With regards to the aetiology of frailty, inflammation may be the primary 
pathophysiological process, or it may be secondary to an insult or infection or a surrogate for 
another pathophysiological process associated with dysregulation of homeostasis64. 
Regardless of the driver for inflammation, the functional outcome remains the same with 
the frail individual having a reduced ability to respond to stressors.  
Ageing and frailty are also associated with an impaired immune system, with a 
reduction in stem cells and immune response65. B cell antibody production is diminished, 
and phagocytic activity of neutrophils and macrophages is reduced. This ageing immune 
system may function adequately in health but fails to respond to acute stressors or insults52. 
Frailty is associated with reduced efficacy of both the influenza and pneumococcal 
vaccination66, likely due to impaired antibody response, and results in the modest clinical 
effectiveness seen in the frail elderly. 
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Mitochondrial dysfunction is associated with ageing and frailty67, 68. Mitochondria are 
ubiquitous intracellular organelles responsible for energy production through oxidative 
phosphorylation. They contain their own DNA encoding several key proteins of the 
respiratory chain. They also have a role in innate immunity, modulation of stem cell activity 
and intracellular signalling68. A decline in mitochondrial number and function has been 
associated with ageing68, 69. As an individual ages, mutations in mitochondrial DNA 
accumulate; this results in excessive production of reactive oxygen species, damaging 
macromolecules and impairing cellular and tissue function67. As a result, apoptosis is 
initiated, a mechanism believed to represent a final common pathway through which 
sarcopenia and physical frailty ensue69.       
Aging is associated with significant changes in major circulating hormones, including 
insulin-like growth factor 1 (IGF-1), oestrogen, testosterone, dehydroepiandrosterone 
sulfate (DHEA-S), and cortisol.  Excessive or abnormal changes in these, individually or in 
combination, may contribute to sarcopenia and the development of frailty.  A reduction in 
growth hormone synthesis leads to a reduction in levels of insulin-like growth factor-1 (IGF-
1) produced by the liver. Both growth hormone and IGF-1 are important in neuronal 
plasticity and skeletal muscle metabolism52. Reduced levels of IGF-1 have been shown to be 
associated with increased levels of frailty in a study of community dwelling older women70. 
Reduced levels of oestrogen, testosterone and dehydroepiandrosterone sulfate (DHEA-S) are 
associated with ageing. In frail individuals the circulating levels of these hormones are 
significantly lower71. DHEA-S plays an important role in maintaining muscle mass and also 
indirectly prevents activation of the inflammatory pathways that, as described above, lead to 
reduced muscle mass72. Several other hormones, including cortisol and Vitamin D have also 
been associated with frailty40. Frailty has been shown to be associated with chronically 
elevated cortisol levels, with a blunted diurnal variation73, 74. Elevated cortisol is associated 
with a catabolic state which may lead to reduced muscle mass, weight loss and subsequent 
frailty.   
Ageing results from a lifelong accumulation of molecular and cellular damage cause 
by many mechanisms that are regulated by complex maintenance and repair networks52. 
The amount of damage required to cause impaired organ physiology is unknown, however, 
most organ systems show significant redundancy, providing the physiological reserve 
required for age or disease related changes75. A gradual decline in physiological reserve 
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occurs with ageing, however, in frailty this decline in accelerated and homeostatic 
mechanisms fail52. These complex mechanisms are determined by genetic and 
environmental factors, in combination with epigenetic mechanisms, which regulate gene 
expression, and are likely especially important in the development of frailty (Figure 1.5)52, 76.  
 
 
Figure 1:5. Schematic representation of the pathophysiology of frailty. Reproduced with permission 
from Clegg et al52. 
 
1.6 Natural History: 
Without intervention, frailty appears to generally be a progressive process with pre-
frail patients progressing to greater and greater degrees of frailty over time.   Gill et al77 in a 
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longitudinal study of 754 people 70 years or older found that over 4.5 years 58% had at least 
one transition between frail states; of which two thirds were from lesser to greater frailty.  
The likelihood of a transition from frail to non-frail was extremely low with rates of 0.9%.  
Similarly, Xue et al78 found in 405 older women over 7.5 years that two thirds of the women 
who were non-frail at baseline became frail within the study period,  and one third had rapid 
progression to frailty without an observable pre-frail stage. However, this is uncommon and 
progression of frailty in the majority is slow, with timescales measured over years.   
Frailty is not inevitable, progression rates vary between individuals, and importantly, 
it appears to not be an irreversible premorbid state. Identification of frail individuals, 
development of interventions to prevent or slow progression, and methods to reverse frailty 
should be a top priority in surgical research.   
1.7 Clinical Significance: 
Frailty is considered to be a high-risk state predictive of adverse health outcomes. 
Fried et al35 showed that in those who were defined as frail at baseline, mortality was six-
fold higher (18%) than that for the non-frail (3%) at 3 years and over threefold higher at 7 
years (43% compared to 12%). The development of frailty often leads to a spiral of decline 
with higher risk of worsening disability, falls, re-admission and death. Frailty assessment may 
provide an insight into heightened vulnerability and allow risk stratification for older patients 
undergoing surgical treatment. 
In a systematic review and meta-analysis by Oakland et al79, the authors looked at 
the association between patient frailty and surgical outcomes. Twelve studies were 
identified which included 7960 patients across multiple surgical disciplines. While definitions 
of frailty differed between studies, the results were similar across studies for in-hospital and 
one-year mortality, length of stay (LOS), and discharge to another care facility when 
comparing frail versus non-frail: 2.77 odds ratio (OR) (95% CI 1.62-4.73) for in-hospital 
mortality; 1.99 OR (95% CI 1.49-2.66) for one-year mortality;  LOS was 1.05 days longer; and  
there was a 5.71 OR (95% CI 3.41-9.55) for discharge to rehabilitation/higher level of care 
facility. Post-operative complications were not reported due to the heterogeneity and meta-
analysis was not performed.  
Consistent with this meta-analysis, our analysis of individual studies highlights the 
observation that more frail patients have worse outcomes than less frail patients.  Dasgupta 
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et al28 performed a prospective observational cohort study of 125 patients 70 years or older 
undergoing elective non-cardiac surgery and looked at the association between frailty and 
post-operative outcomes. Frailty was measured using the Edmonton frail scale (EFS)80 and 
was defined as a score exceeding seven. Frail patients had higher rates of post-operative 
complication, OR 5.02 (95% CI 1.55-16.25) and a lower chance of being discharged home; 
40% versus 69% (p<0.02). The presence of frailty clearly is associated with adverse post-
operative outcomes, and the preoperative identification may allow for treatment 
modification.  
Makary et al14 prospectively measured frailty in 594 patients 65 or older undergoing 
elective surgery and looked at surgical outcomes. The Fried model35 was used to classify 
patient as frail (10.4%), pre-frail (31.3%) or non-frail (58.3%).  The incidence of complications 
following major surgery was 43.5% in the frail, 33.7% in the pre-frail and 19.5% in the non-
frail. Relative to non-frail, this translates into an OR of 2.54 (95% CI 1.12-5.77) in the frail and 
2.06 (95% CI 1.18-3.60) in the pre-frail. The average LOS was 4.2 days for non-frail, 6.2 days 
for the pre-frail and 7.7 days for the frail. The OR of being discharged to a care facility of 3.16 
(95% CI 1-9.99) in the non-frail and 27.64 (95% CI 9.00-84.87) in the frail. The presence of 
frailty was found to be a better predictor of outcome than ASA. Preoperative identification 
of the frail patient may allow for improved decision making by clinicians, patients and their 
families. 
Further systematic reviews looking at frail patients across all surgical specialties by 
Lin et al13, and specifically at patients undergoing surgery for colorectal cancer by Fagard et 
al9 found similar results of increased mortality, LOS, complication rate and discharge to 
higher level of care. Ommundsen et al81 in a multivariate analysis of 178 patients undergoing 
colorectal cancer surgery found that the presence of frailty was a statistically significant 
independent prognostic factor for survival.  
1.8 Frailty Assessment: 
Frailty clearly has an association with worse clinical outcomes; therefore, it becomes 
an important variable the practicing surgeon should consider when assessing a patient.   To 
this end, there are several competing methods to assess and measure for frailty. In the 
literature, there are more than 70 tools for frailty assessment, which differ by their intended 
use, practitioner, and target population. Tools have been developed for screening, case 
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finding and predicting prognosis, for use by geriatricians, general practitioners, 
epidemiologists, allied health professionals etc, and for use in several different population 
settings. Many of the tools available have been only used in the research setting and few 
have been validated and/or reproduced in more than one population or study29. 
Instruments to define frailty have taken differing approaches, ranging from 
measuring a single item, such as grip strength to frailty indices with upwards of 80 
assessment parameters. Frailty screening and assessment likely require different tools, as a 
screening tool needs to be both sensitive and easy to administer, whereas an assessment 
instrument requires more specificity82.  
In a clinical setting the ideal frailty assessment should have high predictive ability and 
be quick and easy to perform83. Single performance measures such as the timed up and go 
(TUG) and grip strength can be performed rapidly and are thus attractive, however, their 
predictive ability is limited84. The timed up and go (TUG) measures the time it takes to rise 
from a chair, walk three metres, turn and return to sitting. Times of 15 seconds or more 
strongly correlate with frailty and increased post-operative complications and 1-year 
mortality85.  
Fried’s frailty phenotype35 is a popular assessment tool amongst researchers82. It 
typically takes less than 10 minutes to perform and is one of two strategies recognised by 
the American College of Surgeons and American Geriatric society for the optimal 
preoperative assessment of older patients86. The strengths of this tool are its speed of 
administration, easy reproducibility and that it has been used and validated across multiple 
studies/populations. Weaknesses are that it requires a dynamometer and stopwatch, 
focuses predominantly on physical frailty/sarcopenia and omits psychosocial components of 
frailty4, 29. 
The frailty index (FI) tool described by Rockwood et al43 is the most widely recognised 
instrument based on deficit accumulation.  Due to its length and complexity, multiple 
derivative instruments have been proposed to facilitate ease of administration. All rely on 
the measurement of multiple, typically between 20 and 70, characteristics or deficits. A FI is 
then calculated by dividing the number of abnormal deficits by the total number measured. 
The use of FIs has been well validated and applied to multiple patient groups as described by 
Dent et al in a review of 29 different frailty measures82. The main limitation of FIs are the 
time-consuming nature and therefore they are often limited to the research setting.  
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A number of different tools have been developed for use in the clinical setting, and 
these include the FRAIL Index87, the Clinical Frailty Scale (CFS)88 and the Edmonton Frail Scale 
(EFS)80. These tools are summarised in Table 1.1. The Fatigue, Resistance, Ambulation, Illness 
and Loss of weight (FRAIL) index was developed by the International Association of 
Nutritional and Ageing87. It is comprised of five components, fatigue, resistance, slow 
walking speed, illness and loss of weight; the presence of three or more constitutes frailty. It 
has been shown to be predictive of mortality in an African-American cohort89, but further 
validation studies are required in other populations. The Clinical Frailty Scale (CFS)88 is a well 
validated scoring tool based on clinical judgement. It is scored on a scale from 1, very fit, to 
9, terminally ill and each point corresponds with a written description of frailty. A score of 5 
or greater is considered frail. It has been shown to be predictive of adverse outcomes in 
hospitalised elderly patients82, 90, 91.  
The Edmonton Frail Scale (EFS) is a multidimensional assessment tool that includes 
assessment across different domains including a TUG test and a test for cognitive 
impairment80. It takes less than five minutes to perform and is feasible for use by non-
geriatricians92 It is scored out of seventeen and has nine components including general 
heath, self-reported health, cognition, functional independence, social support, mood, 
polypharmacy, continence and functional performance. It is valid, reliable and its diagnostic 
accuracy has been reviewed in the hospital setting28, 80, 93. One of its touted benefits is that it 
is able to highlight aspects of frailty that may be amenable to preoperative optimisation, 
such as polypharmacy15, 28. The EFS meets many of the characteristics of an instrument to 
measure frailty that could be used in a routine surgical practice and it is recommended by 






Table 1.1. Commonly used frailty assessment tools 
















1 1 Time taken to stand, walk 3m, turn and 
return to chair and sit 




5 10 Based on presence/absence of 5 
components: weakness, weight loss, 
slowness, exhaustion, low activity 
Presence of ≥3 
criteria.  
1-2 - prefrail 
+ - + - + + + 
Frailty 
Index33 
30+ 20-30 Number of health deficits. Score of 0 – 1.0 Frailty = >0.25 + + + + - + + 
EFS63 9 <5 Assesses domains of cognition, health (x2), 
mood, social support, hospitalisation, 





+ + + + + + + 
FRAIL 
Index72 
5 <5 Score from Fatigue (self-reported), 
Resistance (climbing 10 steps), 
Ambulation, Illness, Loss of weight (>5%/1 
yr) 
Frail =≥3  + - + - - + Further 
studies 
needed 
CFS73 1 2 Score from 1 (very fit) to 9 (terminally ill) 
based on clinical judgement aided by visual 
chart with written descriptions of scale 
Frail =≥5 + - - + - + + 
TPI94 1 5-10 Cross sectional area of both psoas muscles 
at the third lumbar vertebrae, normalised 
for patient height 
Frail 
<385mm2/m2 
in females  
<545mm2/m2 
in males 
+ - - - - - + 
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Radiological measures have also been proposed for the assessment of frailty, given 
the association between sarcopenia and frailty.  Radiological assessment of lean muscle 
mass may be used as an objective and easy to measure marker of sarcopenia95, 96. Reduced 
psoas muscle area on CT has been shown to be associated with an increased risk of 
morbidity and mortality in resection of colorectal cancer94, 97 and pancreatic cancer95, 98. The 
Total Psoas Index (TPI) is a commonly used radiological marker of sarcopenia and frailty. It is 
calculated by measuring the cross-sectional area of the psoas muscle at the height of the 
third lumbar vertebrae and normalising this for patient height94, 96. Gender specific 
thresholds exist to define sarcopenia or frailty.  
The reason measurement of frailty is critical, is that with identification it may be 
amenable to intervention to reduce the peri-operative complication rate in this population.   
1.9 Potential Interventions: 
1.9.1 Perioperative Risk Assessment: 
Defining and quantifying frailty in older surgical patients allows for the potential 
modification of patient care based on frailty assessment findings in two ways. Firstly, the 
aggressiveness and intent of surgery and treatment may be modified. If a patient was found 
to be frail, alternative surgical or non-surgical approaches could be considered, and if not 
available, risk in the operation could be controlled by selecting lower risk anaesthetic or 
surgical options.  In those deemed frail, adverse health outcomes could be carefully 
observed for in the postoperative period. Secondly, in these patient’s appropriate consent 
and counselling of anticipated outcomes could be provided, allowing preparation for their 
post-operative course. Knowledge for needs of post-discharge placement allows appropriate 
planning and potential for a reduced delay to discharge. 
1.9.2 Prehabilitation: 
Preoperative prehabilitation with the aim to improve post-operative outcomes has 
been reviewed number of clinical trials99-103. Exercise, nutrition, counselling and 
pharmacological agents have been studied to look at their effects. Exercise has physiological 
effects on not only the skeletal system, but also the brain, endocrine and immune system40, 
92. Systematic reviews by de Vries et al104 and Clegg et al92 have shown that community 
exercise programmes can improve mobility and functional outcomes with few adverse 
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events even in patients on the frailer end of the spectrum. Preoperative physical therapy 
reduces length of stay and pulmonary complications after cardiac surgery105. In elective 
major abdominal surgery the effects of preoperative exercise on outcomes appears 
mixed106. Boden et al107 in their randomised controlled trial showed preoperative 
physiotherapy was effective in reducing post-operative pulmonary complications. Further 
studies examining the effects of exercise on post-operative outcomes should be the focus of 
ongoing research. 
1.9.3 Multicomponent Geriatric Intervention: 
Comprehensive geriatric assessment (CGA) may improve the peri-operative 
management of patients identified as frail, thus reducing risk. It involves a multidisciplinary 
team led by a geriatrician that can support the surgical team with perioperative medical care 
of older surgical patients.  The acute care for elders has been shown to help maintain the 
functional status of older adults during acute admissions108, 109 and the proactive care for 
older persons undergoing surgery (POPS) model has been shown to improve perioperative 
outcomes in older patients undergoing surgery110, 111. A Cochrane meta-analysis of 22 trials 
compared CGA with standard care112. The use of CGA significantly improved patient survival 
and reduced rates of institutionalisation at 6 and 12 months follow up. A further Cochrane 
meta-analysis113 reviewing patients admitted specifically to a surgical service and comparing 
CGA to standard care showed a reduction in mortality in patients with hip fractures and a 
significantly reduced rate of discharge to a higher level of care.  
Current evidence supporting CGA is predominantly in orthopaedic patients, as this is 
where geriatric liaison services first developed. These services inherently look at elements of 
frailty such as cognition, nutrition and falls risk which may be otherwise overlooked. More 
recently there is increasing evidence to support CGA across other surgical disciplines114, 115.  
1.9.4 Nutritional and Pharmacological Intervention: 
Nutritional intervention may be able to address the weight loss, impaired nutrition 
and catabolic state of frailty. Despite the association between macro- and micro- nutrient 
deficiency and frailty116, there is a scarcity of evidence looking at the effect nutritional 
supplementation may have on surgical outcomes in frail patients.  
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Currently there is no consensus regarding the potential use of pharmacological 
interventions in frail patients117. Hormonal treatment in the form of growth hormone, 
testosterone in males and oestrogen in females has been the focus of many trials. 
Testosterone has been shown to improve muscle mass and strength but has increased rates 
of cardiovascular and pulmonary complications15, 52. Growth hormone and oestrogen 
replacement therapy also have unfavourable side-effect profiles and limited clinical efficacy.  
Despite the role of inflammation in frailty, to date anti-inflammatory treatments 
have not been shown to influence frailty4. Vitamin D prescription in those older patients who 
are deficient has been shown to reduce falls, and in combination with calcium can reduce 
fractures118. The general use of Vitamin D as a treatment for frailty still is unclear and cannot 
currently be recommended119. Angiotensin-converting enzyme (ACE) inhibitors have been 
shown to improve skeletal muscle structure and function. A single randomised control trial 
of 130 healthy older patients120 showed those treated with an ACE inhibitor had improved 
exercise capacity and fewer falls. Whilst ACE inhibitors and Vitamin D have favourable side-
effect profiles, further evidence is required before they can be recommended. The use of 
pharmacological agent for the prevention and management of frailty remains an important 
subject for future research.  
1.10 Questions for this thesis: 
The prevalence of frailty in the community setting has been well described, however 
there is little evidence regarding the burden of frailty in an inpatient setting. Whilst there is 
good evidence that frail patients have poor outcomes following surgical intervention, it 
remains unclear how best to assess for and measure frailty. As outlined above, multiple 
methods exist to measure frailty, however, many of these are subjective and/or difficult to 
perform.  
This thesis aims in Chapter 2 to determine the prevalence of frailty in an inpatient 
population and subsequently examine patient outcomes at 90-days follow-up.  Secondly, 
over the subsequent chapters, this thesis aims to determine the relationship between 
different measures of peri-operative frailty, and post-operative outcomes in patients 
undergoing major colorectal surgery. Chapter 3 retrospectively reviews post-operative 
outcomes in patients classified as frail using a radiological surrogate, the Total Psoas Index 
(TPI) and a clinical frail scale, the modified frailty index (mFI). Chapter 4 prospectively 
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assesses the relationship between three different clinical frailty measures and post-
operative outcomes. Chapters 5 and 6 investigate two novel markers of frailty; patient 
activity levels, as assessed by step count, and patient mitochondrial function; and examines 
the relationship between these novel markers and post-operative outcomes. 
 




Frailty Prevalence in an Adult Inpatient Population 
Abstract 
Introduction: The prevalence of frailty varies greatly in the literature and there is limited 
literature assessing the prevalence of frailty in an inpatient setting. Its significance lies on its 
impact on resource utilisation and costs.  
Aim: To determine the prevalence of frailty in the adult population in a tertiary New Zealand 
hospital. 
Methods: Eligible patients aged 18 years and over were invited to participate, and frailty 
assessment was performed using the Reported Edmonton Frail Scale. A score of 8 or more 
was considered frail. Factors associated with frailty were assessed at baseline and patient 
outcomes were assessed at 90 days. 
Results: Of 640 occupied inpatient beds, 420 patients were assessed and included in the 
study. 220 patients were excluded, of which 89 were absent from their bed-space, 73 
declined and 41 were critically unwell. The overall prevalence of frailty across assessed 
patients was 48.8%. The prevalence of frailty increased significantly with age. Maori patients 
were significantly more likely to be frail (OR 4.0, 95% CI 1.45 – 11.9). Frailty was associated 
with an increased median length of stay (14 vs. 5 days, p<0.01) and a significantly increased 
90-day mortality and unplanned readmission rate.  
Conclusion: Frailty is highly prevalent in the hospital setting with 48.8% of all inpatients 
assessed classified as frail. Frailty is associated with adverse patient outcomes and has 
significant resource implications. An increased understanding of the burden of frailty in this 




Frailty is an important concept in modern healthcare due to its association with 
adverse patient outcomes including prolonged hospital admissions, in hospital complications 
and discharge to residential care facilities8-10, 13, 64, 121, as outlined in Chapter 1.  
The prevalence of frailty in the literature varies considerably, typically as a result of 
varying populations, definitions and diagnostic criteria. Despite the need to identify and 
measure frailty, there is no single operational definition for clinical use122, therefore making 
interpretation and comparison of literature difficult. Collard et al48, in a systematic review of 
21 community based cohort studies, reported rates varying between 4% and 59.1%, with an 
overall weighted prevalence of 10.7% in an elderly population. The Survey of Health, Ageing 
and Retirement in Europe (SHARE) study reported a frailty prevalence of 4.1% in community 
dwelling individuals aged over 50 and of 17% in those aged over 65 across 10 European 
countries50.  
The prevalence of frailty in hospitalised elderly patients also varies significantly in the 
literature with reported rates between 24.7% and 80%123-128.  In a cohort of 220 patients 
aged 70 years and older who were admitted to an acute geriatric ward Joosten et al123 
identified 40% of individuals as frail and 51.5% as pre-frail. In 307 patients admitted with a 
myocardial infarction and aged 75 years and older 48.8% were identified as frail. Typically, 
frailty prevalence assessment focusses on single service or demographic and provided useful 
information on that specific cohort. To our knowledge no prospective study has been 
performed assessing the prevalence of frailty across an entire hospital.    
Multiple frailty assessment tools exist for use in both research and clinical settings.129 
The Edmonton Frail Scale (EFS) is a multidimensional assessment tool that includes 
assessment across different domains80. It takes less than five minutes to perform and is 
feasible for use by non-geriatricians92. It is scored out of seventeen and has nine 
components including general heath, self-reported health, cognition, functional 
independence, social support, mood, polypharmacy, continence and functional 
performance. It is valid, reliable and its diagnostic accuracy has been reviewed in the 
hospital setting28, 80, 93. Due to the potential difficulty of performing a timed up and go test 
on hospital inpatients, an adaptation of the EFS, the reported Edmonton Frail Scale (REFS) 
was created by Hilmer et al130. Instead of a timed up and go test, the REFS utilises a self-
reported performance state, two weeks prior to admission. Hilmer et al were able to 
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demonstrate the reliability and validity of the REFS in acute patients admitted to a Australian 
hospital130.  
2.2 Aims 
The aims of this study were to: 
- Evaluate the prevalence of frailty in adult inpatients in a tertiary hospital. 
- Evaluate the association between frailty and patient outcomes at 90 days follow 
up. 
2.3 Methods 
2.3.1 Patient population: 
Christchurch Hospital is the largest tertiary hospital in the South Island of New 
Zealand with 580 adult inpatient beds with a further 230 beds at the nearby Burwood Health 
Campus. Burwood Health Campus is predominantly a rehabilitation facility, however, does 
have some elective surgical beds. Typical district health board bed occupancy is between 70 
and 80%. On a typical day, based on inpatient prediction models, all inpatients aged 18 and 
over at Christchurch and Burwood Hospitals were invited to participate in a point prevalence 
assessment of frailty.  Patients in the emergency department, birthing suite and intensive 
care units were excluded from the study due to the acuity of their conditions.  
Patients were identified for inclusion in the study by inpatient lists generated by the 
Decision Support team at 0730am on the day of assessment. This list was cross referenced 
by the assessor at the time of assessment to ensure patients who moved location during the 
day were not duplicated.  
Demographic data including age, gender, ethnicity, admission service and mode of 
admission (acute vs elective) was provided by Decision Support from the data warehouse. 
Data on level of care was obtained by the assessor at the point of recruitment.  
2.3.2 Frailty assessment: 
Although there are other well validated frailty indexes, the Reported Edmonton Frail 
Scale (REFS)130 was chosen due to its multidimensional nature, simplicity and its validity in 
the hospital setting. Frailty assessment was performed using the REFS by 24 trained medical 
 26 
and nursing staff who were assigned in pairs to different wards (Appendix A). Frailty 
assessment questions were referenced to the time of admission in an attempt to 
standardise, given varying admission lengths at time of assessment. For example, medication 
usage was asked with regard to the time of admission, rather than at the time of 
assessment. 
On initial contact a patient information sheet and a verbal description of the study 
was provided. Written consent was obtained, baseline demographics collected, and frailty 
assessment completed. Results of all individual components of the REFS were collected and 
a score between 0 and 18 was obtained. Any individual having a score of 8 or greater on the 
Reported Edmonton Frail Scale will be deemed as being frail. Patients were classified as 
having mild frailty with a score of 8 to 9, moderate frailty with a score of 10 to 11 and severe 
frailty with a score of 12 to 18130. Patients scoring 6 to 7 on the Reported Edmonton Frail 
Scale were classified as apparently vulnerable.   
Due to a presumed high prevalence of frailty in confused patients it was felt to be 
important to include this cohort in our analysis if at all possible. Confused patients were 
those who had either an acute confusional state, such as delirium, or a chronic confusional 
state, such as dementia, and their status was alerted to assessors by either the medical staff, 
or by the inability of the assessor to obtain consent. If a patient was confused or unable to 
provide consent the assessor alerted one of the primary investigators who subsequently 
contacted the lead clinician to obtain clarification of the diagnosis of confusion and to obtain 
consent to complete the assessment by review of clinical notes and discussion with the 
patients next of kin.  
2.3.3 Outcomes: 
Outcome data were collected prospectively. The primary outcome assessed was 
length of stay related to the index admission at the point of frailty assessment. Prolonged 
length of stay was defined as an inpatient stay that exceeded the hospital median, which 
based on local data was 7 days.  Secondary outcomes assessed at 90 days following 
assessment were: mortality, unplanned readmission and discharge to rehabilitation or 
higher level of care.  
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2.3.4 Ethics: 
This study was approved by the New Zealand Health and Disability Ethics Committee 
reference 18/STH/173. Locality approval was obtained from the Canterbury District Health 
Board.  
2.3.5 Statistical Analysis: 
Continuous variables were reported as medians with interquartile range (IQR) and 
categorical variables as whole numbers and percentages. Univariable analysis was performed 
to compare baseline characteristics between frail and non-frail patients. This included chi-
square tests for categorical variables and the Kruskal-Wallis test for non-parametric 
continuous variables. The distribution of continues variables were tested for parametricity 
using data visualization and the Shapiro-Wilk normality test. Multicollinearity between 
predictor variables was assessed by variance inflation factor (VIF), with scores of over 3 taken 
to denote unacceptable collinearity. 
Multivariable logistic regression analysis was performed to identify 
sociodemographic factors predictive of patient frailty and patient outcomes using backward 
stepwise selection based on Akaike Information Criterion (AIC). Model performance was 
assessed using Harrell’s concordance index (C-index). Regression coefficients from 
multivariable analysis were reported as odd’s ratios with 95% confidence intervals (95% CI). 
P values <0.05 were considered statistically significant. All statistical analysis was performed 





2.4.1 Frailty Prevalence and Sociodemographic Characteristics: 
On the day of assessment, 640 patients, representing 79% of the total hospital 
occupancy were eligible for inclusion. This included 475 patients from the Christchurch 
Hospital Campus and 165 from the Burwood Hospital Campus. Of the 640 eligible patients, 
386 provided consent and a further 34 confused patients were subsequently included with 
the consent of their lead clinician. This resulted in a total of 420 patients (65.6%) being 
included in this study.  
Reasons for the exclusion of the remaining 220 patients included 89 patients (13.9%) 
being absent from their bed-space, 73 (11.4%) patients declining, 41 (6.4%) patients who 
were either critically unwell or receiving end of life cares, 10 (1.6%) patients who were with 
other health care professionals and 7 (0.9%) patients who declined due to language 
difficulties. Of the 89 patients absent from their bed-space, 22 were in an operating theatre, 
17 were at investigations and the remaining 50 were presumed to be ambulatory and off the 
ward. The final cohort included 420 patients (Figure 2.1). 
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Figure 2:1. Patient recruitment overview 
 
Of the 420 patients assessed, 205 (48.8%) were classified as frail according to the 
REFS (Table 2.1). Seventy-one (16.9%) patients were mildly frail, 58 (13.8%) moderately frail 
and 76 (18.1%) were severely frail. Fifty-six (13.3%) were apparently vulnerable (Figure 2.2).  
640 eligible patients 
420 patients included
34 Confused added









Figure 2:2. Patient frailty classification as assessed by the Reported Edmonton Frail Scale (0-18). 
Patients with a score of 0-5 are classified as not frail and 6-7 as being apparently vulnerable. Patients 
with a score of 8-18 are classified as frail with a score of 8-9 representing mild frailty, 10-11 
moderate frailty and 12-18 severe frailty.  
 
The average age of patients included was 68.2 years (SD 19.4) and the median age 73 
years (IQR 58-83). There was no significant difference between the age of those patients 
included compared to those excluded (p= 0.69).  
Of the 420 included patients, 218 (51.9%) were female and 370 (88.1%) were New 
Zealand European.  The majority of patients (91.7%) were admitted acutely. A total of 168 
patients (40%) were admitted under a medical specialty, 160 (38.1%) under a surgical 
specialty and 92 (21.9%) to rehabilitation. 82.1% of patients came from their own home, 
12.1% from rest home level care and the remainder from hospital level care.  
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The prevalence of frailty increased significantly with increasing age (Figure 2.3). Of 
152 patients aged under 65 years, 38 (25%) were classified as frail, compared to 72 (77.4%) 
of 93 patients aged 85 years or older. Frail patients were significantly older than non-frail 
patients with median ages of 79 and 63 years respectively (p <0.01). Patients aged 85 years 
and older had an odds ratio of being frail of 6.25 (95% CI 3.17-12.7) when compared to those 
aged under 65 (Table 2.2). With increasing age, patients are also more likely to have a higher 
degree of frailty (Figure 2.3). 
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Table 2.2. Multivariable adjusted association between demographic characteristics and frailty status. 
Odds Ratios comparing characteristics between frail patients (REFS ≥8) and non-frail patients.  
Patient variables Adjusted Odds Ratio* 
(95% CI) 
p-value 
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2.25 (0.94 – 5.34) 
1.67 (0.77 – 3.59) 
5.71 (2.59 – 13.1) 
2.90 (1.37 – 6.21) 
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Ref 
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Figure 2:3. Frailty category by age category. Patients with a score of 0-5 are classified as not frail and 
6-7 as being apparently vulnerable. Patients with a score of 8-18 are classified as frail with a score of 
8-9 representing mild frailty, 10-11 moderate frailty and 12-18 severe frailty.  
 
Female patients were more likely to be frail with 117 of 218 (53.9%) female patients 
being classified as frail compared to 88 of 202 (43.6%) male patients (p = 0.04). After 
multivariable modelling, this difference was not statistically significant.  
The majority of patients were New Zealand European, which is representative of the 
local population. Some 49.7% (n=184) of the New Zealand European population were frail, 
41.7% (n=5) of the Pacific population, 63.6% (n=14) of the Maori population and 18.2% (n=2) 
of the Asian population. Maori patients had a significantly higher rate of frailty when 
compared to the New Zealand European population (OR = 4.0,95% CI 1.45 – 11.90, p = 0.02). 
Asian patients had a trend towards reduced levels of frailty (OR = 0.86), and Pacific patients 
had a trend towards increased levels of frailty (OR = 1.70), but neither were statistically 
significant, likely limited by the small sample size. 
The prevalence of frailty differed significantly by admitting service (Tables 2.1, 2.2). 
Patients admitted to a surgical service were significantly less likely to be frail, (OR = 0.52, 
95% CI 0.31 – 0.86, p=0.01). Those admitted to Burwood Health Campus for rehabilitation 
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were significantly more likely to be frail. Patients admitted from care facilities, including rest 
homes and hospital level care, were more likely to be frail than those admitted from their 
own home (Table 2.2). Frail patients had a higher Age-adjusted Charlson co-morbidity index 
(ACCI), with 33.2% of frail patients having an ACCI of 6 or more, compared to 10.2% of the 
non-frail patients. This is significant, as an ACCI score of ≥6 is strongly associated with an 
increased risk of 1-year mortality and patient morbidity131, 132. 
Multivariable analysis was conducted using backward stepwise selection to assess 
the association between demographic factors and frailty. All factors were initially included in 
the model and after backward stepwise selection age, ethnicity, admission service and 
baseline level of care remained significant predictors of frailty, with age being the strongest 
predictor (p <0.01). Adjusted Odds Ratios are presented in Table 2.2.  
2.4.2 Patient Outcomes: 
Patient outcomes were assessed at 90 days. Data was able to be extracted from the 
data warehouse for all 420 included patients. Tables 2.3 and 2.4 summarise patient 
outcomes at 90 days follow up. The overall median length of stay was 8 days (IQR 4 – 18). 
Frail patients had a significantly longer length of stay with a median of 14 days (IQR 6 – 22) 
when compared to non-frail who had median of 5 days (IQR 2 – 12, p<0.01, Table 2.3). There 
was a statistically significant increase in length of stay with successive increments in REFS 
score, when assessed using Spearman’s correlation coefficient with a rs of 0.379 (p<0.01) 
(Figure 2.4). 137 frail patients (66.8%) had a prolonged length of stay (defined as >7 days), 
compared to 84 non-frail patients (39.1%) (OR = 2.18, 95% CI 1.31 – 3.66, p<0.01). 
 
Table 2.3. Comparison between length of stay in frail and non-frail patients as assessed by the REFS. 
Patient outcomes All Patients 
 
(n = 420) 
Not Frail 
 















4 – 18 
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2 – 12 
14 
6 – 23 
 
1.47 (1.22 – 1.77) 
 
<0.01 




Figure 2:4. Correlation between REFS and length of hospital stay. Spearman’s correlation coefficient, 
rs of 0.379, (p<0.01). 
 
Table 2.4. Comparison of 90-day outcomes between frail and non-frail patients as assessed by the 
REFS.  
Patient outcomes All 
Patients 
 
n = 420 
Not Frail 
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p-value* 
Length of Stay 
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2.01 (1.20 – 3.40) 
 
<0.01 
*Adjusted for Age, Gender Ethnicity, Admission Service and Baseline level of care. 
 
At 90 days, frail patients had a significantly higher mortality rate when compared to 
non-frail patients with an odds ratio of 2.92 (95% CI 1.29 – 7.23, p=0.01). Frail patients also 
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had an increased rate of discharge to a rehabilitation or care facility; however, this was not 
statistically significant with a p = 0.09. Frail patients were significantly more likely to have an 
unplanned readmission within 90 days follow-up compared to non-frail patients, (p<0.01).  
Multivariable analysis was conducted using backward stepwise selection to assess 
the association between the baseline sociodemographic factors including frailty and a 
prolonged length of stay, defined as > 7 days. Factors with a p value of ≤0.10 were included 
in the model and after backward stepwise selection frailty, age and admission, service 
remained significant predictors of a prolonged length of stay, with frailty and admission to 
Burwood Hospital being the strongest predictors (p <0.01). 
Patient outcomes were then further assessed with patients classified into an older 
and younger cohort. A total of 152 younger patients aged under 65-years old were identified 
of which 38 (25%) were classified as frail. Despite being younger, frailty in this cohort was 
still associated with significant adverse outcomes including a prolonged length of stay and 
increased 90-day mortality and unplanned re-admission rates, similar to that seen in the 
overall cohort (Tables 2.5, 2.6).  
 
Table 2.5. Comparison between length of stay in frail and non-frail younger patients (age <65 years) 
as assessed by the REFS.  
Patient outcomes All Young 
Patients 
 
(n = 152) 
Not Frail 
 















2 – 12 
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2 – 9 
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4 – 22 
 
2.20 (1.43 – 3.45) 
 
<0.01 




Table 2.6. Comparison of 90-day outcomes between frail and non-frail younger patients (age <65 
years) as assessed by the REFS.  
Patient outcomes All Young 
Patients 
 
(n = 152) 
Not Frail 
 








(95% CI) * 
Adjusted 
p-value* 
Length of Stay 










2.57 (1.09 – 6.15) 
 
0.03 









































2.69 (1.08 – 6.67) 
 
0.03 
*Adjusted for Age, Gender Ethnicity, Admission Service and Baseline level of care. 
 
2.5 Discussion: 
This study highlights the high prevalence of frailty within an adult inpatient 
population, with 48.8% of patients being classified as frail. On multivariable analysis, 
multiple factors were found to be predictive of frailty, with increasing age being the 
strongest predictor with an odds ratio of 1.04 per each additional year, (p <0.01). This study 
also confirmed that frailty is associated with adverse outcomes, even at a relatively short 
follow-up of 90 days with an increased length of stay, 90-day mortality and readmission 
rates.  
The prevalence of frailty identified in this study is in keeping with rates of between 
24.7% and 80% reported in other publications123-128. Prior studies125, 127 have typically 
assessed the prevalence of frailty in elderly patients across a subset of inpatient services. To 
our knowledge, this study is the first to assess frailty across an entire adult inpatient 
population; and although high rates were expected and seen in the elderly cohort, we have 
highlighted a significant burden of frailty in younger patients. To date, although frailty is well 
described in the elderly patient, there is paucity of literature describing frailty in younger 
individuals.  
Although frailty is strongly associated with increasing age, frailty is not a unique 
condition limited to the elderly.  Smart et al133 in a study of 82 younger adults admitted 
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acutely to a surgical service identified 16% of their cohort to be frail. Frailty in the younger 
patient was associated with polypharmacy, multi-morbidity, cognitive impairment and social 
deprivation.  
Consistent with these findings, in our cohort, 25% of patients aged under 65 were 
classified as frail, with the youngest frail patient being aged 25. These younger patients 
typically had chronic health conditions and scored highly on the general health, 
independence, and performance categories of the REFS.   
Despite the above findings, the prevalence of frailty in this younger population 
remains unclear134, 135 and further research into the prevalence and implications of frailty in 
this group is needed. Frailty in this group, although associated with morbidity and mortality, 
is likely a different clinical and biological entity to that encountered in older adults134. Early 
identification and the development of interventions to improve outcomes in this cohort is 
needed.  
Most data in the literature has been collected on Caucasian populations and there is 
limited data on variations in the prevalence of frailty across ethnic groups, as discussed in 
Chapter 1. Fried et al35, in the Cardiovascular Health Study, noted an increased prevalence of 
phenotypic frailty in the African-American cohort of 12% compared to 6% in the Caucasian 
cohort. Similar results were seen in the Women’s Health and Ageing Studies49.  
In our cohort, Maori patients were significantly more likely to be frail, (OR = 4.00, 
95% CI 1.45 – 11.9, p = 0.01) and were significantly more likely to rate their general heath as 
fair or poor and have multiple hospital admissions over the previous twelve months. Pacific 
patients had a trend towards increased frailty and Asian patients towards decreased frailty; 
however, due to the relatively homogeneous population ethnicity this study was not 
powered to identify a significant difference.  
Consistent with our findings, Barrett et al136 in a survey of 2931 individuals found a 
higher prevalence of frailty in a Maori population compared to a New Zealand European 
population, with rates of 11.5% and 7.9% respectively. They also found the prevalence of 
frailty in Maori aged 65 to 70 to be the same as the prevalence of frailty in non-Maori aged 
81 to 84, suggesting an earlier onset of frailty in the Maori population. The higher prevalence 
of frailty among Maori at younger ages may be linked to a shorter life expectancy. Disparities 
between Maori and non-Maori over the life course can be considered to have a cumulative 
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effect that is manifest in later years as frailty. This disparity is also the likely cause of higher 
rates of frailty seen in the Cardiovascular Health Study and the Women’s Health and Ageing 
Studies137. 
Our results are in contrast to prior outpatient based studies, which estimate the 
prevalence of frailty to be in the region of 10%48. Frailty may be defined as a clinical state of 
increased vulnerability across multiple organ systems, resulting in poor physiologic reserve, 
and thus inability to respond to stressors15, 35, 40. This vulnerable cohort are at risk of adverse 
outcomes, including acute hospital admission, and therefore not unsurprisingly a large 
percentage of hospital inpatients are indeed frail, as seen in this study.  
A strength of this study is all adult inpatients were eligible for inclusion, thus we were 
able to estimate the prevalence of frailty across the entire adult inpatient population. To our 
knowledge, this is the first publication to do so. By including patients aged under 65, we also 
were able to describe the prevalence of frailty in younger individuals, where there is 
currently a paucity of literature. 
This study has a number of limitations. Firstly, 89 patients were absent from their 
bed-space at the time of the study. Although we could account for some of these individuals 
being away at investigations and undergoing procedures, it is possible the remainder were 
well and ambulatory, and therefore likely less to be frail than the included population. This 
may have led to an overestimation of the true prevalence of frailty due to sampling error. 
Secondly, data were derived from a single institutional experience on a single day with a 
relatively homogeneous ethnicity, and this therefore may not be generalisable to other 
centres.  
2.6 Conclusion: 
Frailty is highly prevalent in the inpatient hospital setting, with a prevalence of 48.8% 
in the studied population. Frailty is associated with adverse health outcomes. Despite 
typically being seen in an elderly population, it is also seen in younger patients, typically 
those with chronic health conditions. Due to its associated with adverse health outcomes, 
frailty has significant resource implications and should be the focus of ongoing research 
towards interventions to support this vulnerable population and attenuate the progress of 
frailty. Consideration should be given to inpatient frailty assessment in order to identify 




The Association Between Frailty, Sarcopenia  
and Post-Operative Outcomes 
Abstract  
Introduction: Frailty and sarcopenia are important concepts in surgical practice due to their 
association with adverse post-operative outcomes. Radiologically assessed psoas muscle 
mass has been proposed as a surrogate for sarcopenia. The modified frailty index (mFI) is a 
validated measure of frailty in surgical patients.  
Aim: To determine the association between frailty and post-operative outcomes in patients 
undergoing colorectal cancer surgery using two assessment tools; firstly, psoas cross-
sectional area as a surrogate for sarcopenia, and secondly using a modified frailty index.   
Methods: A retrospective analysis of 350 patients undergoing elective resection for 
colorectal cancer at a tertiary centre between 2014 and 2016 was performed. Lean muscle 
mass was quantified by measuring the cross-sectional area of the psoas muscle at the third 
lumbar vertebrae and normalised for patient height. The mFI was calculated from the 
patient’s medical records. Multivariable logistic regression analysis was carried out 
identifying pre-operative risk factors associated with post-operative outcomes.  
Results: Of 350 patients, 115 (32.9%) were identified as sarcopenic by radiological 
assessment and 101 (28.9%) as frail using a mFI. Regardless of the method of frailty 
assessment, frailty was associated with a significantly increased length of stay, (13 days vs 7 
days, IRR 2.12, 95% CI 1.90 – 2.36, p<0.01) and 1-year mortality (13.9% vs 0.9%, OR 16.2, 
95% CI 4.34 – 83.4, p<0.01). Frailty was also associated with a significant increased risk of 
any post-operative complication (85.2% vs 34.5%, OR 15.4, 95% CI 8.39 –29.7, p<0.01) and of 
major complications (30.4% vs 8.9% OR 15.1, 95% CI 7.16 – 33.2, p<0.01). Radiological 
assessment of sarcopenia, as a surrogate for frailty, was easily reproducible and much 
simpler to conduct than a modified frailty index.  
Conclusion: Frail patients have high rates of adverse post-operative outcomes, regardless of 
the method used for identification. CT scans, which are routinely performed as part of 
staging, provide an opportunity to easily assess for sarcopenia in the pre-operative setting. 
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With advances in surgical technique, improvements in medical therapy and an ageing 
population, an increasing number of patients are presenting for surgical treatment of 
colorectal cancer138, 139. Operative mortality has decreased with advances in technique, 
however post-operative morbidity remains high140-142 and is associated with an increased 
length of stay, poor oncological outcomes and a poorer quality of life143.   
As outlined in Chapter 1; frailty is a state of increased vulnerability to stressors, such 
as surgical intervention, and is associated with an increased risk of adverse post-operative 
outcomes9, 13. A lack of operational definition and objective assessment tool makes 
identification of the frail individual difficult; however, accurate identification may allow an 
opportunity for treatment modification and tailored perioperative care to minimise their 
risk. 
A number of groups have proposed the use of sarcopenia as an alternative marker 
for frailty94, 96, 144. Sarcopenia is a clinical syndrome characterised by a progressive and 
generalised loss of muscle mass and strength or physical function145. Multiple studies have 
shown an association between sarcopenia and poor post-operative outcomes in patients 
undergoing surgery for gastrointestinal malignancies 95, 97, 146.  A systematic review by 
Joglekar et al.144 identified sarcopenia as a significant independent predictor of post-
operative morbidity and mortality.  
Radiological assessment of muscle mass may be used as an objective and easy to 
measure marker of sarcopenia95, 96. Preoperative CT scans of the abdomen and pelvis are the 
standard of care for patients undergoing resection for malignancy and the cross-sectional 
view of the psoas muscle provides an objective measurement of lean muscle mass145.  
Reduced psoas muscle area on CT has been shown to be associated with an increased risk of 
morbidity and mortality in resection of colorectal cancer94, 97 and pancreatic cancer95, 98. 
Most studies employ a semi-automated method to measure cross-sectional muscle 
area144, however this is often time consuming and not part of standard radiological 
reporting. It is therefore more suited to a research setting, whereas the clinical environment 
requires an efficient and cost-effective method for assessing muscle mass. Total Psoas Index 
(TPI), which utilises the cross-sectional area of both psoas muscles at the third lumbar (L3) 
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vertebral body, normalised for the height of the patient, takes only a few minutes to 
perform and can be readily measured and reproduced in clinical practice94, 144.  
The modified frailty index (mFI) is a deficit accumulation measure of frailty validated 
across many surgical specialties147. The mFI was derived from the Canadian Study of Health 
and Aging Frailty Index34, 148 by matching its 70 variables to 11 comorbidity and deficit 
variables from the American College of Surgeons’ National Surgery Quality and Improvement 
Project (NSQIP)148, 149. It has been shown to be independently predictive of major 
complication149, mortality and readmission150 in the frail patient.  
3.2 Aim: 
The aim of this study was to determine the correlation between frailty, as identified 
using TPI and mFI, and post-operative outcomes in patients undergoing resection for 
colorectal cancer.  
3.3 Methods: 
3.3.1 Patient population: 
Adult patients undergoing elective colorectal resection for malignant disease 
between August 2014 and July 2016 at Christchurch Public Hospital were identified 
retrospectively through the local prospectively maintained computerised operative 
database. Patients were included if they had an abdominal CT scan within 90 days prior to 
their date of surgery and prior to the commencement of neo-adjuvant therapy. If patients 
did not have an up-to-date CT scan or were having surgery with non-curative intent, they 
were excluded from the study. Clinico-pathological data were collected from the patient 
medical records following Christchurch District Health Board (CDHB) locality approval. Access 
to CT images was through the local Picture Archiving and Communication System (PACS). 
Details of patient demographics, body mass index (BMI), American Society of 
Anaesthesiologists (ASA) grade, tumour location, operation performed, AJCC tumour stage 
and neoadjuvant treatment were collected from patient notes. Post-operative outcomes 
assessed included mortality, length of hospital stay, the development of post-operative 
complications, readmission and discharge to a care facility. Post-operative complications 
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were graded according to the Clavien-Dindo classification, with major complications defined 
as a score of ≥3151.  
3.3.2 Image Analysis: 
For all patients preoperative abdominal CT images, within 90 days of surgery, were 
reviewed using InteleViewerTM Diagnostic Viewer (Intelerad® Medical Systems) on standard 
desktop computer screens. Two observers, blinded to patient outcomes, (SR and SS) were 
trained in the identification of the third lumbar vertebrae on CT and in measurement of the 
Total Psoas Area (TPA) by a consultant radiologist. TPA was assessed in the axial plane at the 
level of the third lumbar vertebrae with both transverse processes being visible. TPA was 
measured in a semi-automated fashion, with manual outlining of both the left and right 
psoas muscle borders at the L3 level96 (see Figure 3.1). This area was then normalised for 




Figure 3:1. CT images at the L3 vertebral body showing the TPA measurement in a non-sarcopenic 
individual (A) and a sarcopenic individual (B) 
 
Sarcopenia was defined using gender specific thresholds of <385mm2/m2 for female 
patients and  <545mm2/m2 for male patients, based on values defined by an international 
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consensus group for the diagnosis of cachexia and malignancy152, and used in other similar 
studies94, 97. Interobserver correlation of CT measurements was assessed by both observers 
analysing 20% of the CT images independently.    
3.3.3 Frailty assessment: 
Preoperative frailty was assessed using a modified frailty index (mFI), which was 
calculated for each patient using a composite score derived from 11 conditions identified by 
the Canadian Study of Health and Aging mapped to the American College of Surgeons NSQIP 
database149. The mFI, as a continuous measure for modelling, is scored by assigning 1 point 
for each frailty component present divided by the 11 possible comorbidities or deficits 
assessed, for an accumulation of deficits ratio indexed from 0 to 1 to account for missing 
variables.  
The 11 mFI components include the following: (1) non-independent functional status 
(partially or totally dependent activities of daily living); (2) history of no diabetes or diabetes 
controlled by diet alone, diabetes treated with oral antihyperglycemic therapy, or diabetes 
treated with insulin therapy; (3) history of chronic obstructive pulmonary disease 
exacerbation or pneumonia within 30 days; (4) history of congestive heart failure 
exacerbation within 30 days; (5) history of myocardial infarction within 6 months; (6) history 
of angina within 30 days or any percutaneous coronary intervention or coronary artery 
bypass grafting; (7) hypertension requiring medication; (8) history of peripheral vascular 
disease; (9) acutely impaired sensorium; (10) transient ischemic attack or cerebrovascular 
accident without deficits; and (11) cerebrovascular accident with deficits (Figure 3.2). 
Variables having multiple levels were simplified to a dichotomous variable, with any positive 
findings clustered together.  Patients with a mFI ≥0.27 were grouped together and 




Figure 3:2. Components of the Modified Frailty Index (mFI). Reproduced with permission from Kim et 
al.153 
3.3.4 Outcomes: 
The primary outcomes assessed were length of hospital stay and the occurrence of 
post-operative complications within 30 days, as graded by the Clavien-Dindo classification. 
Secondary outcomes included post-operative mortality at 90 days and one year, unplanned 
readmissions at 90 days and one year and discharge to a care facility or higher level of care.  
3.3.5 Statistical Analysis: 
Continuous variables were reported as medians with an interquartile range (IQR) and 
categorical variables as whole numbers and percentages. Univariable analysis was 
performed to compare baseline characteristics between sarcopenic and non-sarcopenic 
patients. This included chi-square tests for categorical variables and Mann-Whitney U test 
for non-parametric continuous variables. Multicollinearity between predictor variables was 
assessed by variance inflation factor (VIF), with scores of over 3 taken to denote 
unacceptable collinearity. Interobserver correlation of CT measurements was tested using 
Spearman’s rank correlation co-efficient.  
Multivariable logistic regression analysis was performed on post-operative outcomes 
using backward stepwise selection based on Akaike Information Criterion (AIC). Model 
performance was assessed using Harrell’s concordance index (C-index). Regression 
coefficients from multivariable analysis were reported as odd’s ratios (OR) with 95% 
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confidence intervals (95% CI). Length of stay (LOS) and days in hospital at one year were 
evaluated as Poisson count data, were determined to be over-dispersed and as such, 
analysed using negative binomial regression. Incidence rate ratios from these analyses were 
interpreted as the relative number of days in the hospital when compared the reference 
(non-sarcopenic) group. P values <0.05 were considered statistically significant. All statistical 
analysis was performed using RStudio software (version 3.3.2; www.rstudio.com).  
3.4 Results: 
3.4.1 Sarcopenia as assessed radiologically using TPI 
3.4.1.1 Baseline demographic and clinicopathological characteristics: 
A total of 386 patients had elective colorectal surgery for malignant disease between 
August 2014 and July 2016. Twelve patients were excluded due to not having an up-to-date 
CT scan available for review on the InteleViewerTM system and a further 24 were excluded as 
they did not have surgery with curative intent, typically having a planned resection of a 
symptomatic tumour in the setting of metastatic disease. This left a total of 350 patients 
who were included in the study, all undergoing colorectal resection with curative intent and 
all having a preoperative CT scan of the abdomen, Figure 3.3. The interobserver correlation 
of CT measurements was tested using Spearman’s rank correlation coefficient, showing a 
significant correlation between observers with an r2 of 0.957 (95% CI 0.95 – 0.99, p <0.001), 
Figure 3.4.  
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Figure 3:3. Patient recruitment overview 
 
Baseline demographic, clinicopathological and treatment variables are shown in 
Table 3.1. The median TPI of all patients was 520.3mm2/m2 (IQR 407.8 mm2/m2 – 606.7 
mm2/m2). Female patients had a significantly lower median TPI when compared to male 
patients (425.2 mm2/m2 compared to 585.2 mm2/m2), Figure 3.5.   
Using the total psoas index (TPI) as a marker of sarcopenia, 115 patients (32.9%) 
were classified as sarcopenic. The median age of the study population was 74 years (IQR 67 – 
79). Sarcopenic patients were significantly older with a median age of 77 years compared to 
72 years in non-sarcopenic patients (p <0.01). Sarcopenic patients were more likely to be 
female (53.0% vs 46.4%), however this observed difference was not statistically significant 
(p=0.24). The majority of patients were of New Zealand European ethnicity (90.3%). There 
was no difference in prevalence of sarcopenia between ethnic groups.  
 
Patients screened for eligibility 
n = 386
Patients included in analysis
n = 350
Patients excluded as non-
curative intent
n = 24





Figure 3:4. Interobserver correlation of Total Psoas Index (TPI) between two observers. Spearman’s 
rank correlation coefficient, r2 = 0.957, 95% CI: 0-95 -0.99, p <0.001 
 
 
Figure 3:5. Difference in the Total Psoas Index (TPI) mm2/m2 between male and female patients.  
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Table 3.1. Baseline demographics and clinicopathological characteristics with comparison between 
sarcopenic and non-sarcopenic patients when using Total Psoas Index as an assessment tool. 
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TPI mm2/m2 Median 
(IQR) 
520.3 
(407.8 – 606.7) 
578.1 
(480.2 – 665.1) 
373.0 




The median BMI overall was 26.86 (IQR 24.04 – 30.80). Sarcopenic patients were 
more likely to have a lower BMI than non-sarcopenic patients (p = 0.04). Sarcopenic patients 
were more likely to be ASA grade III or IV with 60.9% of sarcopenic patients being ASA III/IV 
when compared with 22.6% of non-sarcopenic patients (p<0.01). There was no difference in 
tumour location between groups (p=0.47), however sarcopenic patients were more likely to 
have an open operation with 72.2% of patients having an open procedure, compared to 
57.4% of non-sarcopenic patients (p=0.01). There was no difference in stage of the tumour 
or the use of neoadjuvant treatment between the two groups.  
Patients with sarcopenia were more likely to be classified as frail according to the 
mFI, with 54.8% (n=63) of sarcopenic patients having a mFI ≥0.27, compared to 16.2% (n=38) 
of non-sarcopenic patients (p<0.01).  
3.4.1.2 Post-operative outcomes: 
Tables 3.2 and 3.3 summarises post-operative outcomes and complications. The 
overall median length of stay was 8 days (IQR 6 – 12). Sarcopenic patients had a significantly 
longer length of stay when compared with non-sarcopenic patients, staying a median of 13 
days (IQR 9 – 19) compared to 7 days (IQR 5 – 9), (p <0.01). Sarcopenic patients also spent 
more days in hospital over the subsequent year post-operatively with a median of 22 days 
(IQR 13 – 33.5) in hospital compared to 7 days (IQR 5 – 10) in non-sarcopenic patients 
(p<0.01). This is likely accounted for by the high readmission rate in sarcopenic patients with 
rates of 44.3% at 90 days and 68.7% at 365 days, compared to rates of 14.5% and 20.0% 
respectively in non-sarcopenic patients. Sarcopenic patients were significantly more likely to 
be readmitted at both 90 and 365 days (p<0.01). Sarcopenic patients were significantly more 
likely to be discharged to a care facility, typically a rest home or hospital level of care, 
therefore losing their independence. 
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Table 3.2. Comparison of length of stay and days in hospital at 1 year between sarcopenic and non-
sarcopenic patients as assessed by Total Psoas Index (TPI).  
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Table 3.3. Comparison of post-operative outcomes between sarcopenic and non-sarcopenic patients as assessed by Total Psoas Index (TPI).  
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8.59 (5.08 – 14.9) 
 
<0.01 















6.30 (3.17 – 13.1) 
 
<0.01 
*Adjusted for Operative Access. 
 54 
Overall mortality was 1.4% at 90 days and 5.1% at one year. There was a significant 
difference in post-operative mortality between the two groups at 90 days and one year post-
operatively. Within the first year post-operatively, 13.9% (n=16) of sarcopenic patients died, 
compared to 0.9% (n=2) of non-sarcopenic patients (Adjusted OR 16.2, 95% CI 4.34 – 83.4, 
p<0.01). This significant difference persisted despite performing multivariable analysis, 
adjusting for operative access, tumour stage, patient age and gender.  
Post-operative complications occurred in 179 (51.1%) patients within 30 days. The 
majority of these were minor (Clavien-Dindo Grade I/II) and only 56 (16.0%) of patients had 
a major (Clavien-Dindo Grade III-V) complication. Sarcopenic patients were significantly 
more likely to suffer from any complication with 98 (85.2%) sarcopenic patients suffering 
from a complication compared to 81 (34.5%) non-sarcopenic patients (OR 15.4, 95% CI 8.39 
–29.7, p <0.01). They were also significantly more likely to have a major post-operative 
complication with 35 (30.4%) patients having a Clavien-Dindo III-V complication compared to 
21 (8.9%) of non-sarcopenic patients (p<0.01). Multivariable analysis was conducted using 
backward stepwise selection to assess the association between pre-operative patient factors 
and the development of post-operative complications.  All pre-operative demographic 
factors, including the presence of sarcopenia were included in the model. Sarcopenia alone 
remained a significant independent predictor of developing a post-operative complication 
(p<0.001). 
When assessing specific post-operative complications, 11 patients (3.1%) had an 
anastomotic leak requiring re-operation and a further 9 patients (2.6%) had an anastomotic 
leak requiring radiological drainage. Six of the patients with an anastomotic leak requiring 
re-operation and four of the patients requiring radiological drainage were sarcopenic. There 
was no difference in anastomotic leak rate between sarcopenic and non-sarcopenic patients, 
however low patient numbers limit comparison. There was no difference in the rates of 
post-operative bleeding or infective complications between sarcopenic and non-sarcopenic 
patients, however analysis is again limited by low numbers of individual complications.   
  
 55 
3.4.2 Frailty as assessed using the mFI 
Using the modified frailty index (mFI) as a marker of frailty, 101 patients (28.9%) 
were classified as frail. The mFI was significantly more time consuming and difficult to 
perform, talking approximately 15 minutes per patient and often requiring an extensive 
search of patient’s medical records. Demographic, clinicopathological and treatment 
variables of the frail and non-frail cohorts, as defined by their mFI, are displayed in table 3.4. 
When using the mFI as a marker of frailty, the frail cohort had the same median age as the 
sarcopenic cohort, at 77 years; as did the non-frail and non-sarcopenic cohorts, at 72 years. 
When using mFI, the median BMI was lower in the frail group, however, this did not reach 
significance, as it did when using TPI.  The remaining baseline characteristics between the 
frail and non-frail groups were very similar to those seen between the sarcopenic and non-
sarcopenic groups when using the TPI. This suggests that regardless of the method of frailty 
assessment, patients are stratified into similar cohorts demographically.  
With respect to patient outcomes when stratifying patients based on their mFI, these 
are summarised in tables 3.5 and 3.6. Frail patients have a significantly longer median length 
of stay and days in hospital at 1-year, when compared to non-frail patients (p<0.01). The 
absolute difference in median length of stay is less when using mFI as a discriminator 
compared to TPI (4 vs 6 days). Mortality, complication and readmission rates all remain 
significantly higher in the frail group compared to the non-frail group, however the strength 
of the odds ratios presented is less than when compared to those using TPI. Again, this 
highlights that despite the assessment tool, frail (or sarcopenic) patients have worse post-
operative outcomes.  
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Table 3.4. Baseline demographics and clinicopathological characteristics when using modified frailty 
index (mFI) as determinant of frailty. 
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Table 3.5. Comparison of length of stay and days in hospital at 1 year between frail and non-frail 
patients as assessed by modified frailty index (mFI).  
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Table 3.6. Comparison of post-operative outcomes between frail and non-frail patients as assessed 
by modified frailty index (mFI). 
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*Adjusted for Operative Access, AJCC tumour stage, Age and Gender. 
 
3.5 Discussion: 
Sarcopenia and frailty are commonly encountered in the older patient, and this 
population is increasing disproportionately in western societies, as outlined in Chapter 1. 
With expanding indications for surgery, advances in perioperative medicine combined with 
an expectation of reasonable quality of life and function, surgery in this age group will 
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become more common.  Preoperative identification and risk assessment of these patients is 
an increasingly important topic as it may allow for treatment modification and altered 
decision making154. Given 27% of patients in this study are treated with some form of neo-
adjuvant therapy, this may offer an opportunity for prehabilitation with a view to optimise 
outcomes. Exercise and prehabilitation in preparation for surgery is associated with a lower 
postoperative complication rate155 and earlier restoration of functional status156. 
The majority of frailty assessment tools are cumbersome, time-consuming and 
difficult to perform82, and are often more suited to the research environment. The modified 
frailty index, although limited to 11 items, still fits into this category. Some of this limitation 
may be due to our study being retrospective in nature, and therefore calculation required a 
thorough review of the patients’ medical records. The use of CT images, which are routinely 
obtained preoperatively, offers an attractive opportunity to quantify muscle mass quickly 
and provide a risk assessment, without any additional cost or further assessment.  
This study has confirmed that sarcopenia can be easily and reliably identified by using 
the cross-sectional area of the psoas muscle assessed radiologically. This measurement of 
sarcopenia is a useful predictor of surgical morbidity and mortality. The presence of 
sarcopenia was significantly associated with a prolonged length of hospital stay, high post-
operative complication rate, readmission rate and discharge to care facilities. Extended 
length of hospital admissions and post-operative complications can potentially offset any 
oncological benefit gained from surgery157.  After multiple stepwise regression analysis, 
sarcopenia alone remained an independent predictor of post-operative morbidity. The 
strong interobserver correlation seen in our study suggests that this measurement is easily 
reproducible and thus is an accurate, objective marker of sarcopenia.  
The findings in this study are consistent with the conclusions in the review by 
Joglekar et al.144 which evaluated the impact of sarcopenia on post-operative outcomes in 
patients undergoing oncological surgical intervention. They concluded that sarcopenia was 
an independent prognostic factor for complications and survival following surgical resection 
of malignancy and that it can be easily quantified using preoperative CT imaging.  
Sarcopenia has been shown to be predictive of post-operative mortality in patients 
undergoing oncological colorectal surgery in other studies. Reisinger et al.97 identified 
sarcopenia, as measured radiologically to be an independent predictor of 30-day mortality in 
a population of 310 patients. Similarly, Boer et al.158 showed in a series of 91 patients that 
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sarcopenia was predictive of a reduced 1-year overall survival. Miyamoto et al.159 showed 
sarcopenia to be associated with a significantly reduced 5-year overall and recurrence free 
survival in 220 patients undergoing curative colorectal cancer surgery. Despite not 
identifying a significant difference in early post-operative mortality in our cohort, we did 
identify a significant difference in survival at 1-year, consistent with the findings of the above 
studies. 
Consistent with our results, a number of studies have shown sarcopenia to be 
associated with post-operative morbidity and complications in patients undergoing 
colorectal cancer surgery. In a series of 100 patients, Jones et al.94 demonstrated that 
sarcopenia was associated with a significantly increased risk of developing a major 
complication (Clavien-Dindo III – V). Both Nakanishi et al160 and Boer et al158 identified 
sarcopenia as a significant predictor of morbidity in colorectal cancer patients.  Similarly, 
Lieffers et al161, in a cohort of 234 patients, showed a significantly increased length of stay, 
rate of post-operative infection and delayed recovery in sarcopenic patients undergoing 
colorectal cancer surgery.  
In the present paper, a significant number of patients with sarcopenia had a normal 
or elevated BMI. The presence of obesity in combination with sarcopenia is increasing 
worldwide, and this population is synergistically at potential risk of complications related to 
both sarcopenia and obesity162. In the present paper, we did not perform a subset analysis of 
outcomes in the sarcopenic obese, however, there is currently limited published literature, 
and future research should focus on this expanding subset of patients. One limitation of the 
TPI as a measurement, is that it does not adjust for a patient’s body mass index. A number of 
adjusted thresholds for the diagnosis of sarcopenic based on a patient’s body mass index 
have been described.163, 164 
A strength of our study is its relatively large sample size compared to the current 
literature in this field. Prior studies by Boer et al.158 and Jones et al.94 only included 91 and 
100 patients respectively. Whereas, Reisinger et al.97 who included 320 patients, only 
followed their cohort of patients for 90 days. In our study, despite not seeing a difference in 
mortality in the short term, by assessing mortality at 1-year we were able to identify a 
significant difference in sarcopenic patients.  
Several limitations should be considered when interpreting data from this study. 
Firstly, although radiological assessment of muscle mass may indicate the presence of 
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“myopenia”, or reduced muscle mass, the diagnosis of sarcopenia requires impairment of a 
patient’s physical function145, which cannot be assessed radiologically. A patient’s TPI may 
be suggestive, but not diagnostic of sarcopenia. Secondly data were collected 
retrospectively, therefore potentially affecting quality. Thirdly, despite a large sample size of 
350 patients, data were derived from a single institutional experience with relatively 
homogeneous ethnicity, and thus may not be generalisable to other centres. Finally, we 
were unable to account for or comment on other important patient outcomes such as 
quality of life, energy levels and level of function post-operatively. These outcomes are 
important patient centred factors and should be considered in future research.  
3.6 Conclusion: 
Sarcopenia and frailty are important concepts in surgical practice but are often 
difficult to evaluate in the clinical setting. Preoperative identification may be useful as it can 
significantly alter decision making and treatment plans. A routinely performed preoperative 
CT scan provides clinicians an opportunity to quantify sarcopenia using the psoas cross-
sectional area and stratify individual patient’s risk accordingly. It avoids further radiation and 
inconvenience of further assessment. Measurement of TPI is a quick and reliable method of 





Clinical Frailty Assessment and Post-Operative Outcomes 
Abstract 
Introduction: Due to the association between frailty and adverse post-operative outcomes 
there is a clinical need the accurate identification of frailty in the pre-operative setting. 
Multiple assessment tools exist; however, no single tool has been identified as a “gold 
standard”. The Edmonton Frail Scale (EFS) offers many advantages in the clinical setting.  
Aim: To determine the association between frailty, as assessed using the EFS and post-
operative outcomes in patients undergoing elective colorectal cancer surgery. To compare 
the predictive ability of the EFS with two other commonly used frailty assessment tools.  
Methods: A prospective analysis of 86 older patients undergoing elective resection for 
colorectal cancer at a tertiary centre between October 2017 and October 2018 was 
performed. Frailty assessment was conducted preoperatively using the EFS. Primary 
outcomes included length of stay and 30-day post-operative complication rates. 
Multivariable logistic regression analyses were used to analyse the influence of frailty, and 
other preoperative variables, on post-operative outcomes including mortality, prolonged 
hospital admission and complication rates. The predictive ability of the EFS was compared 
with the modified frailty index (mFI) and the total psoas index (TPI). 
Results: Of 86 patients, 12 (14.0%) were identified as frail using the EFS. Frailty was 
associated with a significantly increased length of stay, (20 days vs 6 days, IRR 2.83, 95% CI 
2.10 – 3.86, p<0.01) and a significantly increased risk of major post-operative complications 
(50.0% vs 6.7%, OR 13.8, 95% CI 3.31 – 63.1, p<0.01). Frailty was not associated with an 
increased reduction of patient quality of life at 30 and 90 days. The EFS had a similar 
predictive ability to both the mFI and the TPI. 
Conclusion: Frailty is associated with adverse post-operative outcomes in elderly patients 
undergoing elective colorectal cancer surgery. Despite this, frail patients do not experience a 
greater reduction in quality of life. The Edmonton Frail Scale offers an attractive pre-
operative assessment tool as it is quick and easy to perform and identifies possible targets 
for pre-operative optimisation.  
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4.1 Introduction: 
Due to the association between frailty and adverse post-operative outcomes in the 
elderly there is a clinical need for an accurate method of identifying frailty in the pre-
operative setting. This would facilitate patient risk stratification and aid in appropriate, 
informed treatment selection. It also has the potential to allow for modification of aspects of 
frailty through “prehabilitation”. As discussed in Chapter 1, there are several competing 
methods in the literature for the measurement of frailty, however, no clear “gold standard” 
has been identified. The major limitations of currently available tools are that they are often 
cumbersome to perform, and they have typically been developed for use in a research 
setting and often not validated in a clinical setting29.  
Traditionally frailty has been assessed in the clinical setting using the “eyeball” end of 
the bed test, where clinicians would subjectively assess whether they though a patient was 
fit for surgery. This has shown to be inconsistent with poor inter-clinician reliability and 
correlation with outcomes165. As outlined in Chapter 1, there are two broad categories of 
frailty assessment tools; phenotypic and index-based tools.  
Fried et al. proposed a frailty phenotype, which can be measured by using five 
domains: slow gait, weak hand-grip strength, weight loss, self-reported exhaustion and low 
physical activity35.  Often used in the domain of research, key limitations of phenotypic tools 
are a focus predominantly on the physical aspect of frailty and that they typically are binary 
in nature classifying patients as frail or non-frail. 
Multiple frailty indices exist in the literature. Initially based on the accumulation of 
deficits model by Rockwood et al.43, multiple derivations exist with most tools assessing 
between 30 and 70 domains. The large range of deficits measured considers the 
multidimensional nature of frailty. This approach seeks to mathematically determine the 
ratio of deficits present in an individual in relation to the number of deficits being measured.  
In contrast to the dichotomised approach of a frailty phenotype, a frailty index can be 
regarded as a continuous variable allowing for a gradation of severity of frailty. Typically, 
various cut-off points are considered to identify frailty. The exact list of deficits has been 
shown not to matter, other than that they should increase in incidence with age, be 
reflective of a range of physiological systems and be associated with heath and not age per 
se166. The main limitation of frailty indices is that they are often time consuming to calculate 
and their mathematical nature tends to render them unpopular clinically82.  A recent 
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systematic review of frailty measurement tools concluded that the most suitable tool for 
frailty research was a frailty index45. No review has identified the most appropriate tool in a 
clinical setting.  
In a clinical setting the ideal frailty assessment should have high predictive ability and 
be quick and easy to perform83. Single performance measures such as the timed up and go 
(TUG) and grip strength can be performed rapidly and are thus attractive, however, their 
predictive ability is limited84.  
The Edmonton Frail Scale (EFS) is an easy to perform tool that has been widely 
studied in the clinical setting11, 80, 93, 167, 168. It is a multidimensional tool assessing various 
domains of frailty including a TUG and cognitive assessment80. One if its main advantages is 
that it takes less than five minutes to perform and is feasible for use by non-geriatricians92. It 
is scored out of seventeen and has nine components as outlined in Chapter 1 and below in 
Figure 4.1. Scores of zero to five are typically regarded as non-frail, six to seven as vulnerable 
and eight or more as frail. Its diagnostic accuracy has been reviewed in the hospital setting28, 
80, 93. One of its benefits is its ability to identify aspects of frailty that may be amenable to 
preoperative optimisation, such as polypharmacy and a lack of social support15, 28. 
 
 
Figure 4:1. Components of the Edmonton Frail Scale. Reproduced with permission from Dasgupta et 
al28 
 
Rolfson et al80 evaluated the validity and reliability of the EFS in a population of 
patients undergoing CGA aged 65 years or older in Alberta, Canada. A total of 158 patients 
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were assessed, 60% of these were in the outpatient setting. They concluded that the EFS 
took less than 5 minutes to complete and had good inter-rater reliability (κ = 0.77, P = 
0.0001).  The EFS was found to correlate well with the geriatrician’s clinical impression of 
frailty, obtained during their CGA. Advantages when compared to completing a CGA are its 
rapid administration and the ability for it to be used by non-geriatricians. Meyers et al.93 
found similar utility in colorectal cancer patients undergoing adjuvant treatment. Perna et 
al.167 also found that the EFS correlated well with other markers of frailty such as grip 
strength, comorbidity index, nutrition and functional state.   
The EFS meets many of the characteristics of an instrument to measure frailty that 
could be used in a routine surgical practice and it is recommended by the British Geriatric 
Society for the assessment of frailty in a perioperative setting80. Due to its strengths in a 
clinical environment, as outlined above, we decided to use it as our primary frailty 
assessment tool in this study. We also chose to assess frailty using two other methods, the 
modified frailty index (mFI) and total psoas index (TPI), to act as comparators to the EFS.  
4.2 Aims: 
The aims of this study were to: 
-  Assess the utility of the Edmonton Frail Scale in the identification of frailty pre-
operatively and in the prediction of post-operative outcomes.  
- Compare the Edmonton Frail Scale to both the modified frail scale and total psoas 
index, used as frailty assessment tools in Chapter 3. 
4.3 Methods: 
4.3.1 Patient Population: 
A prospective observational study of older patients presenting for elective colorectal 
surgery was performed. Older patients (defined as aged 65 years or older) undergoing 
elective colorectal resection between October 2017 and October 2018 at Christchurch Public 
Hospital were identified and recruited prospectively through surgical outpatient and 
preadmission clinics. Inclusion criteria were: (i) age 65 years or older; (ii) undergoing an 
elective colorectal abdominal operation within six months; (iii) ambulatory, including with 
the use of walking aids. Exclusion criteria were: (i) inability to obtain valid consent; (ii) stoma 
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reversal surgery; (iii) non-abdominal procedures; (iv) non-ambulatory patients; (v) non-
elective surgery. 
Following identification and confirmation of eligibility, informed consent was 
obtained, and patients were enrolled on a prospectively collected, anonymised computer 
database. Details of patient demographics, body mass index (BMI), American Society of 
Anaesthesiologists (ASA) grade, tumour location and living status were collected at 
enrolment. Mobility status was also recorded, namely whether any walking aids were used. 
Fatigue levels at enrolment were recorded on a visual analogue scale (VAS) from 0 to 10, 
with 10 being the most fatigue imaginable and 0 being no fatigue, Baseline quality of life was 
assessed using the SF-12 questionnaire169 (Appendix B). Operative details including type of 
surgery, surgical access, intra-operative complications, tumour stage (based on the American 
Joint Committee on Cancer 7th edition170) and neoadjuvant treatment were also recorded on 
the study database.  
Postoperative management was not altered by the study and the clinicians caring for 
the patients during their post-operative stay were not part of the study protocol. Post-
operative outcomes assessed included mortality, length of hospital stay, the development of 
post-operative complications, readmission and discharge to a care facility. Post-operative 
complications were graded according to the Clavien-Dindo classification, with major 
complications defined as a score of ≥3151. Patients were assessed post-operatively for 
delirium by the geriatrics service using the Confusion Assessment Method (CAM) tool171. 
Patients were followed up at 30 and 90 days and fatigue, quality of life and EFS were 
reassessed at these time points.  
4.3.2 Frailty assessment: 
Pre-operative frailty was assessed on all patients using three techniques; the 
Edmonton Frail Scale (EFS), the modified frailty index (mFI) and the total psoas index (TPI). 
The EFS was performed at the point of recruitment by one of two trained assessors (SR or 
MF) on a standardised proforma (Appendix C). A score was calculated out of seventeen and 
patients were classified as either frail or non-frail. Patients scoring 8 or more were classified 
as frail. As outlined above, the EFS was again performed at 30 and 90 days post-operatively 
by the same assessors.  
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Pre-operative TPI measurement was performed on all patients using their pre-
operative staging CT scan of the abdomen and pelvis, performed within 90 days prior to 
surgery. All images were reviewed on standard desktop screens by a trained observer (SR). 
TPA was assessed in the axial plane at the level of the third lumbar vertebrae (L3) with both 
transverse processes being visible. TPA was measured in a semi-automated fashion, with 
manual outlining of both the left and right psoas muscle borders at the L3 level96. This area 
was then normalised for patient height (TPA/(height [m] x height [m]) to calculate the TPI. 
Frailty was defined using gender specific thresholds of <385mm2/m2 for female patients and  
<545mm2/m2 for male patients, based on values defined by an international consensus 
group for the diagnosis of cachexia and malignancy152, and used in other similar studies94, 97 
A pre-operative mFI was calculated for each patient from the patients’ electronic 
medical records. As outlined in Chapter 3 a composite score derived from 11 conditions 
identified by the Canadian Study of Health and Aging mapped to the American College of 
Surgeons NSQIP database149 was obtained. Patients with a score of ≥0.27 (or 3 positive 
components) were considered frail.  
4.3.3 Outcomes: 
Primary outcomes assessed were length of hospital stay and the occurrence of any 
and major post-operative complications within 30 days, graded according to the Clavien-
Dindo classification. Secondary outcomes were assessed at 30 and 90 days post-operatively 
and included: patient mortality, unplanned readmission, the need for support on discharge, 
discharge destination, patient fatigue and quality of life. 
4.3.4 Ethics: 
This study was approved by the New Zealand Health and Disability Ethics Committee 
reference 17/CEN/170. Locality approval was obtained from the Canterbury District Health 
Board. This study was registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN126180000452130). 
4.3.5 Statistical Analysis: 
Based on our estimate of the prevalence of frailty in Chapter 2 and the prevalence of 
frailty in the literature48, 172, it is assumed that 20% of the study population will be frail. We 
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sought to identify a minimum effect size of one day difference in hospital length of stay 
between frail and non-frail patients.  For the purpose of this study, frailty was defined as 
having an Edmonton Frail Scale score of 8 or above, as described above. To achieve an 80% 
power with a 2-tailed p-value of less than 0.05, a sample size of 78 was required. To account 
for attrition 100 patients were recruited.  
Statistical analysis was based on an intention to treat analysis. Continuous variables 
were reported as medians with interquartile range (IQR) and categorical variables as whole 
numbers and percentages. Univariable analysis was performed to compare baseline 
characteristics between frail and non-frail patients. This included chi-square tests for 
categorical variables and Mann-Whitney U-test for non-parametric continuous variables. 
Multicollinearity between predictor variables was assessed by variance inflation factor (VIF), 
with scores of over 3 taken to denote unacceptable collinearity. 
Multivariable logistic regression analysis was performed on pre-operative factors that 
were predicted to affect post-operative outcomes using backward stepwise selection based 
on Akaike Information Criterion (AIC). Pre-operative factors with a p value of <0.10 on 
univariate analysis were included in the model.  Model performance was assessed using 
Harrell’s concordance index (C-index). Regression coefficients from multivariable analysis 
were reported as odd’s ratios (OR) with 95% confidence intervals (95% CI). Length of stay 
(LOS) and days in hospital at 90 days were evaluated as Poisson count data, were 
determined to be over-dispersed and as such, analysed using negative binomial regression. 
Incidence rate ratios from these analyses were interpreted as the relative number of days in 
the hospital when compared the reference (non-frail) group. P values <0.05 were considered 
statistically significant. 
The association between each and/or combinations of the different frailty measures 
and subsequent post-operative outcomes were modelled using binary logistic regression 
creating receiver operating characteristic (ROC) curves. The predictive power was measured 
using the area under the curve (AUC). All statistical analysis was performed using RStudio 
software (version 3.3.2; www.rstudio.com) or SPSS, version 25 (IBM). 
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4.4 Results:  
4.4.1 Baseline demographic and clinicopathological characteristics: 
Of 119 patients screened for eligibility, a total of 101 patients were identified that 
met the inclusion criteria and were recruited into the study. Subsequently, 15 patients 
dropped out, six of which no longer required or decided against surgery, six who withdrew 
consent and three who presented acutely. A total of 86 patients were therefore included in 
the final analysis. The patient recruitment process is outlined in Figure 4.2. Eighty-six 
patients (100%) completed follow up to 30 days, and 78 patients (90.7%) completed follow 
up to 90 days. Of the eight patients who did not complete 90 day follow up, two had died, 
one had moved out of the region and the remaining five declined.  
 
 
Figure 4:2. Patient recruitment overview 
 
Patients screened for eligibility
n = 119




- - No longer requiring surgery n =6
- Withdrawn consent n = 6
- Acute presentation n = 3
Included in statistical analysis
n = 86 
Patients excluded as ineligible
n = 19
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There was no significant difference in the age (p = 0.68) or gender (p = 0.84) of those 
patients who dropped out when compared to the studied population.  Of the 86 study 
patients, 12 (14.0%) were classified as frail as per the EFS.  
Baseline demographic, clinicopathological and treatment variables are shown in 
Table 4.1. The median age of the study population was 76 years (IQR 72 – 81). Frail patients 
were significantly older than non-frail patients with a median age of 80.5 years (IQR 77 – 82) 
compared to 75 years (IQR 70 – 79), (p=0.02). Frail patients were more likely to be male with 
66.7% (n =8) of frail patients being make compared to 47.3% (n =35) of non-frail patients, 
however, this difference was not statistically significant (p=0.22). 
The majority of study patients were New Zealand European (90.7%), and there were 
too few patients to identify any differences in the prevalence of frailty between ethnicities 
within our population. The median BMI of the study population was 27.0 kg/m2 (IQR 24.4 – 
32.0) and there was no difference in the median BMI between frail and non-frail patients (p 
= 0.96). Frail patients had a significantly higher baseline ASA score, with 91.7% (n=11) of frail 
patients being classified as either ASA III or IV, compared to 40.5% (n=30) of non-frail 
patients, (p<0.01). All non- frail patients (n=74) came from their own home and were 
independent at baseline, compared to 83.3% (n=10) of frail patients. 2 frail patients required 
assisted care at baseline, being in a residential care facility.  
Frail patients had a higher baseline level of fatigue based on a score of 0-10 on a 
visual analogue scale (VAS). Frail patients had a median score of 5 (IQR 2-5) and a mean 
score of 4.1 (SD=1.6) and non-frail patients had a median score of 2 (IQR 1-5) and a mean 
score of 2.9 (SD=2.4), respectively. This difference was not statistically significant (p=0.11). 
Frail patients had a significantly poorer physical component score (PCS) on the baseline SF-
12 questionnaire with a median score of 32.8 (IQR 30.0 – 40.4), when compared with non-
frail patients who had a median score of 49.7 (IQR 39.4 – 54.5), (p<0.01). Frail patients also 





Table 4.1. Baseline demographics and clinicopathological characteristics of the study population. Frailty classified using the Edmonton Frail Scale with a score of ≥8 
representing frailty. 












Univariable Odds Ratio 
(95%CI) 
p-value 
 Age (y) Median (IQR) 76 (72 – 81) 75 (70 – 79) 80.5 (77 – 82) 1.14 (1.03 – 1.27) 0.02 
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0.82 (0.20 – 2.87) 





ASA (n, %) 1 – 2 


























(VAS 0 – 10) 
Median (IQR) 2 (1 – 5) 2 (1 – 5) 5 (2 – 5) 1.24 (0.95 – 1.64) 0.11 
Baseline Fatigue 










0.52 (0.03 – 3.11) 
 
0.55 
Baseline SF-12 PCS Median (IQR) 46.4 (38.9 – 53.2) 49.7 (39.4 – 54.5) 32.8 (30.0 – 40.4) 0.88 (0.81 – 0.95) <0.01 
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There was no significant difference in tumour location (p=0.15), tumour stage 
(p=0.26) or the use of neo-adjuvant treatment between frail and non-frail patients. 
When categorising patients as frail using the mFI and TPI, 46.5% (n=40) and 26.6% 
(n=22) were categorised as frail, respectively. Of the 12 patients classified as frail using the 
EFS, 100% were also classified as frail using the mFI and 91.7% using the TPI. Of note, when 
classified as non-frail using the EFS, 37.8% (n=28) were classified as frail using the mFI and 
14.9% (n=11) using the TPI. Given it identified almost half of the patients as frail, the mFI was 
the least selective of the three methods used.  
Operative characteristics of the patients are outlined in Table 4.2.  Significantly more 
frail patients had an open operation, 75.0% (n=9), compared to non-frail patients, 37.8% 





Table 4.2. Operative characteristics of the study population. Frailty classified using the EFS and a score of ≥8 represents frailty.  
















































4.17 (1.19 – 16.9) 
 




































0.82 (0.65 – 1.05) 
 
0.10 
























Frail patients were more likely to end up with a stoma, either permanent or 
temporary, when compared to non-frail patients, (p=0.03). There was no difference in 
patients who had a stoma formed with permanent intent, (p=0.46), suggesting frail patients 
were more likely to be given a temporary, or covering stoma. This is likely due to the 
potential catastrophic nature of an anastomotic leak in a frail patient.  The literature 
shows173 that over half of elderly frail patients with a temporary stoma do not get this 
reversed, therefore the rate of permanent stoma formation in our cohort is likely higher. 
Frail patients were more likely to have a drain placed at the time of surgery; however, this 
difference was not statistically significant (p=0.60).  
Frail patients had both a shorter median operative time and total theatre time. This is 
likely accounted for by the higher percentage of open and colonic procedures in frail 
patients.  Frail patients may have also had more limited resections performed, due to their 
perceived peri-operative risk, however, this was not examined.  
4.4.2 Post-operative outcomes: 
Tables 4.3 and 4.4 summarise post-operative outcomes and complications. The 
overall median length of stay was 7 days (IQR 5 – 11). Frail patients had a significantly longer 
length of stay when compared with non-frail patients, staying a median of 20 days (IQR 10 – 
30) compared to 6 days (IQR 5 – 11), (p<0.01). Frail patients also spent significantly more 
time in the intensive care or high dependency units, (p<0.01). At 90 days follow up, frail 
patients had spent a median of 26 days (IQR 16 – 36) in hospital compared to non-frail 
patients who spent a median of 7 days (IQR 5 – 11), (p<0.01).  
 
Table 4.3. Comparison between length of stay and days in hospital at 90 days between frail and non-
frail patients as assessed by the Edmonton Frail Scale (EFS).  
Post-operative outcomes All Patients 
 (n = 86) 
Non-Frail 
 (n = 74) 
Frail 











5 – 11 
6 
5 – 9 
20 
10 – 30 
 
2.83 (2.10 – 3.86) 
 
<0.01 
ICU / HDU 





0 – 1 
0 
0 – 1 
2 
1.75 – 2.25 
 
4.83 (2.66 – 8.83) 
 
<0.01 
Days in Hospital 




5 – 13 
7 
5 – 11 
26 
16 – 36 
 
3.83 (2.71 – 5.56) 
 
<0.01 
*Adjusted for Age, Gender, Tumour Stage and Operative Access. 
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There were only 2 patient deaths at 90 days across all patients, however both 
occurred in the frail cohort, giving this cohort a 90-day mortality rate of 16.7%. Low patient 
numbers and short follow up limit the evaluation of differences in mortality, and this study 
was not designed for such. Frail patients had significantly higher rates of post-operative 
morbidity.  Post-operative complications occurred in 47 patients (54.7%) within 30 days. Frail 
patients were more likely to suffer from any complication when compared to non-frail 
patients, (OR 11.6, 95% CI 2.10 –218, p=0.02). Similar rates of minor (Clavien-Dindo I or II) 
complications occurred between frail and non-frail patients, (p=0.99), however, frail patients 
had a significantly higher rate of major complications (Clavien-Dindo III to V). Of the frail 
patients, 50% had a major complication, compared to 6.7% of the non-frail patients, (OR 
13.8, 95% CI 3.31 – 63.1, p<0.01). 
Multiple stepwise regression analyses were performed on age, gender, operative 
access, tumour location, tumour stage and the presence of frailty.  Frailty alone remained a 
significant independent predictor of having a prolonged hospital admission (p<0.01) 
developing a post-operative complication (p=0.02) and a major post-operative complication 
(p=0.01). 
Frail patients were more likely to require support on discharge or to be discharged to 
a rehabilitation unit or care facility. 58.3% of frail patients were discharged to a care facility 
or rehabilitation unit, compared to 6.8% of non-frail patients, (p<0.01) and 66.7% of frail 
patients were discharged with added supports compared to 10.8% of non-frail patients, 
(p<0.01). These outcomes are typically associated with a loss of functional independence. 
Despite additional support on discharge, frail patients were significantly more likely to be 
readmitted to hospital at 90 days post-operatively. At 90 days, 41.7% of frail patients had 
been readmitted at least once, compared to 14.9% of non-frail patients, (p=0.04).  
At 30 days post-operatively, 95.9% of non-frail patients had returned to their own 
homes independently, compared to only 41.7% of frail patients. 25% of frail patients were 
home with additional care, 8.3% were in a care facility and 25% were hospital inpatients. 
Frail patients were significantly more likely at 30 days to be in hospital, a care facility or 
requiring additional care at home. Similar results were seen at 90 days post-operatively, 
(Table 4.4). 
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At 30- and 90-days frail patients had higher levels of fatigue, when assessed using a 
visual analogue scale. Fatigue levels at follow up, however, did not change significantly from 
baseline levels, suggesting frail patients did not experience more fatigue as a result of the 
operation. At 30 days post-operatively, frail patients had a significantly lower physical 
component score (PCS) on the SF-12, but no difference in the mental component score 
(MCS), as seen pre-operatively. Similar results were seen at 90 days with frail patients having 
lower PCS scores, but similar MCS scores to non-frail patients. Of note, non-frail patients had 
a more significant median decrease in the physical component of the SF-12 compared to frail 
patients, which had not completely recovered by 90 days, however, frail patients attained 
higher scores on physical component by 90 days follow up (Figures 4.3, 4.4).  
 
 
Figure 4:3. Physical Component Scores of Frail and Non-Frail patients, as determined by EFS at 




Figure 4:4. Physical Component Scores of Frail and Non-Frail patients, as determined by EFS at 





Table 4.4. Comparison of post-operative outcomes between frail and non-frail patients as assessed by the Edmonton Frail Scale.  
Post-operative outcomes All Patients 
 
 








(n = 12) 
14.0% 
Adjusted Odds 
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11.6 (2.10 – 218) 
 
0.99 (0.27 – 3.39) 
























9.23 (2.23 – 63.1) 
 
0.03 









4.09 (1.05 – 15.3) 
 
0.01 
Discharge to Rehabilitation or Care 










19.3 (4.68 – 91.4) 
 
<0.01 









16.5 (4.27 – 74.8) 
 
<0.01 
Post-operative day-30 Living Status 
(n, %) 
Home independent 















0.03 (0.01 – 0.14) 
12.0 (1.77 – 101) 
- 





Post-operative day-90 Living Status 
(n, %) 
Home independent 











0.06 (0.01 – 0.25) 








Post-operative outcomes All Patients 
 
 








(n = 12) 
14.0% 
Adjusted Odds 















Post-operative day-30 Fatigue (VAS) Median 
(IQR) 
3 
(2 – 5) 
2 
(2 – 5) 
5 
(4.75 – 6.25) 
 
1.54 (1.08 – 2.19) 
 
0.02 









2.86 (0.67 – 10.9) 
 
0.07 
Post-operative day-90 Fatigue (VAS) Median 
(IQR) 
4 
(2 – 5) 
4 
(2 – 5) 
6 
(4 – 7.25) 
 
1.52 (1.07 – 2.11) 
 
0.01 













3.67 (0.79 – 17.2) 
 
0.09 
Post-operative day-30 SF-12 PCS Median (IQR) 38.2 (31.0 – 44.3) 39.5 (32.6 – 45.2) 31.3 (28.1 – 44.3) 0.81 (0.70 – 0.95) 0.01 
Post-operative day-30 SF-12 MCS Median (IQR) 54.6 (48.7 – 58.6) 54.6 (49.9 – 59.1) 54.1 (41.4 – 56.1) 0.92 (0.84 – 1.01) 0.14 
Post-operative day-90 SF-12 PCS Median (IQR) 42.3 (38.1 – 56.6) 43.4 (38.4 – 51.7) 38.5 (35.1 – 40.8) 0.90 (0.77 – 1.05) 0.18 
Post-operative day-90 SF-12 MCS Median (IQR) 57.0 (54.0 – 59.8) 57.4 (54.2 – 59.8) 52.6 (44.3 – 61.1) 0.89 (0.81 – 0.99) 0.03 
*Adjusted for Age, Gender, Tumour Stage and Operative Access.  
 
 80 
4.4.3 Comparison with other frailty measures: 
When defining frailty, using either the modified frailty index (mFI) or total psoas 
index (TPI), similar post-operative outcomes were observed to the findings above 
(Supplementary Tables S4.1 – S4.4).  Regardless of method of frailty assessment, frailty is 
associated with an increased length of hospital stay, increased rate of post-operative 
complications, increased readmission rate and increased rates of support on discharge.  
The predictive power of the three measure of frailty (EFS, mFI and TPI) with regards 
to post-operative outcomes was assessed using the area under the receiver operating 
characteristic curve (AUC). The post-operative outcomes assessed were; length of hospital 
stay greater than 7 days, the development of any complication (Clavien-Dindo I – V) and the 
development of a major complication (Clavien-Dindo III – V).  When assessing the ability of 
the frailty assessment measures to predict whether a patient has a length of stay of greater 
than 7 days on index admission, the total psoas index (TPI) has the greatest predictive ability 
at 71%, compared to the Edmonton Frail Scale (EFS) at 67% and the modified frailty index 
(mFI) at 63%, (Figure 4.5, Table 4.5). The combination of TPI and either of the two other 
measures offers the best predictive ability at 75%, the addition of a third measure offers 
little further predictive ability. In contrast, age only has a predictive ability of 58% and ASA of 
62%, (Table 4.5).  
 
 
Figure 4:5. Receiver Operator Characteristics (ROC) Curve demonstrating the ability of the frailty 
measures to predict a length of hospital stay of more than 7 days.  
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Table 4.5. Receiver Operating Characteristics Area under the Curve (AUC) by predictor for the 
outcome of prolonged LOS of more than 7 days.  
Test Result Variable(s) AUC p - value 
95% Confidence Interval 
Lower Bound Upper Bound 
Edmonton Frail Scale (EFS) .667 .008 .548 .787 
Total Psoas Index (TPI) .717 .001 .609 .824 
(Modified Frailty Index (mFI) .633 .036 .509 .756 
EFS + mFI + TPI .754 .000 .652 .857 
mFI + TPI .746 .000 .642 .849 
mFI + EFS .669 .008 .550 .789 
TPI + EFS .753 .000 .650 .856 
Age .581 .201 .460 .702 
ASA .622 .054 .503 .742 
 
When assessing the ability of the frailty assessment measures to predict whether 
patients will have a post-operative complication the TPI has the greatest predictive ability at 
69%, compared to the EFS at 64% and the mFI at 56%, (Figure 4.6, Table 4.6). The 
combination of all three measures increases this predictive ability to 72% and using the TPI 
and EFS offers a predictive ability for any complication of 70% (Table 4.6). Age only had a 
predictive ability of 58% and ASA 57%. The addition of age or ASA to any of the frailty 
measures did not improve the predictive ability. 
When assessing the same measures of frailty to predict whether patients will have a 
major post-operative complication (Clavien-Dindo III – V) the mFI has the greatest predictive 
ability at 78%, compared to the EFS at 74% and the TPI at 70%, (Figure 4.7, Table 4.7). In 
combination the mFI and the TPI provide a predictive ability of 83% as does the mFI, TPI and 
EFS (Table 4.7). Again, age and ASA have limited predictive ability at 63% and 56% 
respectively, and when added to any of the frailty assessment measures offer no 
improvement.  
Typically, an AUC value (c-statistic) of >0.8 indicates a strong model and is indicative 
of a good predictive test. As seen above (Figures 4.5 - 4.7), none of the assessment measures 




Figure 4:6. Receiver Operator Characteristics (ROC) Curve demonstrating the ability of the frailty 
measures to predict the occurrence of any complication (Clavien-Dindo I – V).  
 
Table 4.6. Receiver Operating Characteristics Area under the Curve (AUC) by predictor for the 
outcome of any complication (Clavien-Dindo I – V).  
Test Result Variable(s) AUC p – value 
95% Confidence Interval 
Lower Bound Upper Bound 
Edmonton Frail Scale (EFS) .639 .027 .522 .756 
Total Psoas Index (TPI) .686 .003 .573 .799 
(Modified Frailty Index (mFI) .561 .336 .439 .682 
EFS + mFI + TPI .719 .000 .612 .826 
mFI + TPI .691 .002 .578 .803 
mFI + EFS .650 .017 .534 .767 
TPI + EFS .704 .001 .594 .814 
Age .579 .208 .454 .704 




Figure 4:7. Receiver Operator Characteristics (ROC) Curve demonstrating the ability of the frailty 
measures to predict the occurrence of a major complication (Clavien-Dindo III – V).  
 
Table 4.7. Receiver Operating Characteristics Area under the Curve (AUC) by predictor for the 
outcome of a major complication (Clavien-Dindo III – V).  
Test Result Variable(s) AUC p – value 
95% Confidence Interval 
Lower Bound Upper Bound 
Edmonton Frail Scale (EFS) .739 .011 .554 .925 
Total Psoas Index (TPI) .701 .032 .535 .866 
(Modified Frailty Index (mFI) .779 .003 .624 .935 
EFS + mFI + TPI .825 .001 .704 .947 
mFI + TPI .825 .001 .707 .944 
mFI + EFS .777 .003 .615 .939 
TPI + EFS .779 .003 .616 .943 
Age .628 .171 .462 .795 
ASA .563 .501 .376 .750 
 
4.5 Discussion: 
Multiple methods of frailty assessment exist45, however, no single tool to date has 
been identified as being a “gold standard” for use in the clinical setting. In the busy clinical 
environment, an assessment tool needs to be quick and easy to perform whilst being able to 
accurately identify the presence of frailty.  In this prospective study, the presence of pre-
operative frailty was associated with adverse post-operative outcomes, regardless of the 
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method of frailty assessment utilised. Patients identified as frail had longer hospital 
admissions, increased rates of post-operative complications, unplanned readmissions and 
required additional care on discharge.  After multiple stepwise regression analysis, frailty 
alone remained an independent predictor of post-operative morbidity in the form of 
prolonged hospital admissions and complications.  
Similar results have been described in a number of other studies in the literature, 
using various frailty assessment tools79. Despite differing methods of frailty assessment, the 
systematic review and meta-analysis by Oakland et al79 highlights that across 12 studies, 
frailty in surgical patients was associated with increased risk of post-operative morbidity and 
mortality.  
Most surgical studies investigating frailty focus on hospitalisation outcomes such as 
length of stay, complication rates or oncological outcomes174, 175. This, however, is often not 
what is considered important to elderly patients and incompletely describes their recovery 
process. Functional status, fatigue levels and quality of life are often more important to this 
group of patients and may represent more relevant surgical outcomes.  
In the present study, frail patients had a significantly lower baseline physical 
component score (PCS) on the SF-12 quality of life assessment questionnaire when 
compared to non-frail patients, but a similar mental component score (MCS). Interestingly, 
although both groups had a lower PCS score at 30 days post-operatively, the non-frail group 
had a much larger decrease in score or deterioration in their physical quality of life. Both frail 
and non-frail patients had a slight decrease in the MCS score, however, there was no 
difference between the groups. This suggests that the predominant short-term effect of 
surgery is an impairment in patients’ physical quality of life.  
At 90 days the frail group had returned to their baseline PCS score, however, the 
non-frail group had a persisting decrease in their physical quality of life. This suggests that 
although frail patients have a lower baseline physical function and experience more adverse 
outcomes in the immediate post-operative period, they do not experience an increased 
reduction in quality of life post-operatively. Similar findings were seen with fatigue, as 
assessed using a visual analogue scale; frail patients have a higher baseline level of fatigue 
but were not subject to a greater increase in fatigue as a result of surgery. 
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Consistent with our findings, Rønning et al176 in a study of 180 elderly patients 
undergoing colorectal cancer surgery, concluded that although frail patients had a reduced 
baseline quality of life and an increased rate of adverse outcomes, they did not suffer from 
an increased reduction in quality of life as a result of surgery. Sikder et al175 also concluded 
that frailty was not associated with an increased reduction of quality of life or cognition as a 
result of surgery.  
When comparing the Edmonton Frail Scale (EFS) with the modified frailty index (mFI) 
and the total psoas index (TPI), each tool had a similar degree of accuracy when assessing 
their respective abilities to predict post-operative complications and a prolonged hospital 
stay as seen in Figures 4.5 – 4.7. A combination of tools was able to provide a minimal 
increase in predictive ability, however, adds further complexity limiting clinical use.  Given 
the similarities predictive ability, consideration needs to be given to their ease of 
administration and the potential ability to pre-operatively identify modifiable factors, such 
as polypharmacy.  
The EFS took less than 5 minutes to perform in our study and has been shown to take 
a similar time in other studies11, 80, 167. It also assesses multiple components of frailty and has 
the potential to identify modifiable factors including social support, nutrition and 
polypharmacy. Given 16.3% of patients had some form of neoadjuvant therapy pre-
operatively, often spanning a number of months, these factors may be addressed during this 
time period, thus transitioning patients to a lower level of frailty.  
The mFI took between 5 to 10 minutes to perform in our study, depending on how 
easily accessible the information was from the patient and/or their notes. It predominantly 
assesses patient comorbidities and disease history with a view to risk stratification and 
provides little insight into modifiable risk factors. As it identified almost 50% of the cohort as 
frail, it is less selective than the other 2 tools and as a pre-operative screening tool it is likely 
to identify too large a cohort suitable for pre-operative intervention. The TPI also required 5 
to 10 minutes to complete, additionally, it also required training by a radiologist prior to use 
and the use of a computer. Similarly, to the mFI, the TPI acts as a risk stratification tool and 
provides the ability to estimate the risk of post-operative mortality and morbidity to patients 
and their families. This information is important in pre-operative decision making and may 
alter treatment plans150, 177, however, it does not identify targets for pre-operative 
optimisation or prehabilitation.  
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We believe the Edmonton Frail Scale (EFS) offers many advantages as a frailty 
assessment tool in the pre-operative setting. The present study has confirmed the 
association between frailty, as defined by an EFS score of ≥8, and adverse post-operative 
outcomes. It is fast, easy to perform and shows good inter-observer validity. As a number of 
the components of the EFS are potentially amenable to intervention, future research 
focussing on post-operative outcomes after the modification of these factors would help to 
strengthen support for the use of this tool. 
A strength of this study is the inclusion of quality of life and functional outcomes in 
addition to the standard clinical outcomes. We also compare the predictive ability of our 
chosen assessment tool, the EFS, with two other commonly used frailty assessment tools. 
Several limitations should be considered when interpreting data from this study. Firstly, data 
were derived from a single institutional experience with a relatively homogeneous 
population, this limiting generalisability to other centres and countries. Secondly, data were 
only collected in elective colorectal cancer patients and therefore cannot be directly 
extrapolated to other surgical specialties or acute surgery. Findings from other studies, 
however, suggest similar results would be expected in other forms of major surgical 
intervention. Finally, there was a significant difference in the operative approach between 
frail and non-frail patients with significantly more frail patients undergoing open surgery. 
Laparoscopic surgery is typically associated with a decreased length of stay when compared 
to open surgery178 and while all the reported outcomes associated with frailty were adjusted 
for surgical access it remains a potential confounder. 
4.6 Conclusion: 
Frailty is associated with adverse post-operative outcomes in elderly patients 
undergoing elective colorectal cancer surgery. Despite suffering from higher rates of post-
operative clinical outcomes, such as complications, frail patients do not experience an 
increased reduction in quality of life. The Edmonton Frail Scale offers an attractive pre-
operative assessment tool as it is fast and easy to perform, accurate at identifying frailty and 





Table S4.1. Comparison between length of stay and days in hospital at 90 days between frail and 
non-frail patients as assessed by the Total Psoas Index (TPI)  
Post-operative outcomes All 
Patients 
 
(n = 86) 
Non-Frail 
 
(n = 64) 
Frail 
 











(5 – 11) 
6  
(4 – 8) 
15  
(10 – 28) 
 
2.75 (2.19 – 3.47) 
 
<0.01 
ICU / HDU Length 




(0 – 1) 
0  
(0 – 1) 
1.5  
(1 – 2.75) 
 
4.77 (2.73 – 8.49) 
 
<0.01 
Days in Hospital at 




(5 – 13) 
6  
(5 – 8) 
22.5  
(12 – 32) 
 
3.77 (2.91 – 4.91) 
 
<0.01 
*Adjusted for Age, Gender, Tumour Stage and Operative Access. 
 
Table S4.2. Comparison of post-operative outcomes between frail and non-frail patients as assessed 
by the Total Psoas Index (TPI).  
Post-operative outcomes All Patients 
 
(n = 86) 
Non-Frail 
 
(n = 64) 
Frail 
 
(n = 22) 
25.6% 
Adjusted Odds 









I - II 

















6.71 (1.95 – 31.3) 
 
2.0 (0.75 – 5.43) 

















Length of Stay 














































































0.03 (0.01 – 0.14) 































0.10 (0.02 – 0.34) 













(2 – 5) 
2 
(2 – 5) 
5 
(4 – 6) 
 




Post-operative outcomes All Patients 
 
(n = 86) 
Non-Frail 
 
(n = 64) 
Frail 
 
(n = 22) 
25.6% 
Adjusted Odds 






















(2 – 5) 
4 
(2 – 5) 
4 
(3 – 6) 
 


























(31.0 – 44.3) 
40.0  
(32.6 – 45.3) 
35.0  
(28.6 – 39.3) 
 








(48.7 – 58.6) 
54.6  
(49.7 – 59.0) 
54.1  
(45.4 – 57.6) 
 








(38.1 – 56.6) 
44.6  
(35.9 – 51.7) 
40.3  
(35.9 – 44.1) 
 








(54.0 – 59.8) 
57.0  
(54.2 – 59.8) 
56.0  
(52.3 – 61.1) 
 
0.99 (0.92 – 1.06) 
 
0.78 
*Adjusted for Age, Gender, Tumour Stage and Operative Access.  
 
Table S4.3. Comparison between length of stay and days in hospital at 90 days between frail and 
non-frail patients as assessed by the modified frailty index (mFI)  























(5 – 11) 
6  
(4 – 8) 
10  
(6 – 15) 
 
1.75 (1.34 – 2.28) 
 
<0.01 
ICU / HDU Length 




(0 – 1) 
0  
(0 – 1) 
1  
(1 – 2) 
 
5.75 (2.96 – 12.1) 
 
<0.01 
Days in Hospital at 




(5 – 13) 
6  
(4 – 8) 
11  
(7 – 18) 
 
2.39 (1.76 – 3.24) 
 
<0.01 
*Adjusted for Age, Gender, Tumour Stage and Operative Access. 
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Table S4.4. Comparison of post-operative outcomes between frail and non-frail patients as assessed 
by the modified frailty index (mFI)  
Post-operative outcomes All Patients 
 
 




















I - II 

















1.50 (0.64 – 3.57) 
 
0.71 (0.30 – 1.50) 

















Length of Stay 



























































30 Living Status 
(n, %) 
Home independent 















0.08 (0.01 – 0.44) 
- 
- 






90 Living Status 
(n, %) 
Home independent 
































(2 – 5) 
2 
(2 – 5) 
5 
(2 – 5) 
 






















(2 – 5) 
4 
(2 – 5) 
4 
(2 – 6) 
 


























(31.0 – 44.3) 
39.0  
(32.5 – 44.8) 
38.0  
(30.4 – 43.8) 
0.95 (0.86 – 1.06)  
0.37 
Post-operative day-




(48.7 – 58.6) 
54.7  
(50.6 – 59.1) 
53.6  
(48.0 – 58.2) 
 








(38.1 – 56.6) 
45.0  
(38.2 – 52.1) 
41.7  
(36.5 – 46.9) 
 








(54.0 – 59.8) 
57.0  
(54.2 – 59.8) 
57.4  
(53.4 – 61.0) 
 
1.00 (0.94 – 1.06) 
 
0.89 





Pre-Operative Step Count as a Measure of Patient Frailty 
Abstract: 
Introduction: Frailty is becoming an increasingly important concept in perioperative 
medicine due to its association with adverse post-operative outcomes. Reduced physical 
activity is a hallmark of frailty, and we postulate that a low pre-operative step count may be 
an objective measure of frailty.  
Aim: To determine the association between frailty, as defined by low pre-operative step 
count, and post-operative outcomes in patients undergoing elective colorectal cancer 
surgery. 
Methods: A prospective analysis of 85 older patients undergoing major elective colorectal 
surgery was performed at a tertiary centre between October 2017 and October 2018. 
Patients median daily step count was measured using a wearable activity tracker and a cut-
off of <2500 steps/day was used to define frailty. Primary outcomes included length of stay 
and 30-day post-operative complication rate. Multivariable logistic regression analyses were 
used to analyse the influence of frailty, defined by low pre-operative step count and other 
preoperative variables, on post-operative outcomes including mortality, prolonged hospital 
admission and complication rates. 
Results: Of 85 patients, 17 (20%) were identified as frail based on their pre-operative step 
count. A low pre-operative step count was associated with a significantly increased length of 
stay, (14 vs. 6 days, IRR 2.09, 95% CI 1.55-2.83, p=<0.01) and rate of major post-operative 
complications (29.4% vs. 8.8%, OR 3.34, 95% CI 1.03-14.3, p=0.04). It was also associated 
with significantly increased rates of discharge to care facilities (p<0.01) and requiring 
support on discharge (p=0.03). 
Conclusion: Low pre-operative step count (<2500 steps/day) is predictive of an increased 
risk of post-operative morbidity in patients undergoing elective colorectal surgery. The use 
of wearable activity trackers presents a method of objectively assessing pre-operative frailty 
and may also have a role in prehabilitation. 
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5.1 Introduction: 
Surgical risk assessment in the elderly can be difficult, as discussed in Chapter 1. Age 
alone is insufficient to capture the physiologic heterogeneity observed in this population, 
arising from both comorbidity and variable functional status. Previously, most efforts to 
quantify surgical risk in this population were typically based on age and comorbidity as the 
main predictors of adverse post-operative outcome17, 18.   Commonly used metrics are often 
based on a single organ system and none assess a patient’s physiological reserve26. Accurate 
risk assessment is important for three reasons; to facilitate patient centred decision making, 
to identify patients suitable for preoperative intervention and optimisation, and to guide 
perioperative care. 
Frailty assessment incorporates an assessment of a patient’s physiological reserve 
and aims to identify individuals who have a limited capacity to cope with the physiological 
stressors encountered with surgery and the perioperative period. As outline in Chapter 1, 
multiple assessment tools exist and typically combine information from a patient’s history 
and physical exam, medical history and assessment of functional status179. These tools are 
often time-consuming to perform and rely on multiple subjective measurements and are 
therefore often not suited to the clinical environment82. 
Low levels of physical activity are associated with frailty180, 181 and regular physical 
activity has been shown to be protective against the development of frailty182, 183.  Buckinx et 
al180 demonstrated that amongst nursing home residents frailty was linked with a low daily 
step count, measured with a wearable activity tracker (WAT). Daskivich et al184, in a study of 
100 patients undergoing major surgery, showed that patients with a high post-operative 
step count, as measure by a WAT, had a reduced length of stay compared to those with a 
low post-operative step count. They also suggested that patients with a low step count may 
be identified early and may receive targeted interventions to facilitate recovery and 
discharge.  Low post-operative step count has shown to be  predictive of unplanned 
readmission following cardiac surgery185 and the use of activity trackers has been shown to 
enhance post-operative recovery186.  
The advent and broad adoption of WATs raises the possibility of using objective 
activity measures as health indicators among frail older adults181, 187. These tools have 
evolved over time from relatively simple pedometers to more complex accelerometers188 
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and there is good evidence demonstrating their accuracy and reliability when used as step 
counters189, 190. 
Due to the association between low levels of physical activity and frailty, low pre-
operative step count offers an objective surrogate measure of frailty. The provision of a WAT 
to patients pre-operatively may aid in identifying frail individuals, who need enhanced care. 
We hypothesised that frailty, as identified by low pre-operative step count, is associated 
with adverse post-operative outcomes.  
5.2 Aims: 
The aims of this study were to: 
- Determine the correlation between frailty as defined by low pre-operative step count, 
and post-operative outcomes in patients undergoing resection for colorectal cancer.  
- Determine the correlation between frailty as defined by low pre-operative step count, 
and post-operative recovery as assessed by post-operative step count. 
5.3 Methods: 
5.3.1 Patient population: 
A prospective observational study of older patients (defined as aged 65 years or 
older) undergoing elective colorectal resection between October 2017 and October 2018 at 
Christchurch Public Hospital was performed. Patients were identified and recruited 
prospectively through surgical outpatient and preadmission clinics. Inclusion criteria were: (i) 
age 65 years or older; (ii) undergoing an elective colorectal abdominal operation within six 
months; (iii) ambulatory, including with the use of walking aids. Exclusion criteria were: (i) 
inability to obtain valid consent; (ii) stoma reversal surgery; (iii) non-abdominal procedures; 
(iv) non-ambulatory patients; (v) non-elective surgery. 
Following identification and confirmation of eligibility, informed consent was 
obtained, and patients were enrolled on a prospectively collected, anonymised database. 
Details of patient demographics, body mass index (BMI), American Society of 
Anaesthesiologists (ASA) grade, tumour location and living status were collected at 
enrolment. Mobility status was also recorded, namely whether any walking aids were used. 
Fatigue levels at enrolment were recorded on a visual analogue scale (VAS) from 0 to 10 and 
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baseline quality of life was assessed using the SF-12 questionnaire169. Operative details 
including type of surgery, surgical access, intra-operative complications, tumour stage and 
neoadjuvant treatment were also recorded on the study database.  
Postoperative management was not altered by the study and the clinicians caring for 
the patients during their post-operative stay were not part of the study protocol. Post-
operative outcomes assessed included mortality, length of hospital stay, the development of 
post-operative complications, readmission and discharge to a care facility. Post-operative 
complications were graded according to the Clavien-Dindo classification, with major 
complications defined as a score of ≥3151. Patients were followed up at 30 and 90 days and 
fatigue, quality of life and EFS were reassessed at these time points.  
5.3.2 Wearable activity trackers (WAT): 
At the point of recruitment patients were issued with a Garmin vívofit® 3 (Garmin, 
Olathe, KS, USA) wrist worn activity tracker. Steps taken, distance travelled, and calories 
burned are monitored by the WAT and it is water resistant and has a 1-year battery life. This 
WAT syncs to both Android and iOS systems allowing for data acquisition via the Garmin 
connect application. Patients were provided education on the use of the WAT when it was 
issued, written information was provided, and a contact number was available if issues 
arose. Patients were asked to wear their devices continuously and daily step count was 
recorded for 14 days pre-operatively. 
The WAT was retrieved, and data downloaded on the day of surgery. It was then 
returned on post-operative day 3 and worn until post-operative day 30 where it was 
retrieved, data downloaded, and returned to the pool following surface disinfection as per 
infection control guidelines. 
5.3.3 Frailty assessment and determination of step threshold: 
Pre-operative frailty was identified based on a patient’s median pre-operative daily 
step count as a novel measure of frailty. This was compared to two validated frailty scales, 
the Edmonton Frail Scale (EFS)80 and the modified frailty index (mFI).   
A number of techniques were employed in order to identify a median daily step 
threshold of <2500 steps/day to act as a marker of frailty. Patients with a median daily step 
count below this level were labelled as having a low step count (LSC) and were deemed frail. 
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Patients with a median daily step count above this level were labelled as having a normal 
step count (NSC) and were deemed non-frail for the purposes of this study.  
Firstly, due to described association between frailty and low levels of physical 
activity180, it was postulated that frail patients perform minimal physical activity above a 
basal level of activity. Tudor-Locke et al191 describe a basal level of activity as being  <2500 
steps per day, therefore we felt this was an appropriate step threshold to define frailty. 
Secondly, based on the prevalence of frailty in the surgical population being approximately 
20%, as identified in Chapter 2, we sought to identify the median daily step count threshold 
that would classify 20% of our cohort as frail. By using a threshold of <2500 steps/day in our 
cohort, 20% were classified as frail.  Finally, we conducted a receiver operating characteristic 
(ROC) curve analysis for median pre-operative step count based on pre-operative frailty, as 
defined by patient’s pre-operative EFS (Figure 5.1). The area under the curve was 0.93 
showing a strong correlation between pre-operative step count and pre-operative EFS. A 




Figure 5:1. Receiver Operating Characteristic (ROC) Curve analysis for median pre-operative steps. 
(Area Under Curve: 0.93, p<0.01, cut off value <2472, sensitivity 0.75, specificity 0.89) 
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5.3.4 Ethics: 
This study was approved by the New Zealand Health and Disability Ethics Committee 
reference 17/CEN/170. Locality approval was obtained from the Canterbury District Health 
Board. This study was registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN126180000452130). 
5.3.5 Statistical Analysis: 
Based on our assessment of the prevalence of frailty, as outline in Chapter 2, and the 
prevalence of frailty in the literature48, 172, it is assumed that 20% of the study population will 
be frail. We sought to identify a minimum effect size of one day difference in hospital length 
of stay between frail and non-frail patients.  For the purpose of this study, frailty was defined 
as a median daily step count of less than 2500 steps, as described above48, 172. Based on local 
data that showed a mean post-operative length of hospital stay of 7 days (SD 1.5) amongst 
this age group, at a power of 90% and two sided alpha value of 0.05, a minimum sample size 
of 94 patients will be required to detect what was deemed to be the minimum clinically 
significant difference of one day for the inpatient duration between the groups. To allow for 
attrition 100 patients were recruited. 
Continuous variables were reported as medians with interquartile range (IQR) and 
categorical variables as whole numbers and percentages. Univariable analysis was 
performed to compare baseline characteristics between frail and non-frail patients. This 
included chi-square tests for categorical variables and Mann-Whitney U-test for non-
parametric continuous variables.  
Multivariable logistic regression analysis was performed on pre-operative variables, 
including low step count, that were predicted to affect post-operative outcomes using 
backward stepwise selection based on Akaike Information Criterion (AIC). Model 
performance was assessed using Harrell’s concordance index (C-index). Regression 
coefficients from multivariable analysis were reported as odds ratios (OR) with 95% 
confidence intervals (95% CI). Length of stay (LOS) and days in hospital at 90 days were 
evaluated as Poisson count data, were determined to be over-dispersed and as such, 
analysed using negative binomial regression. Incidence rate ratios from these analyses were 
interpreted as the relative number of days in the hospital when compared the reference 
(non-frail) group. P values <0.05 were considered statistically significant. All statistical 
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analysis was performed using RStudio software (version 3.3.2; www.rstudio.com) or SPSS, 
version 25 (IBM). 
5.4 Results: 
5.4.1 Baseline demographic and clinicopathological characteristics: 
The patient recruitment process is outlined in Figure 5.2. Of 119 patients screened 
for eligibility, a total of 100 patients were identified that met the inclusion criteria and were 
recruited into the study. Subsequently, 15 patients withdrew from the study, 6 of which no 
longer required or decided against surgery, 6 who withdrew consent and 3 who presented 
acutely. A total of 85 patients were therefore included in the final analysis. There was no 
significant difference in the age (p = 0.68) or gender (p = 0.84) of those patients who 
withdrew when compared to the studied population. The median daily step count across all 
patients was 4569 steps/day (IQR 2727 – 6830). Of the 85 included patients, 17 (20%) were 
classified as frail, as defined by a median pre-operative step count of <2500 steps/day. The 
patients tolerated the WAT well and only 2 patients removed the device early in the post-
operative period due to discomfort.  
Baseline demographic, clinicopathological and treatment variables are shown in 
Table 5.1. The median age of the study population was 76 years (IQR 72 – 81). Frail patients 
were older than non-frail patients with a median age of 78 years (IQR 76 – 81) compared to 
75 years (IQR 70 – 81), however, this difference was not statistically significant (p = 0.16). 
Frail patients were also more likely to be male (64.7% vs 45.6%), (p = 0.13). The majority of 
patients were of New Zealand European ethnicity (91.8%), and there was no difference in 




Figure 5:2. Patient recruitment overview 
Patients screened for eligibility
n = 119




- - No longer requiring surgery n =6
- Withdrawn consent n = 6
- Acute presentation n = 3
Included in statistical 
analysis
n = 85 




Table 5.1. Baseline demographics and clinicopathological characteristics of the study population. 
Frailty determined by median daily pre-operative step count with <2500 step/day being classified as 
frail 
Patient variables All Patients 
 
n = 85 
Non-Frail 
>2500 steps 




n = 17 
20% 
Odds Ratio (95% 
CI) 
p-value 
 Age (y) Median (IQR) 76 (72 – 81) 75 (70 – 81) 78 (76 – 81) 1.07 (0.97 – 1.19) 0.16 









2.55 (0.80 – 9.06) 
 
0.13 





































2.27 (0.72 – 6.94) 
- 
0.44 (0.11 – 1.39) 




























0.63 (0.15 – 2.32) 
 
0.51 









5.20 (1.57 – 21.0) 
 
0.01 
AJCC Stage (n, 
%) 
I - II 



























2.38 (0.31 - 13.7) 















7.15 (1.75 – 39.0) 
 
0.01 









19.0 (3.68 – 130) 
 
<0.01 

































(38.9 – 53.2) 
50.2 
(41.2 – 54.8) 
33.4 
(29.1 – 43.2) 
 








(50.2 – 59.0) 
57.1 
(51.4 – 58.8) 
55.7 
(48.1 – 60.1) 
 




The median BMI overall was 27.0kg/m2 (IQR 24.5 – 32.1) and there was no difference 
in BMI between the two groups (p = 0.79). Frail patients were more likely to be ASA grade III 
or IV with 76.5% of frail patients being ASA III/IV when compared with 42.6% of non-frail 
patients, (p = 0.06). There was no difference in tumour location between groups (p=0.51), 
however frail patients were more likely to have an open operation with 76.5% of frail 
patients having an open procedure, compared to 38.2% of non-frail (p=0.01). There was no 
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difference in stage of the tumour or the use of neoadjuvant treatment between the two 
groups.  
When assessing for frailty using the Edmonton Frail Scale (EFS) and the modified 
frailty index (mFI), 12 (14.1%) and 40 (47.1%) of the overall patient population were 
classified as frail respectively.  Of the 17 patients classified as frail based on pre-operative 
step count, 9 (52.9%) were classified as frail based on the EFS and 14 (82.4%) based on the 
mFI. Of those not classified as frail based on pre-operative step count, 3 (4.4%) were 
classified as frail based on the EFS and 26 (38.2%) based on the mFI. Pre-operative step 
count has a good specificity when compared with EFS and is more discriminatory then mFI, 
which identified almost half of the cohort as frail.  
Patients classified as frail using pre-operative step count had a higher baseline level 
of fatigue (p = 0.01) and a poorer physical component score (PCS) on the pre-operative SF-12 
questionnaire (p <0.01). There was no difference in baseline mental component score (MCS) 
on the SF-12 questionnaire between the two groups (p = 0.14).  
5.4.2 Post-operative outcomes: 
Tables 5.2 and 5.3 summarise post-operative outcomes and complications. The 
overall median length of stay was 7 days (IQR 5 – 11). Frail patients had a significantly longer 
length of stay when compared with non-frail patients, staying a median of 14 days (IQR 9 – 
17) compared to 6 days (IQR 4.8 – 8), (p = <0.01). The correlation between pre-operative 
step count and post-operative length of stay is shown in Figure 5.3. When assessed using 
Pearson’s correlation coefficient, there was a moderate, but significant correlation between 




Table 5.2. Comparison between length of stay and days in hospital at 90 days between patients with 
low and normal step counts.  
Patient variables All 
Patients 
 
n = 85 
Non-Frail 
>2500 steps 















(5 – 11) 
6 
(4.8 – 8) 
14 
(9 – 23) 
 
2.09 (1.55 – 2.83) 
 
<0.01 
ICU / HDU 





(0 – 1) 
0 
(0 – 1) 
2 
(1 – 2) 
 
3.14 (1.64 – 6.05) 
 
<0.01 
Days in Hospital 




(5 – 13) 
7 
(5 – 11) 
17 
(9 – 31) 
 
2.47 (1.71 – 3.63) 
 
<0.01 
* Adjusted for Age, Gender, Tumour Stage and Operative Access. 
 
 
Figure 5:3. Correlation between median daily pre-operative step count and post-operative LOS. 






Table 5.3. Comparison of post-operative outcomes between frail and non-frail patients as assessed by low pre-operative step count.  
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Frail patients were more likely to spend 7 days or more in hospital on their index 
admission when compared to non-frail patients, with 14 (82.4%) and 33 (48.5%) patients 
respectively.  Frail patients also had a significantly longer high dependency unit (HDU) 
and/or intensive care unit (ICU) stay, (p = <0.01). Over the 90-day post-operative follow up 
period, frail patients spent significantly longer as an inpatient with a median of 17 days (IQR 
9 – 31) compared to 7 days (IQR 5 – 11), (p = <0.01). 
Frail patients were more likely to be readmitted at 90-days with a readmission rate of 
23.5% compared to 17.6% in the non-frail group, however this difference was not 
statistically significant. Frail patients were significantly more likely to be discharged to 
rehabilitation or a care facility (Adjusted OR 10.4, 95% CI 2.53 – 49.2, p<0.01), and were 
more likely to require additional support on discharge (Adjusted OR 5.33, 95% CI 1.35 – 22.8, 
p = 0.04). Two frail patients (11.8%) were discharged to a higher level of care, typically rest-
home or hospital level care, compared to none of the non-frail cohort. This change in level of 
care is typically associated with reduced functional independence.  
There were two patient deaths at 90-days follow-up  in the non-frail cohort and none 
in the frail cohort, thus limiting comparison. This is not unsurprising given the short follow 
up and this study being under-powered to examine for a difference in mortality rates. 
Post-operative complications occurred in 47 (55.3%) patients within 30 days, of 
which 11 (12.9%) were major complications (Clavien-Dindo III – V). Frail patients were more 
likely to suffer from any complication with 13 (76.5%) frail patients suffering from a 
complication compared to 34 (50.0%) non-frail patients (Adjusted OR 2.02, 95% CI 0.58 –
8,23, p = 0.29). They were also significantly more likely to have a major post-operative 
complication with 5 (29.4%) frail patients having a Clavien-Dindo III-V complication 
compared to 6 (8.7%) of non-frail patients (p = 0.04), (Figure 5.4). Multivariable analysis was 
conducted using backward stepwise selection to assess the association between pre-
operative patient factors and the development of post-operative complications.  All pre-
operative demographic factors, including the presence of pre-operative frailty, were 
included in the model. Frailty, as defined by a low pre-operative step count, alone remained 




Figure 5:4. Percentage of patients who experienced a major post-operative complication within 30 
days (Clavien-Dindo III-V) by frailty, defined as low step count (<2500 steps/day). 
 
5.4.3 Comparison with other frailty measures: 
The predictive ability of a low pre-operative step count with regards to post-
operative outcomes was assessed using the area under the receiver operating characteristic 
curve (AUC) and compared to the assessment tools utilised in Chapter 4 (Table 5.4).  Low 
pre-operative step count has a similar predictive ability when compared to the EFS, TPI and 
mFI, with regards to the outcomes of prolonged length of stay (64%) and the occurrence of 
any complication (68%). Low pre-operative step count, however, did not perform as well as 
the other tools when assessing the occurrence of major complications (67%).  
In combination with the other clinical assessment tools, low pre-operative step count 
was a stronger predictor of adverse outcomes (Table 5.5). In combination with the EFS, low 
pre-operative step count was a significant predictor of prolonged length of stay (76%), any 
post-operative complication (80%) and a major post-operative complication (78%), (Table 
5.5). Similar results were seen with the combination with other clinical assessment tools, but 
to a lesser extent. Multiple combinations of tools did not appear to increase this predictive 
ability further, as seen in Chapter 4.  
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Table 5.4. Receiver Operating Characteristics Area under the Curve (AUC) for low step count with 
regards to adverse outcomes 
Outcome(s) AUC p – value 
95% Confidence Interval 
Lower Bound Upper Bound 
Prolonged Length of Stay (>7days) .638 .030 .514 .761 
Any Post-Operative Complication 
(Clavien-Dindo I-V) 
.675 .060 .478 .729 
Major Post-Operative 
Complication (Clavien-Dindo I-V) 
.667 .074 .473 .861 
 
Table 5.5. Receiver Operating Characteristics Area under the Curve (AUC) for low step count in 
combinations with EFS with regards to adverse outcomes 
Outcome(s) AUC p – value 
95% Confidence Interval 
Lower Bound Upper Bound 
Prolonged Length of Stay (>7days) .755 .000 .651 .858 
Any Post-Operative Complication 
(Clavien-Dindo I-V) 
.798 .000 .687 .809 
Major Post-Operative 
Complication (Clavien-Dindo I-V) 
.775 .004 .612 .936 
 
5.4.4 Post-operative activity levels: 
Post-operatively the wearable activity trackers were well tolerated with only 2 
patients removing the trackers prematurely before the completion of follow-up. There was a 
statistically significant increase in daily step count with successive postoperative days in 
aggregate (r2 = 0.35; 95% bootstrapped CI, 0.23-0.48; P < 0.01) (Figure 5.5). The non-frail 
cohort had a higher median post-operative step and a steeper trajectory than the frail 
cohort. Frail patients, however, returned to their baseline step count faster than non-frail 
patients. At 30 days post-operatively frail patients had a median post-operative step count 
that was 99.0% of their median pre-operative step count, compared to non-frail patients 
who had achieved 67.7% of their pre-operative step count (Figures 5.6, 5.7). Given frail 
patients had a lower median pre-operative step and therefore fewer steps to achieve their 
baseline, this result is expected.  
When evaluating post-operative median daily step count by pre-operative frailty 
status, as assessed by using the EFS, TPA or the mFI, frail patients had a lower post-operative 
median step count over the follow up period. When classifying patients as frail using the EFS, 
frail patients had a median post-operative daily step count of 777.5 steps/day (IQR 623.1 – 
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1288.4) compared to non-frail patients who had a median step count of 2269.2 steps/day 
(IQR 1588.6 – 3947.5). Similar results were seen when patients were classified as frail using 
the mFI or TPA. 
 
 
Figure 5:5. Median daily post-operative step count for frail and non-frail patients as defined by a 
median pre-operative step count of <2500 steps/day.  
 
 
Figure 5:6. Daily post-operative step count as a percentage of a patients median pre-operative step 




Figure 5:7. Daily post-operative step count as a percentage of a patients median pre-operative step 
count for non-frail patients (defined as ≥2500 steps/day). 
 
There was a statistically significant increase in post-operative length of stay with 
decreasing median daily step count (r=0.33, 95% bootstrapped CI 0.11 – 0.50, p <0.01). 
Similarly, patients who had a prolonged length of stay or were discharged to rehabilitation 
or a care facility had a significantly lower post-operative median daily step count. Patients 
who had an index admission length of more than 7 days had a median post-operative step 
count of 1395 steps/day (IQR 807 – 3042) compared to 2392 steps/day (IQR 1655 – 4693) in 
those who stayed 7 days or less. Similar results were seen in those patients discharged to a 
rehabilitation service or higher level of care, such as a rest home or hospital level care 
(Figure 5.8).  
Post-operative daily step count was typically lower in patients who suffered from 
post-operative morbidity. The 11 patients who suffered a major post-operative complication 
(Clavien-Dindo III-V) had a median post-operative step count of 837 steps/day, compared to 
the 74 patients who did not, who had a median post-operative step count of 2241.5 
steps/day. Whilst patients with a low post-operative step count may be more likely to suffer 
from a major complication, it is likely that the complication event itself is likely to be 
associated with increased morbidity and decreased patient activity levels as a result of the 
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complication. Of the 11 patients who suffered a major post-operative complication, 10 had a 
significantly lower step count than average, prior to the complication being reported.  
 
 
Figure 5:8. Comparison in median daily post-operative step counts between patients discharged to 
rehabilitation or care facility and those who were not. 
 
5.5 Discussion: 
Multiple tools exist assessing a patient’s pre-operative risk, however quantifying 
surgical risk in the elderly population can be difficult17. Frailty is commonly encountered in 
the elderly patient, and this population is increasing disproportionately in western societies. 
In 2015, an estimated 8.5% of the world’s population was aged 65 years or older1, and it is 
estimated this will increase to be 17% by 20501. With expanding indications for surgery, 
advances in perioperative medicine combined with an expectation of reasonable quality of 
life and function, more elderly patients will present for surgery. 
Frailty is often characterised as easy to identify, but hard to define, and multiple 
assessment tools exist82. Due to often being time consuming and cumbersome to perform, 
they are often not suitable for clinical use. The use of WATs offers a convenient way to 
measure a patient’s pre-operative step count and may provide a more accurate assessment 
of functional reserve than a snap-shot clinical assessment. 
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This study has shown that frailty, as defined by a low (<2500 steps/day) pre-operative 
step count, is predictive of post-operative morbidity and delayed recovery, often associated 
with a loss of independence. The presence of frailty was strongly associated with a 
prolonged length of hospital stay, high post-operative complication rate and discharge to 
supported care facilities. After multiple stepwise regression analysis, frailty alone remained 
an independent predictor of post-operative morbidity. This is significant to patients, as in 
frail patients any potential benefit gained from surgery may be offset by post-operative 
morbidity and loss of function. If accurately identified pre-operatively, frail patients may be 
better managed using alternative treatment pathways, or if surgery planned with enhanced 
peri-operative care154. 
Our study’s finding of frailty being associated with adverse post-operative outcomes 
is not novel, and multiple other studies examining this association in the literature exist. In a 
systematic review and meta-analysis by Oakland et al79, the authors examined at the 
association between patient frailty and surgical outcomes. Twelve studies were identified 
which included 7960 patients across multiple surgical disciplines. While definitions of frailty 
differed between studies, the results were similar across studies for in-hospital and one-year 
mortality, length of stay, and discharge to another care facility when comparing frail versus 
non-frail patients. As highlighted in this review, multiple methods exist for the assessment of 
frailty, and no “gold-standard” exists.  
Our study, however, presents a novel method of pre-operative frailty assessment 
using patient activity levels in the form of daily step count as a surrogate for functional 
reserve. The use of WATs has the ability to assess a patient over a number of days, rather 
than being a snap-shot clinical assessment. It is well tolerated by patients and relatively 
simple to administer, only 2 patients failed to wear their tracker for the entire study period. 
The chosen devices, Garmin vívofit® 3, are robust waterproof and do not require charging by 
patients making them an ideal choice for this use. Multiple patients reported that the 
presence of a WAT was intrinsically motivational, and it pushed them walk further. This 
raises the possibility of using a WAT as a prehabilitation / rehabilitation tool and is an avenue 
for future studies.  
This study also demonstrated an association between a low post-operative step 
count and patient morbidity. Patients assessed as frail pre-operatively typically had a lower 
post-operative step count. A lower post-operative step count was significantly associated 
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with an increased length of stay, complication rate and discharge to care facilities or 
rehabilitation. Identification of low post-operative step count, as early as the first post-
operative day184, may identify patients who need further intervention, such as 
multidisciplinary assessment to facilitate patient discharge and improve patient outcomes.  
Prehabilitation must be considered an essential intervention for optimising peri-
operative outcomes. While the first randomized trial of multimodal prehabilitation in 
colorectal surgery is now recruiting192, it is possible that a simple targeted improvement in 
step count may also be effective. Anecdotally, many patients in our study population 
reported that wearing the WAT was intrinsically motivating even at its most basic setting of 
simply displaying a daily step count. There was clearly some training effect with patients 
independently choosing to try and improve their daily totals  
A strength of our study is that it is the first published investigating the use of WATs in 
pre-operative frailty assessment.  Previous publications have demonstrated limited 
applications in the post-operative period185, 186, but this current publication is the first 
looking at their use in pre-operative risk assessment.  
Several limitations should be considered when interpreting data from this study. 
Data were collected exclusively in elective colorectal cancer patients and therefore cannot 
necessarily be extrapolated to other major surgery groups. Despite this, the multi-
dimensional nature of step count and quantitative similarity to larger community data is 
encouraging for generalizability. Data were derived from a single institutional experience 
with a relatively small group of treating clinicians and a relatively homogeneous patient 
population, which may limit application to other settings or ethnicities. Significantly more 
patients with a low pre-operative step count underwent open as opposed to laparoscopic 
surgical resection. This surgical decision was made by treating teams independent of any 
knowledge of step count or formal frailty assessment undertaken as part of this study. While 
all the reported outcomes associated with low step count were adjusted for surgical access it 
remains a potential confounder. Deciding between open vs. laparoscopic access in colorectal 
surgery is multifaceted and clinicians will be aiming to balance perceived recovery benefits 
with a prolonged intra-operative phase. While it is generally accepted that one of the 
benefits of laparoscopic access in colorectal resection is reduced length of stay, this has not 
been able to be demonstrated in study populations aged 65 years and older193. Finally, 
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pedometer accuracy has been shown to be compromised by slow walking speed194, and it 
may be that step count is under estimated in those frail patients with a slow walking speed. 
5.6 Conclusion: 
Frailty is an important concept in peri-operative medicine due to its association with 
adverse post-operative outcomes. Pre-operative step count offers an objective method of 
assessing frailty and a low pre-operative step count is associated with an increased risk of 
post-operative morbidity in this study. Identification of frailty pre-operatively may allow for 
treatment modification and/or prehabilitation. Identification of a low step count post-
operatively may aid in identification of patients as risk of adverse outcomes and allow 
targeted intervention. 
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 Chapter 6 
 
Mitochondrial dysfunction and oxidative stress  
as biomarkers of frailty 
Abstract: 
Introduction: Mitochondria play a central role in cellular energy provision and redox 
homeostasis. Mitochondrial dysfunction has been hypothesised to play a critical role in 
ageing and the development of the frailty syndrome. Based on the association between 
mitochondrial dysfunction and frailty, it was hypothesised that elevated biomarkers of 
mitochondrial dysfunction or oxidative stress would be associated with adverse post-
operative outcomes in older patients. 
Aim: To determine the association between mitochondrial dysfunction, biomarkers of 
oxidative stress and clinical frailty scores and post-operative outcomes in patients 
undergoing resection for colorectal cancer. 
Methods: A prospective analysis of 85 older patients undergoing major elective colorectal 
surgery was performed. Blood samples were taken pre-operatively and at 30-days post-
operatively measuring mitochondrial oxygen consumption, the redox status of cytoplasmic 
and mitochondrial peroxiredoxins and plasma protein carbonylation, as biomarkers of 
mitochondrial dysfunction and oxidative stress. Correlation between biomarkers and post-
operative outcomes including length of stay and the occurrence of post-operative 
complications were assessed.  
Results: Of 85 eligible patients, blood was taken and assessed for mitochondrial dysfunction 
in 68 (79.1%) patients. No significant difference was seen in mitochondrial oxygen 
consumption rates between frail and non-frail patients, however a trend to an increased 
length of stay and risk of adverse outcomes was seen with reduced maximal and reserve 
mitochondrial oxygen consumption rates.  Frail patients had significantly increased 
biomarkers of oxidative stress when compared to non-frail patients, with a higher pre-
operative percentage of Prx2 and Prx3 oxidation and higher protein carbonyls. No significant 
association was seen between biomarkers and the occurrence of adverse post-operative 
outcomes; however, this study was underpowered. 
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Conclusion: Elevated biomarkers of mitochondrial dysfunction are seen in patients with the 
clinical syndrome of frailty. Although an association between elevated biomarkers and 





Mechanistically, frailty is a synergistic, multifactorial phenomenon and at present, a 
single underlying cause to frailty has yet to be identified. Initial research predominantly 
focussed on the clinical features of frailty; however, these need ultimately to be understood 
in terms of biological mechanisms, and to date the connection has yet to be established. The 
vital functions carried out by mitochondria in the context of energy provision, redox 
homeostasis, and regulation of multiple catabolic pathways confer these organelles a vital 
position in the maintenance of cell viability. As a result, mitochondrial dysfunction has been 
proposed to play a critical role in both ageing and the development of frailty68, 69, 195. The 
mitochondrial theory of ageing, proposed by Harman in 1972, remains one of the leading 
theories on ageing, whereby a vicious cycle of events leads to increased oxidative stress and 
subsequent cellular senescence196. Frailty appears to share multiple common pathways with 
ageing, but is typified by an accelerated decrease in reserve and subsequent vulnerability to 
stressors relative to physiologic ageing51. Given frailty appears to represent “pathological 
ageing”, it is theorised that oxidative stress and mitochondrial dysfunction are central to the 
development of frailty 6, 41. 
Mitochondria are ubiquitous intracellular organelles, present in almost all 
mammalian cells. Their primary role is of adenosine triphosphate (ATP) production through 
oxidative phosphorylation. Mitochondria contain their own DNA encoding several key 
proteins of the mitochondrial respiratory chain. The mitochondrial respiratory chain 
comprises 5 multi subunit complexes, the last of which is ATP synthase. Electrons are 
exchanged down the chain from complexes I through to IV, allowing the shuttling of proteins 
across the mitochondrial membrane creating a proton gradient. Proton flux through ATP 
synthase then provides the energy driving ATP production. Premature electron leak leading 
to superoxide production and hydrogen peroxide has been measured in pathological 
situations197, and is presumed to occur during normal metabolism, though this is difficult to 
measure (Figure 6.1).  
ATP generation occurs at a basal rate; however, the cell has the capacity to increase 
respiration to a maximal rate enabling a sudden burst of ATP production. The difference 
between ATP produced by oxidative phosphorylation at basal and that at maximal activity is 
the mitochondrial “reserve respiratory capacity”. Under certain conditions, such as stress, a 
sudden burst of additional cellular energy is required, and if the reserve respiratory capacity 
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is not sufficient cells risk being driven into senescence or cell death198. Due to this innate 
reserve capacity, mitochondrial deficits may not become apparent until they are required to 
work under maximal capacity. This lack of “mitochondrial reserve” has marked similarities to 
the clinical syndrome of frailty.  
 
 
Figure 6:1. Diagram of the inner mitochondrial membrane showing the processes underlying 
oxidative phosphorylation, the electron transport chain, ATP synthesis and the uncoupling of 
oxidation from phosphorylation via proton leak. Reproduced with permission from Conley199. 
 
Exposure to reactive oxygen species (ROS) over time damages mitochondrial DNA, 
and as a result mutations in the mitochondrial DNA accumulate67. The mutation rate of 
mitochondrial DNA is much higher than that of nuclear DNA for the following reasons: 1) the 
mitochondrial genome is located on the inner mitochondrial membrane adjacent to the 
electron transport chain, the major source of ROS production; 2) the mitochondrial genome 
lacks protective histones; 3) the DNA repair mechanisms are limited compared with the 
nuclear genome195. As a result, mitochondrial DNA mutations occur earlier than nuclear 
mutations, this in turn damaging the electron transport chain leading to the vicious cycle of 
further ROS production and mitochondrial DNA mutations. Increased cellular levels of ROS  
in turn damages cellular proteins and DNA resulting in the dysregulation of physiological 
functions200. The presence of ROS also accelerates the onset of replicative senescence as 
well as contributing to ongoing cellular DNA damage that sustains the accumulation of 
inflammatory mediators as part of the senescence-associated secretory phenotype (SASP), 
(Figure 6.2)201. As a result, apoptosis is initiated, a mechanism believed to represent a final 
common pathway through which ageing and physical frailty ensue69. The cellular senescent 
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phenotype, secreting proinflammatory cytokines, may also contribute to the dysregulated 
inflammatory state seen in frailty, as discussed in Chapter 1.  
In support of the mitochondrial theory of ageing a progressive relationship between 
age and the accumulation of mitochondrial DNA mutations has been established202. 
Progressive mitochondrial dysfunction is considered a hallmark of aging67, 203 and impaired 
mitochondrial function has been demonstrated to cause an accelerated aging phenotype204, 
205. Deficits in bioenergetics caused by a decline in mitochondrial function impairs normal 
cellular activities resulting in an impaired ability to adapt to various physiological stresses 
leading finally to frailty and disability67. Excessive ROS also  results in an increase in 
proteolysis and a reduction in protein synthesis leading to a reduction in muscle mass and 




Figure 6:2. Reactive Oxygen Species (ROS) production from dysfunctional mitochondria as the driving 
force of cellular ageing. Reproduced with permission from Wiley et al.201. 
 
A number of clinical studies have shown a relationship between mitochondrial 
dysfunction, oxidative stress and the development of frailty207, 208. The Framingham 
Offspring Study showed increased levels of proinflammatory and oxidative stress biomarkers 
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in both in pre-frail and frail elderly subjects209. They measured levels of the following 
biomarkers: C-reactive protein, interleukin-6, tumour necrosis factor receptor 2, lipoprotein 
phospholipase A2, osteoprotegerin, intracellular adhesion molecule-1 and P-selectin and 
found an association with frailty. A recent systematic review210 demonstrated frailty and pre-
frailty to be associated with higher levels of oxidative stress, however, given its cross-
sectional design it was not possible to establish the directionality of the association. High 
levels of markers of oxidative stress pre-operatively have been shown to be associated with 
adverse post-operative outcomes in patients undergoing major surgery211. 
 
 
Figure 6:3. Relationship between Ageing, Oxidative Stress, Inflammation and Frailty. Reproduced 
with permission from Liguori et al.206 
 
Multiple biomarkers of mitochondrial dysfunction and oxidative stress have been 
described and studied206, 210, 212, 213. They offer the potential for use as diagnostic tools and 
therapeutic targets. Identification of biomarkers of frailty offers the potential to identify 
patients at risk of becoming frail prior to the development of clinical manifestations and may 
therefore provide a window of opportunity for intervention to attenuate or prevent the 
development of clinical frailty. The search for biomarkers in the field of frailty is an area of 
ongoing active research214. 
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Broadly speaking currently available biomarkers can be broken down into the 
following groups: ROS-induced protein modifications, markers of ROS generation, markers of 
antioxidant defense and downstream functional markers of ROS-induced damage206.  
Protein carbonylation (PC) occurs when carbonyl groups are produced on protein 
side chains when they are oxidised in the presence of ROS. Oxidative stress can give rise to 
protein carbonyl derivatives, via a variety of mechanisms that include fragmentation and 
amine oxidation215. High levels of PC have been shown to be associated with skeletal muscle 
dysfunction in older respiratory patients216 and associated with sarcopenia and frailty217-219. 
Peroxiredoxins (Prx) are thiol-specific proteins that react as scavengers of hydrogen 
peroxide (H2O2), converting hydroperoxides to water and act as antioxidants countering the 
effects of ROS220. Six known mammalian isoforms exist, Prx 1-6, varying in oligomeric states 
and interfaces. During their catalytic cycle Prx 1-4 are converted to disulfide-linked 
homodimers that can be visualised by western blotting221. Prx2 is a cytosolic protein, and is 
the third most abundant protein in the human erythrocyte playing an important role in 
defense against oxidative stress222. Prx3 is a mitochondria specific protein, that regulates 
mitochondrial apoptotic signalling and Prx3 depletion has been shown to result in 
accelerated apoptosis and  cellular damage223.  
Prxs undergo redox interconversions where peroxidatic cysteines on reduced Prxs are 
oxidised by hydroperoxides to a sulfenic acid. The sulfenic acid then reacts with an adjacent 
resolving cysteine to form an intermolecular disulfide. Oxidised Prxs are in turn reduced by 
the thioredoxin system (Figure 6.4). In vitro studies suggest that reduction of Prx by the 
thioredoxin system is the rate limiting step in the Prx catalytic cycle224 and therefore 
accumulation of oxidised Prx would be expected in cells placed under oxidative stress221 
Addition of a bolus of H2O2 to diluted whole blood causes complete oxidation of Prx2 and by 
30 min the protein has returned to its reduced state 222.  Previous work in the laboratory of 
Prof. Mark Hampton has also shown there are differences in the rate of reduction of Prx2 
following incubation of diluted whole blood with H2O2 between donors (unpublished 
observations).  Increased levels of oxidized Prxs have been proposed as a novel biomarker of 
cellular oxidative stress221. They have been shown to be potential biomarkers of Alzheimer’s 
disease in the elderly225, a predictor of mortality in older patients presenting to hospital226, 




Figure 6:4. Redox interconversions of typical Prxs. The peroxidatic cysteine (SpH) reacts with H2O2 to 
form a sulfenic acid. The oxidized cysteine can then condense with the resolving cysteine (SrH) on the 
opposing Prx subunit to form an intermolecular disulfide bond that is reduced by the 
Trx/TrxR/NADPH system. The sulfenic peroxidatic cysteine (SpOH) can also react with hydrogen 
peroxide molecule to form the hyperoxidized sulfinic form (SpO2H). Reproduced with permission 
from Poynton and Hampton221. 
 
Based on the apparent association between mitochondrial dysfunction, oxidative 
stress and frailty; it was hypothesised that mitochondrial dysfunction contributes to the 
clinical syndrome of frailty and elevated biomarkers of oxidative stress would be associated 
with adverse post-operative outcomes in older patients.  
6.2 Aims: 
The aims of this study were to: 
- Determine the association between biomarkers of oxidative stress and clinical 
markers of frailty. 
- Determine the correlation between mitochondrial function and post-operative 
outcomes in patients undergoing resection for colorectal cancer.  
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6.3 Methods: 
6.3.1 Patient Population: 
A prospective observational study of older patients (defined as aged 65 years or 
older) undergoing elective colorectal resection between October 2017 and October 2018 at 
Christchurch Public Hospital was performed. Patients were identified and recruited 
prospectively through surgical outpatient and preadmission clinics. Inclusion and exclusion 
criteria were as described in Chapter 4. Following identification and confirmation of 
eligibility, informed consent was obtained, and patients were enrolled on a prospectively 
collected, anonymised computer database. Details of patient sociodemographic details were 
collected at enrolment. Operative details, tumour stage and treatment were also recorded 
on the study database.  
Postoperative management was not altered by the study and the clinicians caring for 
the patients during their post-operative stay were not part of the study protocol. Post-
operative outcomes assessed included mortality, length of hospital stay, the development of 
post-operative complications, readmission and discharge to a care facility. Post-operative 
complications were graded according to the Clavien-Dindo classification, with major 
complications defined as a score of ≥3151.  
6.3.2 Assessment of Mitochondrial function: 
Blood samples were collected from patients preoperatively on the day of surgery. 
Two tubes of blood were collected from each patient, one containing lithium heparin and 
the other containing ethylenediaminetetraacetic acid (EDTA) and 200 mM of N-
ethylmaleimide (NEM) buffer to prevent artefactual thiol oxidation during processing. After 
collection, these tubes were delivered directly to the laboratory where they were processed 
immediately by the laboratory team. Analysis of the blood samples was performed by the 
laboratory team (Drs Andree Pearson and Masuma Zawari) and an outline of their 
methodology is described below.  
6.3.3 Assessment of Mitochondrial function using Seahorse Analyser: 
Monocytes and lymphocytes were isolated using magnetic activated cell sorting of 
peripheral blood mononuclear cells preparations obtained following Ficoll-Hypaque 
separation of blood.  Cell purity was confirmed by flow cytometry.  Cells were seeded onto 
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plates and changes in dissolved oxygen was measured in a small volume (7 L) isolated 
above the cell monolayer. Injection ports in the Seahorse Analyzer allowed inhibitors of the 
mitochondrial respiratory chain to be added sequentially at specific time points which 
generated a profile of oxygen consumption over time.  Basal, maximal, ATP-linked and non-
mitochondrial oxygen consumption rates (OCRs) as well as reserve capacity and proton leak 
could then be calculated228, 229. Based on the hypothesis that frailty may be manifested with 
stressors, cells were subsequently stressed by the addition of 20 µM bolus of hydrogen 
peroxide (H2O2) to assess for differences in cellular bioenergetics. For cells treated with 
H2O2, a percentage inhibition of reserve capacity was calculated as the percentage of H2O2-




Figure 6:5. Schematic profile of effect of mitochondrial modulators on cellular oxygen consumption 
using the Seahorse XF Analyzer. Profile of oxygen consumption of lymphocytes following addition of 
oligomycin (Oligo), FCCP and antimycin A (AntiA). Reproduced with permission from Chacko et al.228. 
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6.3.3.1 Measurement of markers of oxidative stress: Peroxiredoxin 2, Peroxiredoxin 3 and 
Protein Carbonylation 
To analyse erythrocyte Prx2 and platelet Prx3 redox status, 4 mL of blood was 
collected into a 9 mL vacutainer containing EDTA and 4 mL NEM and incubated for at least 
15 min incubation at room temperature to allow NEM to alkylate all reduced thiols. After 
that time, 50 L of whole blood + NEM was removed from the vacutainer and added to an 
equal volume of 2 x sample buffer (SB; non-reducing; 125 mM Tris-HCl pH 6.8, 4% SDS, 10% 
-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue).  Samples were frozen until 
required for analysis.  
The remaining blood + NEM was centrifuged for 15 min at 500 g to collect platelets 
for analysis of Prx3 oxidation. Platelets were washed in 4 mL PBS containing 1 g/mL PGI2 
centrifuged again and resuspended in 50 L lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, and 1% NP-40 containing 1 
protease inhibitor cocktail (Roche, USA) and then a freeze–thaw cycle was performed). 
Samples were stored at -80˚C until required.  
From the same draw, blood was also collected into a 6 mL vacutainer containing 
lithium/heparin and an aliquot was removed for the H2O2 challenge study which took place 
immediately following collection of blood. For this experiment, 100 L of whole blood from 
the lithium/heparin tubes was diluted to 1 mL in PBS/glucose (PBS/glc) and 1 mM H2O2 
added. Tubes were incubated at 37˚C for 20 min after which an aliquot was removed and an 
equivalent volume of NEM (final concentration of NEM 100 mM) was added to ‘trap’ Prx2 in 
its oxidised state. After addition of NEM aliquots were incubated at room temperature for 
15 min prior to addition of an appropriate volume of 3 x SB before storage at -80˚C.    
The remainder of the lithium heparin tube was centrifuged, and plasma stored 
at -80˚C until determination of protein carbonyls using an enzyme-linked immunosorbent 
assay (ELISA) as described by Buss and Winterbourn et al.215. 
6.3.3.2 Western blot analysis of Prx2 and Prx3 oxidation 
The redox status of Prx2 in circulating erythrocytes, after challenge with H2O2, and of 
Prx3 in platelets, was measured using immunoblotting. For determination of the redox 
status of Prx2 in circulating blood the sample was further diluted (1:500 in 2 x SB) and 5 L of 
sample was electrophoresed using 12% sodium dodecyl sulphate-polyacrylamide gel 
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electrophoresis (SDS-PAGE). For determination of Prx3 oxidation in platelets the protein 
concentration of the lysed platelets was determined and  20 L of lysate was diluted into 
non-reducing SB and also resolved using SDS-PAGE.  Samples from the H2O2 challenge study 
were diluted 1:50 in 2 x SB and 5 L was electrophoresed as above. Following 
electrophoresis proteins were transferred to Hybond polyvinylidene fluoride (PVDF) 
membranes and then incubated overnight with appropriate antibodies. The antibody to Prx2 
was obtained from Sigma (1:10000) and the antibody to Prx3 from AbFrontier (1:10000). 
Bands were visualized with the enhanced chemiluminescence (ECL) reagent (Thermo 
Scientific™ Pierce™) and images were obtained using the Uvitec Alliance imaging system 
(Uvitec Cambridge, UK) and densitometry determined using ImageJ software230.    
6.3.4 Clinical Frailty assessment: 
Pre-operative frailty was assessed on all patients using the Edmonton Frail Scale (EFS) 
and the modified frailty index (mFI). The EFS was performed at the point of recruitment by 
one of two trained assessors (SR or MF) on a standardised proforma (Appendix C). A score 
was calculated out of seventeen and patients were classified as either frail or non-frail. 
Patients scoring 8 or more were classified as frail. As outlined above, the EFS was again 
performed at 30 and 90 days post-operatively by the same assessors. A pre-operative mFI 
was calculated for each patient from the patients’ electronic medical records. As outlined in 
Chapter 3 a composite score derived from 11 conditions identified by the Canadian Study of 
Health and Aging mapped to the American College of Surgeons NSQIP database149 was 
obtained. Patients with a score of ≥0.27 (or 3 positive components) were considered frail.  
6.3.5 Outcomes: 
Primary outcomes assessed were length of hospital stay and the occurrence of any 
and major post-operative complications within 30 days, graded according to the Clavien-
Dindo classification. Secondary outcomes were assessed at 30 and 90 days post-operatively 
and included: patient mortality, unplanned readmission, the need for support on discharge 
and discharge destination. 
6.3.6 Ethics: 
This study was approved by the New Zealand Health and Disability Ethics Committee 
reference 17/CEN/170. Locality approval was obtained from the Canterbury District Health 
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Board. This study was registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN126180000452130). 
6.3.7 Statistical Analysis: 
Pre-operative biomarkers were compared, and binary outcomes assessed using t-tests 
with Satterthwaite’s correction for unequal variances. Correlation between pre-operative 
biomarkers and post-operative continuous outcomes were tested using Pearson’s correlation 
coefficient.  All tests were two sided and were considered statistically significant at p <0.05. 
The association between various biomarkers the primary outcomes were modelled using 
binary logistic regression creating receiver operating characteristic (ROC) curves. The 
predictive power was measured using the area under the curve (AUC).  All statistical analysis 
was performed using RStudio software (version 3.3.2; www.rstudio.com) or SPSS, version 25 
(IBM).  
6.4 Results:  
6.4.1 Patient recruitment: 
As outlined in Chapter 4, of 119 patients screened for eligibility, 86 patients 
consented and were recruited into the study (Figure 4.2). Blood samples were successfully 
collected in 68 (79.1%) patients and mitochondrial function and markers of oxidative stress 
were evaluated. 
6.4.2 Assessment of Mitochondrial function with Seahorse Analyser: 
A total of 26 patients had pre-operative blood samples taken to assess mitochondrial 
respiratory function using the Seahorse analyser. Subsequent patients were not analysed 
due to a mechanical malfunction in the analyser. Of these 26 patients, 2 were classified as 
frail using the EFS and 12 using the mFI.  Of the 26 patients, 10 patients, 4 of whom were 
frail, had blood taken and analysed at 30 days follow-up. As only 2 patients were classified as 
frail using the EFS, further comparison was conducted classifying patient frailty according to 
the mFI. 
Basal, maximal, ATP-linked and non-mitochondrial oxygen consumption rates (OCRs) 
as well as reserve capacity and proton leak were assessed in isolated lymphocytes and 
results compared between non-frail and frail patients (Figure 6.6), (Table 6.1). When 
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comparing frail and non-frail patients, no significant difference was observed in any of the 
pre-operative OCRs. 
Mitochondrial OCRs were subsequently analysed following the addition of H2O2 as an 
oxidative challenge (Figure 6.7 and Table 6.1). A reduction was seen in both the maximal and 
reserve OCR’s in samples treated with H2O2 in both the frail and non-frail cohorts, however 
there was no significant difference between the two.  
 
Table 6.1. Mean (SD) pre-operative mitochondrial OCRs in frail (n=12) and non-frail (n=14) patients 
(pmol/ml). Patient frailty as per the mFI 
Mitochondrial OCR’s 
(pmol/ml)  
 Patient Frailty  p - value 
No (n =14) Yes (n= 12) 
 
Basal  81.0 (12.6)  76.9 (11.1) 0.39 
Maximal 225.7 (45.2) 209.4 (39.7) 0.35 
Reserve 144.7 (37.1) 132.5 (36.7)  0.42 
Basal H2O2 79.8 (13.7) 74.1 (13.8) 0.31 
Maximal H2O2 170.7 (44.1) 143.2 (30.0) 0.08 
Reserve H2O2 90.8 (36.3) 69.2 (25.2) 0.10 
 
 
Figure 6:6. Pre-operative mitochondrial OCR measurements in frail (n=12) and non-frail (n=14) 
patients. Frailty as per the modified frailty index (mFI).  Basal, maximal, ATP-linked and non-




Figure 6:7. Pre-operative mitochondrial Oxygen Consumption Rate measurements in frail (n=4) and 
non-frail (n=8) patients after the addition of hydrogen peroxide (H2O2). Frailty as per the modified 
frailty index (mFI). 
 
Percentage inhibition of mitochondrial reserve capacity following a challenge with 
H2O2 was calculated with respect to pre-challenge reserve capacity. No significant difference 
was seen between frail and non-frail patients, with median percentage inhibitions of 53.5% 




Figure 6:8. Percentage inhibition of mitochondrial reserve capacity following the addition of H2O2 
with respect to untreated mitochondrial reserve capacity (%) in frail and non-frail patients, classified 
according to the mFI (p= 0.84). 
 
Correlation between pre-operative basal, maximal and reserve OCR and length of 
post-operative stay (LOS) was also assessed. No correlation was seen between basal OCR 
and LOS, Pearson’s correlation coefficient r = 0.07 (p=0.76). A trend towards a decreased LOS 
was seen with increasing maximal and reserve OCR’s, this was not statistically significant 




Figure 6:9. Correlation between maximal mitochondrial oxygen consumption rate and hospital length 
of stay, r = -0.214 (p=0.30). 
 
 
Figure 6:10. Correlation between mitochondrial reserve oxygen consumption rate capacity and 
hospital length of stay, r = -0.269 (p=0.19). 
 
A non-significant trend towards a decreased LOS was also seen with an increased 
resilience of maximal and reserve OCR to inhibition by H2O2. There was no correlation 
between percent inhibition of mitochondrial reserve capacity and hospital LOS (p=0.80).  
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The association between pre-operative mitochondrial OCR’s and the binary 
outcomes of prolonged LOS (greater than 7 days), the occurrence of any complication or 
major complications (Clavien-Dindo III-V) were assessed using 2-sided t-tests. Of 25 patients, 
14 (56%) had an index admission of greater than 7 days. No association was seen between 
basal OCR (p=0.93), maximal OCR (p=0.92), reserve OCR (p=0.93) and a prolonged LOS with 
or without H2O2 challenge.  
A total of 14 patients (56%) suffered from a post-operative complication. No 
significant difference was seen in pre-operative mitochondrial OCR’s in those patients who 
suffered a complication, compared to those who did not. Four (16%) patients suffered from 
a major post-operative complication (Clavien-Dindo III – V). Mitochondrial OCR’s were lower 
in patients who had a major post-operative complication across all domains, with and 
without the addition of H2O2, and significantly so for maximal mitochondrial OCR with the 
addition of H2O2 (p = 0.01), (Table 6.2). Low numbers of patients suffering from a major 
complication limited further comparison of mitochondrial function.   
 
Table 6.2. Mean (SD) pre-operative mitochondrial oxygen consumption rates (OCRs) with and 
without the addition of H2O2. Major post-operative complications defined as Clavien-Dindo III – V 
Mitochondrial OCRs 
(pmol/ml) 
Occurrence of a major post-operative 
complication 
Mean (SD) p - value 
No (n= 21) Yes (n= 4) 
 
Basal 79.7 (11.1) 73.4 (18.4) 0.40 
Maximal 221.5 (43.9) 190.9 (18.4) 0.07 
Reserve 141.8 (36.6) 117.5 (36.1) 0.37 
Basal H2O2 78.3 (12.3) 67.9 (23.3) 0.27 
Maximal H2O2 160.8 (41.3) 133.2 (6.2) 0.01 
Reserve H2O2 82.5 (34.1) 65.3 (17.6) 0.13 
 
Ten patients had bloods taken at 30-days post-operatively for assessment of 
mitochondrial function, of which 4 were classified as frail using the mFI. The percentage of 
reserve OCR capacity was calculated at 30-days with respect to pre-operative reserve 
capacity, both before and after the addition of H2O2. There was no difference in the absolute 
change in mitochondrial reserve capacity or percentage change between frail and non-frail 
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patients both with and without the addition of H2O2. Given the low patient number, no 
further analysis was performed.  
6.4.3 Peroxiredoxins as markers of oxidative stress: 
A total of 46 patients had pre-operative blood samples taken to assess the redox 
status of Prx2 in freshly harvested erythrocytes, and in erythrocytes treated with H2O2 for 20 
min to determine how effectively they can reduce Prx2 oxidised in this time. Of these 46 
patients, 32 (70%) had further blood samples assessed at 30-days post-operatively. In 
addition, 41 patients had pre-operative blood samples taken to assess the redox status of 
Prx3 in platelets. Of the 46 patients who had blood taken pre-operatively to assess the 
percentage oxidation of Prx2, 11 (23.9%) were classified as frail when using the EFS and 26 
(56.5%) when using the mFI.  Of the 41 patients who had samples taken for Prx3 oxidation 
assessment, 11 (26.8%) were classified as frail according to the EFS and 24 (58.5%) according 
to the mFI.  These proportions were representative of the larger overall patient cohort, as 
seen in Chapter 4.  
Median basal erythrocyte Prx2 oxidation was 1.2% (IQR 0.7 – 2.5) pre-operatively and 
1.4% (IQR 0.9 -2.8) at 30-days post-operatively. When patients were classified as frail or non-
frail using the EFS, frail patients had a median Prx2 oxidation of 1.4% (IQR 0.8 – 2.6) 
compared to 0.8% (IQR 0.5 – 1.4) in non-frail individuals (p = 0.07). When patient frailty was 
classified using the mFI, similar results were seen with a median Prx2 oxidation of 1.4% (IQR 
0.6 – 2.6) in frail individuals and 1.1% (IQR 0.8 – 1.9) in non-frail individuals, (p = 0.45). At 30-
days post-operatively, Prx2 oxidation was similar between frail and non-frail patients, with a 
median Prx2 oxidation of 1.5% (IQR 0.8 – 2.3) in frail patients and 1.4% (IQR 1.1 – 3.2) in 
non-frail patients, (p = 0.94).  
Patient samples of whole blood were then challenged with the addition of H2O2 for 
20 min to assess the redox status of erythrocyte Prx2. After 20 min, median Prx2 oxidation 
was 14.9% (IQR 10.3-20.5). Frail patients, when classified according to the EFS, had a median 
Prx2 oxidation with the addition of H2O2 of 15.8% (IQR 11.8 – 19.2) compared to 14.2% (IQR 
9.4 – 20.6) in non-frail patients, (p = 0.56). When frailty was classified using the mFI, again no 
significant difference was seen in Prx2 oxidation.   
Patient whole blood samples were subsequently challenged again at 30-days post-
operatively.  Median Prx2 oxidation was 22.8% (IQR 10.2 – 32.2) following the addition of 
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H2O2. Patient post-operative samples were plotted again pre-operative samples in matched 
pairs (Figure 6.11). Prx2 oxidation was significantly higher at 30-days post operatively when 
compared to pre-operatively (p = 0.03), suggesting that in the post-operative period cells 
may have lost reductive capacity (Figure 6.12).  
 
 
Figure 6:11. Comparison between percentage oxidation of Prx2 with the addition of H2O2 in patients 
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Figure 6:12. Comparison between percentage oxidation of Prx2 with the addition of H2O2 in blood 
samples taken pre-operatively and post-operatively. Percentage Prx2 oxidation was significantly 
higher at 30-days post-operatively (p=0.03).  
 
No significant difference was seen in Prx2 oxidation in blood treated with H2O2 at 30-
days post-operatively between frail and non-frail patients using either the EFS or mFI to 
classify patient frailty.  
Median basal pre-operative Prx3 oxidation was 20.3% (IQR 9.8 – 26.3). When 
patients were classified as frail using the EFS, frail patients had a pre-operative Prx3 
oxidation of 22.0% (IQR 9.2 – 25.3), compared to 17.5% (IQR 10.0 – 27.3) in non-frail patients 
(p=0.59). When patients were classified as frail according to the mFI, frail patients had a 
significantly higher Prx3 oxidation of 22.3% (IQR 13.7 – 31.0) compared to 11.1% (IQR 9.4– 
21.7) in non-frail patients (p=0.04). Prx3 oxidation was not measured post-operatively.  
Correlation between Prx oxidation and post-operative outcomes were subsequently 
assessed. The correlation between Prx oxidation and post-operative LOS was assessed using 
Pearson’s correlation coefficient. No correlation was seen between pre-operative Prx2 
oxidation and LOS with a correlation coefficient of r = 0.08 (p = 0.62) (Figure 6.13). No 





Figure 6:13. Correlation between post-operative LOS and pre-operative Prx2 percentage oxidation. 
Pearson’s correlation coefficient r = 0.08 (p = 0.62) 
 
The association between pre-operative oxidation of Prxs and the binary outcomes of 
prolonged LOS (greater than 7 days), the occurrence of any complication or major 
complications (Clavien-Dindo III-V) were assessed using 2-sided t-tests. Of the 46 patients 
who had pre-operative Prx2 oxidation assessed, 21 (45.7%) patients had a prolonged 
hospital admission and 23 (50%) patients suffered from a complication of which 10 (21.7%) 
were major complications. In the Prx3 oxidation cohort, 18 (43.9%) patients had a prolonged 
admission, 25 (60.9%) had a complication and 8 (19.5%) had a major complication. No 
significant difference was seen in percentage pre-operative peroxiredoxin oxidation in those 




Table 6.3. Mean (SD) pre-operative percentage peroxiredoxin (Prx) oxidation with and without the 
addition of hydrogen peroxide (H2O2) for each adverse post-operative outcome. Prolonged length of 
stay defined as greater than 7 days, major post-operative complications defined as Clavien-Dindo III – 
V 
Peroxiredoxin Oxidation Prolonged Hospital Stay (>7 days), Mean (SD) p - value 
  No Yes 
 
% Prx2 oxidation 1.6 (1.2) 1.9 (2.4) 0.57 
% Prx2 oxidation + H2O2 14.9 (9.7) 17.3 (9.3) 0.44 
% Prx3 oxidation 20.5 (15.8) 21.5 (11.6) 0.82 
 
Any Complication, Mean (SD) p - value 
  No Yes 
 
% Prx2 oxidation 1.6 (1.3) 1.8 (2.2) 0.82 
% Prx2 oxidation + H2O2 13.5 (8.5) 17.7 (10.1) 0.15 
% Prx3 oxidation 18.2 (11.3) 25.2 (16.9) 0.16 
 
Major Complication, Mean (SD) p - value 
  No Yes 
 
% Prx2 oxidation 1.7 (1.9) 1.9 (1.2) 0.76 
% Prx2 oxidation + H2O2 15.2 (9.0) 18.2 (11.1) 0.45 
% Prx3 oxidation 15.6 (8.9) 22.2 (14.8) 0.12 
 
There was no significant difference in Prx2 oxidation at 30-days post-operatively in 
patients who suffered from a post-operative complication (p = 0.36) or a major post-
operative complication (p = 0.93) when compared to those patients who did not.  
6.4.4 Protein Carbonylation as a marker of oxidative stress 
A total of 42 patients had blood taken to assess PC as a marker of oxidative stress 
pre-operatively. Median pre-operative PC was 0.036 pmol/mg (IQR 0.02 – 0.04). A total of 9 
(21.4%) patients were classified as frail using the EFS and 26 (61.9%) using the mFI. Patients 
classified as frail according to the EFS had a significantly higher level of PC in pre-operative 
bloods samples with values of 0.049 pmol/mg and 0.032 pmol/mg in frail and non-frail 
patients respectively, (p = 0.04). No difference was seen in levels of PC between frail and 
non-frail patients when classified using the mFI, (p = 0.72). 
A significant correlation between pre-operative PC and post-operative LOS was seen 
when assessed using Pearson’s correlation, with a correlation co-efficient of r= 0.42 (p = 




Figure 6:14. Correlation between pre-operative PC (pmol/mg) and hospital LOS. r = 0.42, (p = 0.01). 
 
The binary outcomes of prolonged length of hospital stay, the occurrence of any 
post-operative complication or major post-operative complication were assessed using 2-
sided t-tests (Table 6.4).  A total of 20 (47.6%) patients had a prolonged length of stay, 22 
(52.4%) suffered from a post-operative complication and 9 (21.4%) suffered a major 
complication. Patients who suffered from one of these adverse outcomes had higher levels 
of PC than those who did not, however across each outcome this difference was not 
statistically significant (Table 6.4). Other binary outcomes were not assessed due to their low 
frequency of occurrence. Although a trend towards increased PC was seen in patients who 
suffered from an adverse outcome, the limited sample size likely limited statistical 




Table 6.4. Mean (SD) pre-operative protein carbonylation (PC) for each adverse post-operative 
outcome. Prolonged length of stay defined as greater than 7 days, major post-operative 
complications defined as Clavien-Dindo III – V 
Adverse Outcome 
 
Occurrence of an adverse outcome 
Mean (SD) p - value 
  No Yes 
 
Prolonged Length of 
Stay (>7 days) 0.031 (0.011) 0.042 (0.021) 0.09 
Any Complication 0.032 (0.008) 0.040 (0.028) 0.23 
Major Complication 
(Clavien-Dindo III-V) 0.034 (0.013) 0.047 (0.020) 0.11 
 
6.4.5 Predictive ability of biomarkers alone and in combination: 
The predictive ability of each and/or a combination of biomarkers (Prx2, Prx2 with 
H2O2 challenge, Prx3, PC and mitochondrial reserve OCR) with regards to the primary 
outcomes were then assessed using the area under the receiver operating characteristic 
curve (AUC). The post-operative outcomes assessed were; length of hospital stay greater 
than 7 days and the development of any complication (Clavien-Dindo I – V). Due to limited 
numbers of patients having mitochondrial function (OCRs) and oxidative biomarkers 
measured concurrently, combination with mitochondrial OCRs was not possible.  
When assessing the ability of oxidative biomarkers to predict a prolonged length of 
stay, all markers had a poor predictive ability. PC as a single biomarker was the strongest 
predictor at 65%; the remainder had no predictive ability (Table 6.5 and Figure 6.15). In 
combination, Prx2 and PC improved the predictive ability to 67%, and a combination of Prx2, 
Prx3 and PC increased this to 72% (Table 6.5). No single biomarker or combination had a 




Table 6.5. Receiver Operating Characteristics Area under the Curve (AUC) by mitochondrial and 
oxidative biomarker(s) for the outcome of prolonged LOS of more than 7 days. As Prx2 and Prx2H 
offered the same predictive ability only Prx2 was used in combination 
Mitochondrial and Oxidative 
Biomarker(s) AUC p - value 
95% Confidence Interval 
Lower Bound Upper Bound 
Peroxiredoxin 2 (Prx2) .552 0.66 .314 .791 
Peroxiredoxin 2 + H2O2 
(Prx2H) 
.552 0.66 .317 .788 
Peroxiredoxin 3 (Prx3) .577 0.40 .394 .761 
Protein Carbonyls (PC) .650 0.21 .423 .878 
Mitochondrial Reserve OCR .481 0.87 .239 .722 
Mitochondrial Reserve OCR + 
H2O2 
.532 0.78 .299 .766 
Prx2 + Prx3 .650 0.21 .429 .872 
Prx2 + PC .671 0.16 .449 .893 
 Prx3 + PC .650 0.21 .417 .884 
Prx2 + Prx3 + PC .720 0.06 .512 .928 
 
 
Figure 6:15. Receiver Operator Characteristics (ROC) Curve demonstrating the ability of oxidative 
biomarker(s) to predict a length of hospital stay of more than 7 days 
 
When assessing the predictive ability of mitochondrial and oxidative biomarkers with 
respect to the occurrence of any post-operative complication, the combination of Prx2, Prx3 
and PC performed well with an 83% predictive ability (p <0.01). The remaining biomarkers 
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performed relatively poorly alone and in combination (Table 6.6 and Figure 6.16). Due to the 
low incidence of major post-operative complications, the predictive ability of the 
abovementioned biomarkers was not assessed.  
 
Table 6.6. Receiver Operating Characteristics Area under the Curve (AUC) by mitochondrial and 
oxidative biomarker(s) for the outcome of any post-operative complication (Clavien-Dindo I – V) 
Mitochondrial and Oxidative 
Biomarker(s) AUC p - value 
95% Confidence Interval 
Lower Bound Upper Bound 
Peroxiredoxin 2 (Prx2) .625 0.17 .452 .811 
Peroxiredoxin 2 + H2O2 
(Prx2H) 
.623 0.18 .444 .801 
Peroxiredoxin 3 (Prx3) .498 0.95 .311 .684 
Protein Carbonyls (PC) .567 0.46 .383 .752 
Mitochondrial Reserve OCR .552 0.66 .311 .793 
Mitochondrial Reserve OCR + 
H2O2 
.584 0.48 .354 .815 
Prx2 + Prx3 .636 0.16 .451 .821 
Prx2 + PC .697 0.07 .504 .890 
 Prx3 + PC .682 0.11 .473 .891 




Figure 6:16. Receiver Operator Characteristics (ROC) Curve demonstrating the ability of oxidative 
biomarker(s) to predict the occurrence of any complication (Clavien-Dindo I – V).  
 
6.5 Discussion:  
In this present study there appears to be an association between elevated levels of 
biomarkers of mitochondrial dysfunction and the clinical syndrome of frailty as assessed 
using two commonly used frailty measures, the EFS and the mFI. Although no difference was 
seen in pre-operative baseline mitochondrial OCRs using the Seahorse analyser, results were 
limited by a suboptimal sample size due to external factors. After challenging mitochondria 
with H2O2, a non-significant reduction was seen in maximal (p= 0.08) and reserve (p= 0.10) 
mitochondrial OCRs in frail patients.  
Frail patients had higher levels of peroxiredoxin oxidation and protein carbonyls 
when compared to non-frail patients, and pre-operative platelet Prx3 oxidation was 
significantly higher in patients classified as frail using the mFI. A significant increase in the 
percentage oxidation of Prx2 with the addition of H2O2 was seen in post-operative samples, 
when compared to pre-operative, possibly suggesting lymphocytes already stressed by 
surgery may be more susceptible to a challenge with H2O2. 
 140 
When assessing the occurrence of adverse binary outcomes including prolonged 
length of stay and post-operative complication rates, these were typically associated with 
increased levels of biomarkers of mitochondrial dysfunction, however statistical significance 
was limited due to sample size. A significant correlation was seen between protein 
carbonylation and post-operative length of stay (p = 0.01), however, all other potential 
biomarkers failed to show any significant correlation. Low patient numbers and the 
infrequent occurrence of adverse outcomes resulted in the current study being 
underpowered to assess this association. In combination, the oxidative biomarkers had an 
increased predictive ability for the occurrence of adverse post-operative outcomes 
compared to their use alone.  
The association between biomarkers of mitochondrial dysfunction/oxidative stress 
and the clinical syndrome of frailty has been examined previously by multiple authors206, 210, 
212, 213, 219, and although an association exists, the currently published evidence base remains 
limited and no single biomarker appears superior to another. The present study again 
suggests an association exists between markers of mitochondrial dysfunction and frailty with 
a significant association between pre-operative levels of protein carbonylation and Prx3 
oxidation.  
Previous studies, as discussed in the review by Soysal et al.210, have typically used 
indirect markers of oxidative stress and mitochondrial dysfunction, such as C-reactive 
protein, vitamin assays and isoprostanes, as indicators of patient frailty. Ingles et al.218 The 
assessment of direct functional assays in the form of mitochondrial OCR’s and a 
mitochondrial specific biomarker (Prx3) in frail and non-frail individuals has not been 
published previously.  
To date, limited published evidence exists examining the relationship between pre-
operative biomarkers of mitochondrial dysfunction or oxidative stress and post-operative 
outcomes. A single published study by Tsuchiya et al.211, demonstrated high levels of pre-
operative derivatives of reactive oxygen metabolites were predictive of delayed recovery 
and complications in patients undergoing oesophageal cancer surgery. No other published 
studies currently exist examining the relationship between biomarkers and post-operative 
outcomes in surgical patients and no studies currently exist assessing their use as pre-
operative surrogates for frailty. This present study, although failing to reach statistical 
significance, suggests elevated pre-operative biomarkers of mitochondrial dysfunction are 
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associated with adverse post-operative outcomes in patients undergoing elective surgery. 
Further studies are needed not only examining the relationship between pre-operative 
biomarkers and post-operative outcomes, but also examining the role of these biomarkers 
as potential pre-operative surrogates of frailty and increased operative risk. 
A strength of this study is that it is the first to examine the relationship between pre-
operative biomarkers and post-operative outcomes in elective colorectal patients. It is also 
the first published study examining the use of direct biomarkers of mitochondrial 
dysfunction as a surrogate for clinical frailty in the perioperative environment. Several 
limitations to the present study exist. Firstly, although a non-statistically significant 
relationship between elevated biomarkers of mitochondrial dysfunction and adverse post-
operative outcomes appears to exist, low patient numbers limited the power of the study. 
This is especially evident in the number of patients who had samples taken at 30-days post-
operatively. A number of technical and systems factors limited the number of blood samples 
obtained at each time point, thus limiting study power.  Secondly, as a result of limited 
sample sizes, only outcomes occurring with relatively common frequency could be assessed, 
and outcomes such as readmission and mortality were unable to be assessed.  
6.6 Conclusion:  
Elevated biomarkers of mitochondrial dysfunction are seen in patients with the 
clinical syndrome of frailty. Although an association between elevated biomarkers and 
adverse biomarkers is suggested, further studies with greater patient numbers are needed 




 Chapter 7 
 
Summary and Discussion 
7.1 Overview: 
With an ageing population, an increasing number of elderly patients are presenting 
for surgical intervention. Perioperative risk assessment in this population is difficult and 
commonly used tools often fail to accurately predict risk in this cohort26. Accurate risk 
assessment is important to facilitate patient centred decision making, to identify patients 
suitable for preoperative optimisation, and to guide perioperative care. Fundamentally, as 
patients age, their physiological reserves diminish so that they are less equipped to respond 
to significant external stressors, such as major surgery. Frailty, which can be conceptualised 
as a state of increased vulnerability as a result of this decline in physiological reserve, offers 
a potential surrogate of risk, and is becoming an integral component of perioperative risk 
assessment in older patients6, 231. Frailty has been demonstrated to be independently 
associated with an increased risk of perioperative morbidity and mortality, prolonged 
hospital admission and a reduction on quality of life9, 13. 
It is commonly observed that frailty is easy for a clinician to identify, but hard to 
define37. The lack of a universal operational definition and standardised assessment tool has 
limited quantitative research and left myriad options for identifying frail individuals. Many 
assessment tools are time-consuming to perform, rely on multiple subjective measures and 
may not be well suited to the non-research clinical environment82. Chapter 1 discusses the 
difficulties in defining and assessing frailty in current clinical practice and highlights the 
importance of identifying methods to optimally assess for frailty and target interventions 
towards this at-risk population. This thesis then aimed to examine the relationship between 
post-operative outcomes and a number of previously established frailty assessment tools, 
including the EFS and the mFI.  Subsequently, Chapters 5 and 6 have evaluated the use of 
pre-operative step counts and biomarkers of mitochondrial dysfunction as novel markers of 
patient frailty. 
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7.2 Frailty prevalence: 
Due to differing operational definitions, the prevalence of frailty in the literature 
varies significantly48. Limited data on the inpatient prevalence of frailty has been previously 
published123-128. Chapter 2 aimed to evaluate the prevalence of frailty in an adult inpatient 
population and assess short term outcomes in those patients identified as frail at 90-days 
follow up. In this chapter, frailty was defined according to the REFS. This chapter highlighted 
the high prevalence of frailty within an inpatient population, with 48.8% of 420 adult 
patients (aged 18 years or older) being identified as frail.  
Not unsurprisingly there was a significant burden of frailty in older patients, with 
77.4% of patients aged 85 and older being classified as frail, which is concordant with rates 
described in the literature 125, 127. A significant burden of frailty was also seen in younger 
patients, with 25% of the 152 patients aged under 65 years being identified as frail. There is 
limited published data on the prevalence of frailty in younger patients, however, it is often 
associated with polypharmacy, multi-morbidity, cognitive impairment and social deprivation 
133-135. Although frailty is often felt to be synonymous with ageing, frailty exists in younger 
patients, however it is likely a different clinical and biological entity to that encountered in 
older adults134. Despite this, frailty in this cohort is still associated with adverse health 
outcomes and further research into the prevalence and implications of frailty in this group is 
essential.  
Patients identified as frail had a significantly increased length of stay (14 vs 5 days) 
and a significantly increased rate of mortality and unplanned re-admission at 90-days, 
regardless of patient age. Due to a clear association with adverse outcomes, frailty has 
significant resource implications, and consideration should be given to inpatient frailty 
assessment to identify patients who might benefit from targeted intervention.  
7.3 Clinical Assessment of Frailty and Post-operative Outcomes: 
Chapters 3 and 4 demonstrate a significant association between pre-operative frailty 
and adverse post-operative outcomes. Chapter 3 retrospectively assesses the relationship 
between pre-operative frailty determined by radiological assessment (TPI) and by a clinical 
frailty scale (mFI) and post-operative outcomes in adult patients undergoing elective 
colorectal surgery. Chapter 4 prospectively assesses the relationship between frailty 
determined by TPI measurement and two clinical frailty scales (EFS and mFI) and post-
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operative outcomes in older patients undergoing elective colorectal surgery. It also 
compares the predictive ability of the three measures. 
In Chapter 3, a retrospective analysis of 350 patients undergoing major elective 
colorectal surgery was performed. Pre-operative CT scans were reviewed and used to 
calculate a TPI, from which gender specific cut-offs determined the presence or absence of 
sarcopenia. The presence of sarcopenia was extrapolated as a radiological measure of 
patient frailty. 32.9% of patients were classified as frail using this method, and 28.9% of 
patients when using the mFI. Frail patients had a significantly increased length of stay 
regardless of method of assessment (IRR = 2.12, 95% CI 1.90 – 2.36, p <0.01) and a 
significantly increased incidence of adverse post-operative outcomes; including any post-
operative complication (85.2% vs 34.5%, OR 15.4, 95% CI 8.39 –29.7, p <0.01) and of major 
complications (30.4% vs 8.9% OR 15.1, 95% CI 7.16 – 33.2, p <0.01).  
In Chapter 4, a prospective analysis of 86 older patients undergoing major elective 
colorectal surgery was performed. Frailty was classified pre-operatively using the EFS, the 
mFI and patient TPI. The percentage of frailty differed significantly depending on the method 
of classification with 14% of patients classified as frail using the EFS, 26.6% using patient TPI 
and 46.5% using the mFI. Consistent with our findings in Chapter 3, regardless of the method 
of frailty assessment, patients classified as frail pre-operatively had a significantly increased 
risk of adverse post-operative outcomes.  
Chapters 3 and 4 highlight the significant burden of frailty in elderly patients 
undergoing elective colorectal surgery with up to 46.5% of patients presenting being 
classified as frail. The results are also concordant with the published literature79, with frail 
patients being at significantly increased risk of adverse post-operative outcomes. Calculation 
of a patient’s TPI offers a relatively quick and easy objective measure of sarcopenia on a pre-
operative CT scan and is a reasonable surrogate for patient frailty. The EFS has been shown 
to be an ideal assessment tool in that it is quick and easy to perform, assesses frailty across 
multiple domains and identifies targets for possible pre-operative optimisation. The mFI is 
cumbersome to perform and lacks the sensitivity for use in a clinical setting identifying 
almost half of assessed patients as frail; it is more suited for use in the research 
environment. Given the significant association between frailty, regardless of the method of 
assessment, and adverse outcomes, significant consideration needs to be given to the 
routine implementation of pre-operative frailty assessment in the older patient.  
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7.4 Novel Markers of Frailty and Post-operative Outcomes: 
Due to the aforementioned difficulty in identifying and assessing for frailty in the pre-
operative setting, Chapters 5 and 6 examined the use of 2 novel surrogate markers of 
patient frailty. Chapter 5 examined the use of wearable activities trackers and pre-operative 
step count as a marker of patient frailty, and Chapter 6 assessed biomarkers of 
mitochondrial dysfunction as a surrogate measure of patient frailty.  
Chapter 5 presented a novel objective measure of patient frailty with low pre-
operative step count being significantly associated with adverse post-operative outcomes. 
Patients were dichotomised into a low step count and a normal step count cohort, based on 
the previous estimates of frailty prevalence, and 17 (20%) of 85 patients were classified as 
frail. Low step count patients had a significantly longer inpatient stay, rate of post-operative 
complications and discharge to care facilities or supported accommodation. Pre-operative 
use of wearable activity trackers offers a convenient way to measure a patient’s pre-
operative step count and may provide a more accurate assessment of functional reserve 
than a snap-shot clinical assessment. They may also identify at-risk patients who would 
benefit from prehabilitation or targeted intervention prior to surgery. Wearable activity 
trackers also appear to be intrinsically motivational and providing patients with targeted 
step counts and feedback may in itself be a tool for prehabilitation. In the post-operative 
setting early identification of low post-operative step counts may help identify patients at 
risk of complication and those requiring further assessment and/or targeted intervention.  
Chapter 6 examined a number of possible biomarkers of mitochondrial dysfunction 
and oxidative stress as surrogates for patient frailty. An association was seen between 
elevated biomarkers and the clinical syndrome of frailty; however, no significant association 
was seen between biomarkers and the occurrence of adverse post-operative outcomes. The 
lack of any significant association between a single biomarker and adverse post-operative 
outcomes was likely due to the study being underpowered, however the results suggest an 
association may exist. Clearly further studies are needed assessing these biomarkers in the 
search for an objective blood test for the clinical syndrome of frailty.  
7.5 Summary and Future Research: 
Frailty is becoming an increasingly significant component of modern surgical practice. 
An ageing surgical demographic, in conjunction with advances in surgical technique and 
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perioperative medicine has resulted in more elderly patients and thus more frail patients 
presenting for surgery. The prevalence of frailty across an inpatient population is significant, 
as highlighted in Chapter 2, especially so in the elderly population. These patients are at an 
increased risk of adverse post-operative outcomes and of requiring prolonged hospital stays 
and additional support on discharge. As a result, these patients typically suffer from 
significant impairment in their quality of life. From a healthcare perspective, these patients 
place significant stress on the system with long inpatient admissions, increased costs and 
resource utilisation. Identifying and targeting these patients for potential intervention to 
attenuate frailty and improve outcomes in this cohort is of critical importance. 
Despite the clear need for accurate frailty assessment, especially in the peri-
operative environment, the optimal tool remains uncertain. This thesis has highlighted a 
number of possible tools that may be used in the pre-operative setting, however, the EFS 
offers a significant advantage due to its simplicity, assessment of multiple domains and the 
potential to identify targets for pre-operative optimisation. Pre-operative patient step count 
offers a convenient surrogate for patient frailty and further studies examining the 
relationship between low step count and post-operative outcomes across a broader surgical 
cohort is suggested. Biomarkers of oxidative stress and mitochondrial dysfunction offer the 
potential for an objective blood test marker of frailty, however, further studies with larger 
patient numbers are clearly required to examine for a significant relationship between these 
markers and adverse outcomes. 
Pre-operative frailty assessment offers the potential for early identification of at-risk 
patients and allow prehabilitation or treatment modification based in the appropriate 
patient. Prehabilitation is a rapidly expanding facet of perioperative medicine, however, 
identifying suitable patients remains challenging 100. Conceptually prehabilitation seeks to 
improve physiological reserve232, therefore identifying and treating those patients with a 
reduced physiological reserve through frailty assessment appears logical. To date, there is 
limited evidence supporting the use of pre-operative prehabilitation in frail patients and 
further large randomised controlled trials are needed232. Wearable activity trackers offer not 
only an assessment of patient frailty, but also may have a role through intrinsic motivation 
as a prehabilitation tool. Finally, aspects of frailty, such as polypharmacy, identified through 
the EFS may be optimised pre-operatively. Comprehensive geriatric assessment has shown 
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promise in orthopaedic patients113 and is likely to benefit all pre-operative elderly patients, 
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Participant Information Sheet 
 
THE P-PrOF STUDY – POINT PREVALENCE OF FRAILTY IN ADULT 
HOSPITAL INPATIENTS 
 
Location:  Christchurch Public Hospital 
 
Lead Investigator: Dr Simon Richards 
Christchurch Department of Surgery 
Contact phone number 03 3640 640 
 
Thank you for showing an interest in this project. Please take your time to read this information 
sheet carefully and decide whether you want to take part. You are welcome to discuss this with your 
support people, whanau and health care providers. Whether or not you take part is your choice, and 
if you choose not to you do not have to give a reason and will not be disadvantaged in any way. This 
is an observational study and the treatment you receive at this hospital will be the same regardless 
of whether you are in the study or not.  
 
If you do decide to take part, thank you. If you do not wish to take part, we thank you for considering 
our request.  
 
What is the purpose of this research project? 
The purpose of this project is to identify the prevalence (or rate) of frailty in a hospital setting.  
‘Frailty’ in medicine refers to age-related changes that affect people’s ability to tolerate medical 
illnesses and treatments. Research has been done assessing the prevalence of frailty in the 
community, but there is little knowledge on rates in hospital.  Research has shown that measuring 
frailty enables doctors to predict how well people will recover and who may need extra support or 
cares.   
 
Who are we seeking to participate in this project? 
We are looking to recruit people over 18 years of age who are admitted to hospital 
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If I decide to participate, what will I be asked to do? 
Your care will be identical to standard care, apart from an extra frailty assessment. This is done using 
a questionnaire about your daily function taking around 5 minutes.  
 
What about my confidentiality and privacy? 
The anonymity and confidentiality of your health information will be ensured by a process called de-
identification. This means you are allocated a study ID and only primary investigators will be able to 
link your study ID to your identity and health information. All of your electronic information relating 
to the study will be stored on a secure password protected database and all hardcopy information 
will be stored under lock and key. These will only be accessible to the primary investigators. If any 
information is shared with a third party (e.g., a statistician or an overseas researcher), no information 
identifying you will be provided to them. 
 
What happens after the study or if I change my mind? 
Any data will be securely stored for up to ten years.  
 
You are entitled to receive a summary of the findings at the completion of this study.  
 
You may change your mind about taking part in this study at any stage. If you do change your mind 
you will be withdrawn from the study at no disadvantage to you.   
 
Any Questions? 
If you have any questions, concerns or complaints about the study you can contact: 
 
Simon Richards  
Department of Surgery 
Phone 03 364 0640 
simon.richards@cdhb.health.nz 
 
If you want to talk to someone who isn’t involved with the study, you can contact an independent 




PARTICIPANT CONSENT FORM 
 
THE P-PrOF STUDY– POINT PREVALENCE OF FRAILTY IN ADULT HOSPITAL PATIENTS 
 
Lead Investigator: Dr Simon Richards 
Christchurch Department of Surgery 
Contact phone number 03 3640 640 
 




Name of Participant………………………………………………………………… 
 
1. I have read and understand the participant information sheet provided 
 
2. I have had sufficient time to discuss my participation in this study with the researchers and any support 
people of my choosing, and have had the opportunity to ask questions  
 
 
3. I know that participation in the study is entirely voluntary and that I am free to withdraw from the study at 
any time without disadvantage 
 
4. I understand that the study will involve the completion of a questionnaire assessing frailty 
 
5. I understand the results of the study may be published and available in the University of Otago library 
 
6. I understand there is no payment for the study and that no commercial use will be made of the data 
 
7. I understand the researchers may access my medical records  
 
 
8.  I give permission for my participation in this study 
 




Declaration by member of research team: 
 
I have given a verbal explanation of the research project to the participant, and have answered the participant’s 
questions about it.   








Appendix E: Patient information and Consent Forms Used in Chapters 




Participant Information Sheet 
 
The FRAME Study: Frailty, activity and mitochondrial 
efficiency in perioperative outcomes 
 
Location:  Christchurch Public Hospital 
 
Lead Investigator: Professor Frank Frizelle 
Christchurch Department of Surgery 
Contact phone number 03 3648174 
 
 
Thank you for showing an interest in this project. Please take your time to read this 
information sheet carefully and decide whether or not you want to take part. You are 
welcome to discuss this with your support people, whanau and health care providers. 
Whether or not you take part is your choice, and if you choose not to you do not have to 
give a reason, and will not be disadvantaged in any way.  
 
This is an observational study and the treatment you receive at this hospital will be the same 
regardless of whether you are in the study or not.  
 
If you do decide to take part, thank you. If you do not wish to take part we thank you for 
considering our request.  
 
What is the purpose of this research project? 
The purpose of this project is to identify the presence of frailty in people undergoing 
abdominal surgery and to see how frailty affects their recovery.  
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‘Frailty’ in medicine refers to age-related changes that affect people’s ability to tolerate 
medical treatment, including operations. Research has shown that measuring frailty enables 
doctors to predict how well people do after their operations. We are measuring frailty in 
three different ways – a questionnaire about your daily function, a watch that tracks your 
activity levels, and a blood test. The latter two have not been studied before.  
 
Who are we seeking to participate in this project? 
We are looking to recruit people over 65 years of age who are undergoing planned colorectal 
surgery, and who are able to walk (this includes with a stick or a frame). We are not 
recruiting people who partake in regular activity that is non-walking based (i.e. swimming or 
cycling).  
 
If I decide to participate, what will I be asked to do? 
Your care will be identical to standard care, apart from three extra assessments 
1. Frailty assessment 
This is done using a questionnaire about your daily function with two brief practical 
tests. The whole assessment takes around 5 minutes. We will carry this out once you 
enter the study, and again at 1 and 3 months after your operation. There will be 
other short (12 questions or fewer) questionnaires we will ask you to fill in regarding 
your fatigue levels and quality of life. Some of these surveys may be carried out over 
the phone, and we will ask for permission to phone you as part of consenting to the 
study. 
2. Wearable activity tracker 
We will be providing you with a watch that is also an activity tracker – i.e. it counts 
the number of steps you take. We ask that you wear it at all times until your 
operation, and for 1 month after your operation. You do not need to take it off to 
wash unless you wish to. A separate information form will be provided with the 
activity tracker.  
 
3. Blood test 
One part of the study involves taking your blood to test the function of your 
mitochondria (these are like the batteries of your cells, and their function reduces as 
you age). We will be taking a blood test on 4 separate occasions for this study. Most 
of these we can include with your routine blood tests that you would be getting 
anyway.  
 
Is there any risk of discomfort or harm from participation? 
Blood tests are a normal part of coming in to hospital for an operation and wherever 
possible we will use blood for the study that is taken as part of your routine blood tests. 
However, there may be times where we need to take blood specifically for the purpose of 
the study. It is very unlikely this will happen more than twice.  
 
 175 
There is a very small chance that wearing the step counter may cause irritation to your skin 
(as any watch or wearable device may).  
 
What about my confidentiality and privacy? 
The anonymity and confidentiality of your health information will be ensured by a process 
called de-identification. This means you are allocated a study ID and only primary 
investigators will be able to link your study ID to your identity and health information. All of 
your electronic information relating to the study will be stored on a secure password 
protected database and all hardcopy information will be stored under lock and key. These 
will only be accessible to the primary investigators. If any information is shared with a third 
party (e.g., a statistician or an overseas researcher), no information identifying you (e.g., NHI 
number or name) will be provided to them. 
 
It is possible that data generated in this study, but not reported, will be made available for 
use in future research. If this happens, it will be ensured all data will be provided in an 
entirely de-identified manner. 
 
Some people have expressed concerns that the wearing of activity trackers may provide 
information about their whereabouts and activities to unauthorised entities. The device 
used in this study has no GPS function and as such cannot provide any such information 
about you.  
 
What happens after the study or if I change my mind? 
Blood taken will be disposed of at the end of the study according to the hospital’s guidelines. 
Any data will be securely stored for up to ten years.  
 
You are entitled to receive a summary of the findings at the completion of this study. Please 
check the box if you wish to receive this by mail or email.  
 
You may change your mind about taking part in this study at any stage. If you do change 
your mind you will be withdrawn from the study at no disadvantage to you.  
 
Information for Maori participants 
Some whanau may have issues with the storage of blood and the sending of those samples 
overseas citing the protection of whakapapa. Therefore, controlling access to your samples 
and limiting unauthorised use of your blood sample are important questions that you may 
need to think about before consenting to this research. You may also like to think about the 
direct benefits that this research will have for yourself, your whanau and for maori as a 
people. We advise participants to consult with their whanau prior to consenting to 
participate in a research study and suggest that your family/whanau are involved with you at 




If you have any questions, concerns or complaints about the study you can contact: 
 
Professor Frank Frizelle  
Principal investigator 




Dr Christian Brett 





Dr Pippa Jerram 




Dr Simon Richards 





Clinical studies Research Nurse 
Department of Surgery 
Phone 03 364 1154 
michelle.falloon@cdhb.health.nz 
 
If you want to talk to someone who isn’t involved with the study, you can contact an 
independent health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 







PARTICIPANT CONSENT FORM 
 
The FRAME study: Frailty, activity and mitochondrial 
efficiency in perioperative outcomes 
 
Lead Investigator: Professor Frank Frizelle 
Christchurch Department of Surgery 
Contact phone number 03 3648174 
 





Name of Participant………………………………………………………………… 
 
1. I have read and understand the participant information sheet provided 
 
2. I have had sufficient time to discuss my participation in this study with the researchers and 
any support people of my choosing, and have had the opportunity to ask questions  
 
3. To the best of my knowledge I fit the criteria for inclusion in this study as outlined in the 
information sheet 
 
4. I know that participation in the study is entirely voluntary and that I am free to withdraw 
from the study at any time without disadvantage 
 
5. I understand that if I withdraw from the study all information collected up until the time of 
my withdrawal will be kept by the Investigators 
 
6. I understand that the study will involve a number of questionnaires 




7. I understand the study will involve the wearing of a Garmin activity tracker device for up 
to 2 months total before and after my operation 
 
8. I understand that as part of the study I will have my blood taken by a trained professional 
 
9. I understand the results of the study may be published and available in the University of 
Otago library 
 
10. I understand there is no payment for the study and that no commercial use will be made 
of the data 
 
11. I understand the researchers may access my medical records  
 
12. I understand the researchers may contact me by telephone for the purposes of the study 
including completing questionnaires 
 
13. I wish to receive a summary of the results of this study…Yes        No    
 
14. I request that any blood samples collected from me in the course of this study are 
disposed of in a ceremony with karakia …………Yes        No    
 
15. I give permission for my participation in this study 
 





Declaration by member of research team: 
 
I have given a verbal explanation of the research project to the participant, and have answered 
the participant’s questions about it.   
 
I believe that the participant understands the study and has given valid informed consent to 
participate. 
Researcher’s name: 
Signature: Date: 
 
 
  
